

www.ah.viamedica.pl

arterial hypertension

JOURNAL OF THE POLISH SOCIETY OF HYPERTENSION

2019

vol. 23, no. 4

pages 203–274



Polish Society of Hypertension
2019 Guidelines for the Management of Hypertension. Part 8–9

Marina Lozinska *et al.*
Cardiac remodeling in CYP11B2 polymorphism

Mikhail Bochkarev *et al.*
Sleep duration and cardiovascular risk

Paweł Deska, Michał Nowicki
Physical exercise and markers of skeletal muscle damage
in hypertensive patients

Ahmed Bendary *et al.*
Central-to-peripheral SBP different phenotypes

Anna Szymańska *et al.*
Left atrial enlargement in atrial fibrillation

13131_Post_AHA_20

WARSZAWA
29 LUTEGO 2020 ROKU

Hotel Golden Tulip Warsaw Centre
ul. Towarowa 2

SYMPOZJUM POST AHA

**POD PATRONATEM
KLUBU 30 PTK ORAZ CZASOPISMA
CARDIOLOGY JOURNAL**



Klub 30
Polskiego Towarzystwa
Kardiologicznego

Przewodniczący:

dr hab. n. med. Miłosz Jaguszewski, prof. nadzw., FESC
Professor Juan Luis Gutiérrez-Chico, MD, Ph.D., FESC, FACC
prof. dr hab. n. med. Krzysztof J. Filipiak, FESC



19-0130.001.011

Szczegółowe informacje oraz rejestracja na stronie internetowej:

www.postaha.viamedica.pl

ORGANIZATOR



PATRONAT MEDIALNY



PARTNER



Konferencja jest skierowana do wszystkich osób zainteresowanych tematyką. Sesje satelitarne firm farmaceutycznych, sesje firm farmaceutycznych oraz wystawy firm farmaceutycznych są skierowane tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (Dz. U. z 2017 r. poz. 2211, z późn. zm.)

arterial hypertension

JOURNAL OF THE POLISH SOCIETY OF HYPERTENSION



2019
vol. 23, no. 4
pages 203–274

Editor-in-Chief Krystyna Widecka (Szczecin, Poland)

Vice Editor Grzegorz Dzida (Lublin, Poland)

Past Editor-in-Chief

Andrzej Rynkiewicz (Olsztyn, Poland)

Andrzej Tykarski (Poznań, Poland)

Editorial Assistant Marta Sottysiak (Szczecin, Poland)

Managing Editor Justyna Łapińska (Gdańsk, Poland)

Associate Editor

Jacek Wolf (Gdańsk, Poland)

International Editorial Advisory Board

Renata Cifková (Prague, Czech Republic)

Anna Dominiczak (Scotland, UK)

Csaba Farsang (Budapest, Hungary)

Jarostaw Fedorowski (New York, US)

Peter Gross (Dresden, Germany)

Thomas Hedner (Göteborg, Sweden)

Peter Heering (Flensburg, Germany)

Stevio Julius (Michigan, US)

Sverre E. Kjeldsen (Oslo, Norway)

Lyudmila Korostovtseva (St. Petersburg, Russian Federation)

Franz Messerli (New York, US)

Marius Miglinas (Vilnius, Lithuania)

Peter Nilsson (Malmö, Sweden)

Paolo Palatini (Padua, Italy)

Roland Schmieder (Erlangen, Germany)

Anna Shalimova (Kharkiv, Ukraine)

Jan Staessen (Leuven, Belgium)

Margus Viigimaa (Tallinn, Estonia)

National Editorial Advisory Board

Krzysztof J. Filipiak (Warszawa, Poland)

Zbigniew Gaciong (Warszawa, Poland)

Jerzy Głuszek (Poznań, Poland)

Tomasz Grodzicki (Kraków, Poland)

Andrzej Januszewicz (Warszawa, Poland)

Włodzimierz Januszewicz (Warszawa, Poland)

Kalina Kawecka-Jaszcz (Kraków, Poland)

Mieczysław Litwin (Warszawa, Poland)

Jacek Maniatus (Bydgoszcz, Poland)

Krzysztof Narkiewicz (Gdańsk, Poland)

Aleksander Prejbisz (Warszawa, Poland)

Katarzyna Stolarz-Skrzypek (Kraków, Poland)

Filip M. Szymański (Warszawa, Poland)

Andrzej Tykarski (Poznań, Poland)

Andrzej Więcek (Katowice, Poland)

Tomasz Zdrojewski (Gdańsk, Poland)



18-0247.004.001

Arterial Hypertension (ISSN 2449–6170) previously *Nadciśnienie Tętnicze* is published by VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland, tel: (+48 58) 320–94–94, fax: (+48 58) 320–94–60, e-mail: viamedica@viamedica.pl; www.viamedica.pl

Editorial Address: VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland, tel: (+48 58) 320–94–94, fax: (+48 58) 320–94–60, e-mail: redakcja@viamedica.pl; www.viamedica.pl

Subscription Rates: The annual subscription rate for 2018 is 200 zł for foreign institutions and 100 zł for foreign individual subscribers. The above prices are inclusive of regular postage costs. Payment should be made to: VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, Bank BGŻ BNP Paribas S.A., Gdańsk, Poland

Acc.: 15 1600 1303 0004 1007 1035 9021; SWIFT: PPABPLPK

Single issues, subscriptions orders and requests for sample copies should be sent to e-mail: prenumerata@viamedica.pl

Electronic orders option available at www.ah.viamedica.pl

Advertising: For details on media opportunities within this journal please contact the advertising department, ul. Świętokrzyska 73, 80–180 Gdańsk, tel: (+48 58) 326–78–18; e-mail: marketing@viamedica.pl

All rights reserved, including translation into foreign languages. No part of this periodical, either text or illustration, may be used in any form whatsoever. It is particularly forbidden for any part of this material to be copied or translated into a mechanical or electronic language and also to be recorded in whatever form, stored in any kind of retrieval system or transmitted, whether in an electronic or mechanical form or with the aid of photocopying, microfilm, recording, scanning or in any other form, without the prior written permission of the publisher. The rights of the publisher are protected by national copyright laws and by international conventions, and their violation will be punishable by penal sanctions.

Arterial Hypertension is indexed at Index Copernicus (117.69), Ulrich's Periodicals Directory and Ministry of Education (8 pts.).

The journal Arterial Hypertension is financed under Contract No. 790/P-DUNdem/2019 by the funds of the Minister of Science and Higher Education for the science promotion activities.



Ministerstwo Nauki
i Szkolnictwa Wyższego

Editorial policies and author guidelines are published on journal website: https://journals.viamedica.pl/arterial_hypertension



Copyright © 2019 Via Medica

IX Zaawansowany kurs hipertensjologii dla specjalistów



12950_IX_Hipertensjo_2020



26–28 czerwca 2020 roku

**IV Letnie Spotkanie
Seksji Farmakoterapii Sercowo-Naczyniowej
Polskiego Towarzystwa Kardiologicznego**



Szczegółowe informacje oraz rejestracja:

www.zaawansowanykurs.viamedica.pl

ORGANIZATORZY



VIA MEDICA

PATRONAT MEDIALNY

tvmed

PARTNER



ikamed.pl
Innowacyjne. Inteligentne. Indywidualne.



Konferencja jest skierowana do wszystkich osób zainteresowanych tematyką. Sesje satelitarne firm farmaceutycznych, sesje firm farmaceutycznych oraz wystawy firm farmaceutycznych są skierowane tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (Dz. U. z 2017 r. poz. 2211., z późn. zm.)

arterial hypertension

JOURNAL OF THE POLISH SOCIETY OF HYPERTENSION



2019
vol. 23, no. 4
pages 203–274

Contents

GUIDELINES

2019 Guidelines for the Management of Hypertension. Part 8–9

Recommendations of the Polish Society of Hypertension 203

ORIGINAL PAPERS

The inappropriateness of left ventricular mass and echoreflectivity in males with essential hypertension and different CYP11B2 gene polymorphisms

Marina Lozinska, Vadym Zhebel, Sergiy Lozinsky 240

Sleep duration and cardiovascular risk: results of the large-scale epidemiology study ESSE-RF

Mikhail Bochkarev, Lyudmila Korostovtseva, Elena Medvedeva, Oxana Rotar, Yuri Sviryayev, Yulia Zhernakova, Svetlana Shalnova, Alexandra Konradi, Irina Chazova, Sergey Boytsov, Eugene Shlyakhto 248

Effect of short-term physical exercise on serum markers of skeletal muscle damage in hypertensive patients treated with a combination of statin and angiotensin-converting enzyme inhibitor

Paweł Deska, Michał Nowicki 256

Central-to-peripheral systolic blood pressure different phenotypes and relation to accuracy of daily used cuff devices

Ahmed Bendary, Mina Magdy, Sahar Abdoul Aal, Hisham Rashid 263

The prevalence of left atrial enlargement in Polish patients with atrial fibrillation — a single center study

Anna Szymańska, Anna E. Platek, Joanna Syska-Sumińska, Anna Gorajek, Mirosław Dłużniewski 271

13050_XVII_PTNT_2020



XVII Zjazd Polskiego Towarzystwa Nadciśnienia Tętniczego

Ryzyko sercowo-naczyniowe: nadciśnienie tętnicze, hipercholesterolemia, hiperglikemia i inne ważne czynniki ryzyka sercowo-naczyniowego

Gdańsk, 15–17 października 2020 roku

Polska Filharmonia Bałtycka im. Fryderyka Chopina
ul. Ołowianka 1



www.zjazd.ptnt.pl



17zjazdptnt@viamedica.pl



58 320 94 94

ORGANIZATOR



Konferencja jest skierowana do wszystkich osób zainteresowanych tematyką. Sesje satelitarne firm farmaceutycznych, sesje firm farmaceutycznych oraz wystawy firm farmaceutycznych są skierowane tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (Dz. U. z 2017 r. poz. 2211, z późn. zm.)





Polish Society of Hypertension

2019 Guidelines for the Management of Hypertension

Part 8–9

Recommendations of the Polish Society of Hypertension

Guideline editors: Andrzej Tykarski, Krzysztof J. Filipiak, Andrzej Januszewicz, Mieczysław Litwin, Krzysztof Narkiewicz, Aleksander Prejbisz, Danuta Ostalska-Nowicka, Krystyna Widecka, Katarzyna Kostka-Jeziorny

Experts: Marcin Adamczak, Marta Buraczewska, Ludwina Szczepaniak-Chicheł, Marzena Chrostowska, Danuta Czarnecka, Piotr Dobrowolski, Grzegorz Dzida, Zbigniew Gaciong, Jerzy Gąsowski, Tomasz Grodzicki, Dagmara Hering, Beata Woźakowska-Kapłon, Przemysław Kosiński, Beata Begier-Kraśńska, Jan Krekora, Jacek Manitius, Małgorzata Myśliwiec, Anna Niemirska, Arkadiusz Niklas, Łukasz Obrycki, Agnieszka Olszanecka, Sylwester Prokurat, Grażyna Brzezińska-Rajszys, Marek Rajzer, Katarzyna Stolarz-Skrzypek, Agnieszka Szadkowska, Filip M. Szymański, Anna Szyndler, Andrzej Więcek, Barbara Wizner, Jacek Wolf, Tomasz Zdrojewski

Arterial Hypertens. 2019, vol. 23, no. 4, pages: 203–239
DOI: 10.5603/AH.a2019.0021

8. Secondary hypertension

8.1. Introduction

Secondary hypertension is present in 5–10% of all hypertensive patients. Appropriate investigations followed by therapy directed at the cause of secondary hypertension may lead to elimination of the underlying cause, resulting in improved control or normalization of BP values with cardiovascular risk reduction.

Clues to the presence of secondary hypertension include:

- severe BP elevation (including paroxysmal hypertension and hypertensive crisis);
- rapidly progressing development of hypertension or worsening of BP control;
- resistant hypertension;
- development of malignant hypertension;
- poor response to antihypertensive drugs;
- presence of target organ damage that is disproportionate to the duration or severity of hypertension.

Suggestive signs and symptoms and diagnostic procedures to investigate for specific forms of secondary hypertension are summarized in Table XXXVII.

8.2. Obstructive sleep apnoea

8.2.1. Prevalence

Obstructive sleep apnoea (OSA) is present in a relatively large proportion of hypertensive patients, particularly among those with resistant hypertension (about 80%). Studies indicate that moderate to severe OSA that requires appropriate therapeutic management may be present in as many as 40–50% of patients with resistant hypertension. Of note, OSA is also associated with a 70% relative increase in the cardiovascular morbidity and mortality risk.

Due to frequent coexistence, common pathogenic mechanisms with hypertension, and a limited effect of specific OSA treatment on BP values, some European experts have postulated to consider it a concomitant condition and not a secondary form of hypertension. However, American guidelines (JNC7) have listed OSA as an important and reversible cause of secondary hypertension.

8.2.2. History, physical examination, and routine and additional laboratory test abnormalities

The most common symptoms of OSA are habitual snoring, episodes of apnoea, and excessive daytime somnolence. Other manifestations of OSA include the following nocturnal symptoms: nycturia, increased motor activity and sweating during the night, awakenings, dyspnoea and/or choking during sleep, difficulties with falling asleep, insomnia, pal-

pitations, mouth and throat dryness, and symptoms of gastroesophageal reflux. In addition to excessive daytime somnolence, other symptoms during the day include morning tiredness, morning headaches, impaired memory and concentration, decreased libido and impotence, psychoemotional problems, and an increased rate of traffic and workplace accidents. Studies also indicate that in some hypertensive patients, daytime symptoms of even severe OSA may be modest.

Obesity is the most common finding on physical examination, in particular abdominal obesity. The corrected neck circumference above 48 cm (measured neck circumference in centimetres plus 4 cm in hypertensives plus 3 cm if habitual snoring, and plus 3 cm if nocturnal choking/dyspnoea) is associated with a significantly increased risk of OSA.

Major underlying causes may include anatomical abnormalities of the upper airways, such as tongue hypertrophy, elongation of the soft palate, tonsil hypertrophy, and impaired nasal patency. Less frequent abnormalities include an abnormal anatomy of the splanchnocranium, for example mandibular hypoplasia and/or retraction.

Most commonly, OSA coexists with metabolic syndrome and thus abnormal glucose and lipid metabolism is often indicated by basic laboratory tests in these patients.

In patients with OSA, ABPM may reveal a reduced nocturnal BP fall, non-dipping BP pattern, or even BP elevation during the night. The presence of OSA may also be indicated by increased morning BP values as detected by HBPM. Holter monitoring in patients with OSA may show intermittent periods of brady- and tachycardia. Echocardiography may show left ventricular hypertrophy (usually of the concentric pattern), left atrial enlargement, diastolic dysfunction, and other abnormalities.

8.2.3. Investigations

Investigations for OSA should be considered in hypertensive patients with:

- clinical symptoms suggesting OSA;
- resistant hypertension;
- abdominal obesity and metabolic disturbances (particularly diabetes);
- concomitant coronary artery disease;
- a history of stroke/TIA;
- non-dipping BP pattern;
- nocturnal arrhythmia and/or conduction disturbances.

Available questionnaires, such as the Epworth Sleepiness Scale and the Berlin Questionnaire, lack specificity to allow excluding OSA. However, they

Table XXXVII. Suggestive symptoms, signs and laboratory test results, and specific investigations for secondary forms of hypertension

Cause of hypertension	Symptoms, signs, and routine and additional laboratory test results suggesting a secondary form of hypertension				Investigations	
	History	Physical examination	Routine tests	Additional tests	First choice (screening) tests	Confirmatory tests
Obstructive sleep apnoea	Characteristic daytime and nocturnal symptoms* Symptom evaluation using questionnaires*	Abdominal obesity Increased neck circumference* Abnormalities of the spleen/pancreas	Elevated glucose level Dyslipidaemia	Reduced or absent nocturnal BP fall in ABPM Elevated morning BP values in HBPM Arrhythmia and/or conduction disturbances in Holter ECG monitoring becoming worse during sleep	Evaluation using questionnaires and nocturnal study using a type IV device*	Nocturnal study using a type I-III device*
Paraneoplastic renal disease	History or urinary tract infection or abnormal anatomy Haematuria Overuse of analgesics Family history of kidney disease	Palpable enlarged kidneys (in cystic kidney disease)	Presence of protein, erythrocytes, or leukocytes in urine Reduced GFR	Albuminuria/proteinuria of varying severity	Renal ultrasound	Detailed investigations for kidney disease
Primary hyperaldosteronism	Muscle weakness Family history, particularly of severe hypertension or early onset hypokalaemia and cerebrovascular events at < 40 years of age	Cardiac arrhythmia	Hypokalaemia (spontaneous or diuretic-induced)	Incidentally found adrenal lesion Severe target organ damage Reduced or absent nocturnal BP fall in ABPM	Aldosterone-renin ratio* in ABPM	Confirmatory hormonal testing* Adrenal CT/MRI Adrenal venous sampling
Atherosclerotic renal artery stenosis	Hypertension: <ul style="list-style-type: none">sudden onsetincreasing severityworsening of BP controlresistant or malignant hypertensionRecurrent flash pulmonary oedema	Vascular bruit in mid-abdomen	Rapid worsening of renal function (spontaneous or during treatment with RAAS inhibitors) Hypokalaemia	Renal ultrasound: kidney length difference > 1.5 cm, small kidney	Doppler renal ultrasound	CTA MRA Invasive angiography
Renal artery stenosis due to fibromuscular dysplasia	Age < 30 years Women of reproductive age Hypertension: <ul style="list-style-type: none">sudden onsetincreasing severityworsening of BP controlresistant or malignant hypertensionHistory of fibromuscular dysplasia	Vascular bruit in mid-abdomen	Rapid worsening of renal function (spontaneous or during treatment with RAAS inhibitors) Hypokalaemia	Renal ultrasound: kidney length difference > 1.5 cm, small kidney	CTA MRA Doppler renal ultrasound (in experienced centres)	CTA MRA Invasive angiography
Catecholamine-secreting tumour	Paroxysmal BP elevations Headaches Increased sweating Palpitations, pallor Family history of pheochromocytoma	Skin lesions typical for neurofibromatosis (café au lait spots, neurofibromas)	Hyperglycaemia	Incidentally found adrenal (or sometimes extra-adrenal) lesion	Plasma free metanephrines or urinary fractionated metanephrines	CT or MRI of the abdomen and pelvis ¹²³ I-MIBG scintigraphy Screening genetic testing for pathogenic mutations
Cushing syndrome	Rapid increase in body weight Polyuria Polydipsia Mood disturbances	Typical body physique (central obesity, moon face, buffalo hump) Red striae Hirsutism Easy bruising	Hyperglycaemia	Incidentally found adrenal lesion	24-hour urinary free cortisol excretion Low-dose (1 mg) dexamethasone suppression test	Dexamethasone suppression tests

Table XXXVII. Suggestive symptoms, signs and laboratory test results, and specific investigations for secondary forms of hypertension

Cause of hypertension	Symptoms, signs, and routine and additional laboratory test results suggesting a secondary form of hypertension				Investigations	
	History	Physical examination	Routine tests	Additional tests	First choice (screening) tests	Confirmatory tests
Coarctation of the aorta	Intermittent claudication Headaches Syncope Epistaxis	Murmur heard in the precordial or interscapular area Diminished and delayed femoral artery pulse and decreased blood pressure in the femoral artery compared to simultaneous arm measurement Blood pressure difference between the left and right arm	Reverse E sign and rib notching on chest X-ray	Abnormalities on echocardiography	Echocardiography	CTA MRA
Renin-secreting tumour	Severe/resistant hypertension Polydipsia Polyuria	Cardiac arrhythmia (in severe hypokalaemia)	Hypokalaemia	Incidentally discovered kidney lesion	Renin level or plasma renin activity and aldosterone level	Kidney CT or MRI

*details see text: ABPM — ambulatory blood pressure monitoring; BP — blood pressure; CT — computed tomography; CTA — computed tomography angiography; ECG — electrocardiographic; HBP — home blood pressure monitoring; GFR — glomerular filtration rate; MIBG — metaiodobenzylguanidine; MRA — magnetic resonance angiography; MRI — magnetic resonance imaging; RAAS — renin-angiotensin-aldosterone system

may be helpful in identifying patients at an increased risk of OSA and should be included in the basic evaluation of a hypertensive patient.

Investigations for OSA include 4 types of diagnostic devices and systems:

- I. Complete polysomnography performed in a sleep laboratory.
- II. Portable (unsupervised) polysomnography, recording a minimum of 7 channels, including all that are necessary to evaluate the sleep structure and the breathing pattern.
- III. Respiratory polygraphy, or a limited recording of at 4 least parameters, including respiratory movements of the chest and abdomen, air flow through the upper airway, and arterial oxyhaemoglobin saturation, without evaluation of the sleep structure.
- IV. Recording of maximum 2 parameters, e.g., nocturnal pulse oximetry.

Use of different diagnostic devices and the diagnostic algorithm in cases of suspected OSA are summarized in Figure 9.

8.2.4. Diagnostic criteria¹

For the diagnosis of OSA, the criteria A, B, and D, or C and D must be met.

A. At least one of the following:

- inadvertent falling asleep, excessive daytime somnolence, ineffective sleep, tiredness, or insomnia;
- awakenings with the feeling of breathing cessation, dyspnoea or choking;
- habitual snoring or episodes of apnoea noted by the partner of the patient.

B. Polysomnography findings:

- at least 5 disordered breathing events per hour of sleep (AHI ≥ 5);
- respiratory muscle activity noted during these episodes;

C. Polysomnography findings:

- at least 15 disordered breathing events per hour of sleep (AHI ≥ 15);
- respiratory muscle activity noted during these episodes;

D. The above findings are not related to other sleep disturbances, conditions (including neurological disease), or use of medications or other substances.

Classification of the severity of OSA:

- mild OSA (AHI ≥ 5 and ≤ 15);
- moderate OSA (AHI > 15 and ≤ 30);
- severe OSA (AHI > 30).

¹Modified American Academy of Sleep Medicine (AASM) criteria. In the original document, the diagnosis is based on the respiratory disturbance index (RDI) which includes apnoeas, hypopnoeas, and respiratory effort related arousals (RERA). However, many authors use the apnoea-hypopnoea index (AHI) for the diagnosis and evaluation of the severity of OSA, particularly in studies on the prevalence of OSA among hypertensives. Clinically, the difference between RDI and AHI is usually not significant, and reliable evaluation of RERA episodes requires oesophageal pressure measurement during sleep, and the latter is not routinely recorded during polysomnography. If RERA episodes cannot be evaluated, then AHI = RDI




Figure 9. Diagnostic algorithm for obstructive sleep apnoea. AASM — American Academy of Sleep Medicine; BP — blood pressure; OSA — obstructive sleep apnoea; TIA — transient ischemic attack

8.2.5. Management of obstructive sleep apnoea

The management of OSA includes the following:

- body weight reduction (in all patients);
- avoidance of a supine position during sleep (in patients with confirmed positional OSA) or sleeping in a semi-sitting position (in patients with mild or moderate OSA without severe obesity);
- avoidance of alcohol intake (in all patients);
- smoking cessation (in all patients);
- avoidance of sedative-hypnotics and narcotic analgesics (in all patients);
- mandibular advancement devices (simple snoring and mild OSA not responsive to behavioural treatment);
- continuous positive airway pressure (CPAP) therapy [all patients with AHI > 30; patients with AHI > 15 and excessive daytime somnolence (Epworth Sleepiness Scale score > 10) or cardiovascular disease; in some cases CPAP may be considered in patients with AHI 5–15];
- surgical upper airway procedures (indications set on an individual basis, particularly in non-obese patients).

Studies indicate that regular use of CPAP for an appropriately long period of time during the night may be associated with BP lowering, particularly in patients with resistant hypertension, and may have a beneficial effect on the reduction of cardiovascular event risk.

8.2.6. Treatment of hypertension in patients with obstructive sleep apnoea

Limited data are available to develop recommendations regarding antihypertensive therapy in patients with OSA. Some evidence suggests benefits of diuretics, in particular aldosterone antagonists, in terms of not only improvement of BP control but also reduction of the severity of OSA. However, these studies were performed in small groups of patients and further studies are required. Further research is also necessary to determine potential benefits of renal denervation in these patients.

8.2.7. Care for patients with hypertension and concomitant obstructive sleep apnoea

The following issues should be evaluated during each visit related to the treatment of hypertension:

- in patients with previously undiagnosed OSA:
 - symptoms suggestive for, and the risk of OSA,
 - indications for investigations to diagnose OSA;
- in patients with established OSA without previous indications for CPAP therapy:
 - compliance regarding behavioural therapy for OSA,
 - indications for reassessment of the severity of OSA;
- in patients with established OSA and indications for CPAP therapy:
 - compliance regarding behavioural therapy for OSA,
 - compliance regarding CPAP therapy, and factors associated with noncompliance,

- frequency and duration of CPAP use during the night (based on data retrieved from the device memory).

8.3. Atherosclerotic renal artery stenosis

8.3.1. Definition

Hypertension due to renal artery stenosis, also known as renovascular hypertension, is a secondary form of hypertension caused by excessive renin production in the ischemic kidney. Significant renal artery stenosis does not only produce hypertension but also impairs excretory, endocrine, and homeostatic renal function and results in ischemic nephropathy. In some patients, renal artery stenosis is a cause of end-stage renal disease and the need for renal replacement therapy. Most commonly, renal artery stenosis is of atherosclerotic origin. The second most common cause of renal artery stenosis is fibromuscular dysplasia, which is discussed in a separate section of the present document.

8.3.2. Clinical presentation of atherosclerotic renal artery stenosis

Investigations for atherosclerotic renal artery stenosis should be considered particularly in patients with:

- hypertension that is:
 - severe,
 - resistant to treatment,
 - malignant (accelerated);
- episodes of unexplained flash pulmonary oedema (Pickering syndrome) and/or unexplained congestive heart failure;
- unexplained renal failure (including patients in whom renal replacement therapy is initiated);
- new-onset azotaemia or worsening of renal function following administration of a RAS inhibitor;
- hypokalaemia, particularly in patients treated with diuretics;
- an abdominal bruit;
- difference in kidney length > 1.5 cm or a small kidney of unknown cause.

Atherosclerotic renal artery stenosis should also be suspected in hypertensive patients with atherosclerosis in other vascular beds, including coronary arteries. The rates of atherosclerotic renal artery stenosis correlate with the severity of atherosclerosis in other vascular beds.

Symptoms and signs and laboratory test findings suggestive of atherosclerotic renal artery stenosis are summarized in Table XXXVII.

8.3.3. Screening and confirmatory diagnostic methods for atherosclerotic renal artery stenosis

8.3.3.1. Doppler renal ultrasonography

Doppler renal ultrasonography is recommended as the first-line noninvasive diagnostic test in patients

with suspected renal artery stenosis. It allows evaluation of the extra- and intrarenal arteries and localization of the stenosis. Assessment of the resistive index (RI) may be helpful for evaluating significance of a stenosis (difference versus the contralateral kidney ≥ 0.05) or predicting procedural outcomes.

In case of normal Doppler renal ultrasonography findings in patients with a significant clinical suspicion of renal artery stenosis, computed tomography angiography (CTA) or magnetic resonance angiography (MRA) of the renal arteries should be performed.

Doppler renal ultrasonography allows long-term follow-up of patients after correction of renal artery stenosis (to exclude recurrent stenosis) and evaluation of disease progression in medically treated patients. Follow-up examinations in revascularized patients should be performed immediately after the revascularization procedure and 6–12 months afterwards. Follow-up examinations to evaluate progression of borderline lesions treated medically should be performed annually. In these patient groups, urgent Doppler renal ultrasound reevaluation should be performed in case of acute worsening of BP control and/or renal function.

8.3.3.2. Computed tomography angiography

Computed tomography angiography is indicated to confirm the diagnosis of renal artery stenosis (in patients with $\text{eGFR} > 30 \text{ mL/min/1.73 m}^2$). Normal CTA findings exclude a hemodynamically significant stenosis of the main renal artery.

8.3.3.3. Magnetic resonance angiography

Magnetic resonance angiography is indicated to confirm the diagnosis of renal artery stenosis (recommendation class I, level of evidence B). The most effective imaging sequence is three-dimensional gradient echo (3D GRE) following intravenous administration of a contrast agent. Contrast-enhanced MRA allows excluding a hemodynamically significant stenosis of the main renal artery. Paramagnetic contrast agents in doses used for magnetic resonance imaging (MRI) are not nephrotoxic. However, a possibility of nephrogenic systemic fibrosis in patients with renal dysfunction should be borne in mind. Gadodiamide, gadopentetate dimeglumine and gadoversetamide are contraindicated in patients with eGFR below $30 \text{ mL/min/1.73 m}^2$, including those on dialysis therapy and patients with acute kidney injury. In patients with eGFR $30\text{--}60 \text{ mL/min/1.73 m}^2$, these contrast agents may be used provided that a 7-day interval between subsequent studies is maintained. Other paramagnetic contrast agents not listed above

may be used in patients with eGFR below 30 mL/min/1.73 m² provided that a 7-day interval between subsequent studies is maintained, and they may be used without these restrictions in patients with eGFR 30–60 mL/min/1.73 m².

8.3.3.4. Invasive renal angiography

Invasive renal angiography is performed to image the renal artery and its branches. It involves introduction of a pigtail catheter to the aorta at the level of renal arteries and injecting an iodine contrast agent. This method allows very good visualization of both the main renal artery and accessory renal arteries, and particularly their origin from the aorta. Selective renal angiography using catheters with appropriately curved tips is also recommended. Invasive renal angiography may be considered to confirm the diagnosis of renal artery stenosis in patients with a clinical suspicion of renal artery stenosis and equivocal non-invasive imaging findings.

8.3.4. Management of atherosclerotic renal artery stenosis

Until now, no randomized study showed a significant effect of interventional treatment on the course of hypertension, renal function, and cardiovascular event rate. The decision to implant a stent into a renal artery with an atherosclerotic stenosis should be based on multiple additional clinical factors and laboratory parameters, including the degree of BP control, presence and/or progression of renal dysfunction, and occurrence of the Pickering syndrome (unexplained flash pulmonary oedema). Decisions to proceed with invasive treatment and performance of revascularization procedures should be left to appropriately experienced hypertension units.

The 2017 ESC guidelines do not recommend routine revascularization of atherosclerotic renal artery stenosis. According to these guidelines, balloon angioplasty with or without stenting may only be considered in patients with atherosclerotic renal artery stenosis and recurrent unexplained congestive heart failure or flash pulmonary oedema, and in patients with bilateral renal artery stenosis and acute oligo- or anuric renal failure without renal atrophy.

In patients with unilateral renal artery stenosis, ACEI and ARB are effective in the treatment of hypertension and may decrease progression of nephropathy. Even in unilateral renal artery stenosis, however, treatment with ACEI or ARB requires caution and monitoring of renal function parameters. ACEI and ARB are contraindicated in bilateral renal artery stenosis and renal artery stenosis in the single kidney. It is difficult to accept the opinion voiced in the 2017

ESC guidelines that these drugs may also be used in the latter patient groups provided that they are tolerated (no adverse effect on the renal function) and the treatment is strictly monitored.

Diuretics, calcium antagonists, and β -blockers are also effective in lowering BP to target values in patients with renal artery stenosis (with some reports indicating an adverse effect manifested by eGFR reduction in patients with bilateral renal artery stenosis).

All patients with atherosclerotic renal artery stenosis should be treated in accordance with the guidelines on secondary cardiovascular disease prevention. This includes use of antiplatelet and lipid-lowering therapies.

8.4. Renal artery stenosis due to fibromuscular dysplasia

The present section of the guidelines was developed based on the most recent First International Consensus on the diagnosis and management of fibromuscular dysplasia (FMD), published in *Journal of Hypertension* and *Vascular Medicine* in early 2019.

8.4.1. Definition of fibromuscular dysplasia

Fibromuscular dysplasia is an idiopathic, segmental, non-atherosclerotic, and non-inflammatory vascular disease that leads to the development of stenoses in small- and medium-sized arteries. In addition to atherosclerosis, FMD is the second most common cause of renal artery stenosis, responsible for about 10% of cases. The diagnosis and confirmation of FMD requires that the following conditions are excluded:

- renal artery spasm or artifacts during CTA imaging;
- atherosclerotic origin of arterial lesions;
- inflammatory arterial disease;
- monogenic arterial disease (e.g., neurofibromatosis type I).

8.4.2. Clinical presentation

Fibromuscular dysplasia most commonly involves renal arteries and leads to the development of hypertension. Cervicocephalic (carotid, vertebral and intracranial) arteries are the second most common location of FMD. However, FMD may be present in virtually all vascular beds, and is often concomitantly present in several areas in the vascular system. The arterial wall affected by FMD is prone to dissection and the development of aneurysms.

Renal artery dissection may have serious clinical consequences, leading to an acute development of severe hypertension, loss of kidney function, and renal infarction. In patients with FMD, dissection

may also involve other arteries, including carotid arteries (which may lead to stroke or TIA) and coronary arteries (which may result in an acute coronary syndrome).

Based on radiological findings, arterial wall lesions typical for FMD are categorized as unifocal or multifocal.

The diagnosis of FMD requires that at least one unifocal or multifocal lesion is identified in the arterial wall.

If uni- or multifocal FMD lesions are present in one vascular bed, the presence of an aneurysm, dissection or tortuosity within another artery suggests a multivessel involvement. In contrast, an isolated presence of an arterial aneurysm, dissection or tortuosity is not sufficient for the diagnosis of FMD.

Indications for investigating a possibility of renal artery stenosis due to FMD in hypertensive patients include:

- age below 30 years, particularly in women;
- grade 3 hypertension ($\geq 180/110$ mm Hg), accelerated or malignant hypertension;
- resistant hypertension (BP above target values despite use of 3 antihypertensive medications in optimal doses, including a diuretic);
- unilateral small kidney without a previous history of uropathy;
- abdominal bruit without evidence of atherosclerosis or its risk factors;
- established FMD in at least one other vascular bed.

Of note, no specific genetic testing for FMD is available, and genetic testing is not justified in asymptomatic relatives of patients with FMD.

While awaiting further advances in genetic testing targeted at FMD, relatives of patients with FMD should currently undergo clinical evaluation and imaging to evaluate potentially involved vascular beds, particularly as suggested by clinical symptoms.

Symptoms and signs and laboratory test findings suggestive of renal artery stenosis due to FMD are summarized in Table XXXVII.

8.4.3. Investigations for renal artery stenosis due to fibromuscular dysplasia

— screening and confirmatory tests

Doppler renal ultrasonography should be performed as a screening test for renal artery stenosis due to FMD in all hypertensive women of reproductive age, particularly those planning pregnancy.

While duplex ultrasound to evaluate renal arteries is used as a screening method in women of reproductive age (particularly those planning pregnancy), in patients with a suspicion of renal artery stenosis due to FMD (with indications for testing as outlined

above) it remains a first-line imaging test only in tertiary care units with extensive experience with the use of this modality for the evaluation of the vascular system.

In patients with a suspicion of renal artery FMD, CTA remains the imaging test of choice, and MRA is the alternative imaging modality if CTA is contraindicated.

Imaging to identify FMD within renal, carotid, vertebral, and intracranial arteries should be considered if typical symptoms of FMD are present.

Invasive digital subtraction angiography of the renal arteries is recommended in patients with FMD confirmed by CTA or MRA if revascularization is clinically indicated. It may also be considered in patients with a high degree of suspicion of renal artery stenosis due to FMD if the diagnosis is uncertain based on non-invasive studies.

A separate issue is the choice of imaging modality in patients with suspected FMD in carotid, vertebral and intracranial arteries, as currently there is no evidence that would clearly favour any single modality. In most centres investigating for FMD, CTA or MRA remains the first-line imaging test.

In experienced centres, duplex ultrasound may be used for the initial evaluation of FMD in carotid arteries but it does not allow adequate assessment of distal segments of the internal carotid arteries, vertebral arteries, and intracranial arteries.

In patients with FMD, regardless of the presence and location of FMD lesions in various vascular beds, evaluation for intracranial aneurysms using CTA or MRA should be performed at least once.

It is also recommended that regardless of the location of initially identified FMD lesions, patients with FMD undergo, at least once, imaging of the vascular system from the brain to the pelvis to identify FMD in other vascular beds and screen for asymptomatic aneurysms or dissections.

8.4.4. Management of renal artery stenosis due to fibromuscular dysplasia

Antiplatelet therapy (acetylsalicylic acid 75–100 mg), if not contraindicated, is reasonable to prevent thrombotic and thromboembolic complications in patients with FMD.

Renal angioplasty is the treatment of choice for significant renal artery stenosis due to FMD (defined as translesional pressure gradient of 10% of the mean aortic pressure, i.e., $P_d/P_a < 0.90$). Stenting is not recommended, except for periprocedural dissection, primary renal artery dissection, or as a part of interventional treatment for renal artery aneurysm.

Surgical treatment of significant renal artery stenosis due to FMD should be considered in patients with:

- stenosis associated with a complex aneurysm;
- recurrent stenosis after two unsuccessful angioplasty procedures;
- a lesion involving renal artery bifurcation and its branches.

In hypertensive patients with renal artery stenosis due to FMD in whom revascularization is not indicated, appropriate follow-up is recommended:

- patients with FMD should undergo annual clinical follow-up on an outpatient basis;
- long-term clinical follow-up in patients with FMD should include clinical evaluation, renal function testing (in patients with FMD within renal arteries), and imaging studies (with insufficient data to suggest a specific algorithm for imaging during long-term clinical follow-up in patients with FMD);
- it seems reasonable to suggest that the extent of imaging — taking into account local availability of imaging modalities — should be determined individually based on the severity of FMD, the need to monitor progression of FMD complications (aneurysm or dissection), and previous revascularization procedures;
- in patients after spontaneous coronary artery dissection, imaging of the whole arterial system from the brain to the pelvis using CTA or MRA should be performed at least once to evaluate the presence of FMD and its complications in non-coronary arteries.

8.5. Primary hyperaldosteronism

8.5.1. Definition and prevalence

Primary hyperaldosteronism (PHA) is defined as a hormonally mediated form of hypertension caused by autonomous aldosterone production. Using this definition, PHA is diagnosed by showing that aldosterone level is unaffected by factors that affect its production in physiological conditions.

Primary hyperaldosteronism is not a pathogenetically uniform condition, and several forms of PHA are distinguished depending on the hormonal profile and the management approach:

- bilateral adrenal hyperplasia;
- adrenal cortex adenoma;
- familial hyperaldosteronism type I, II, III or IV;
- aldosterone-producing adrenal carcinoma;
- ectopic aldosterone production (by neoplastic tissue).

The prevalence of PHA in hypertensive patients depends on BP values. In the general hypertensive

population, PHA is present in up to 7% of patients (depending on the definition of PHA), while the prevalence of PHA in patients with resistant hypertension has been estimated at 6–23%.

8.5.2. Clinical presentation

Compared to patients with primary hypertension, patients with PHA have been found to have more frequent target organ damage such as left ventricular hypertrophy, increased carotid artery intima-media thickness, reduces arterial compliance, and microalbuminuria.

An adverse effect of aldosterone excess on the cardiovascular system has been highlighted, resulting primarily in myocardial, vascular, and renal damage. Myocardial hypertrophy and fibrosis lead to diastolic dysfunction, which may result in overt heart failure and is a substrate for arrhythmia (such as atrial fibrillation provoked by concomitant hypokalaemia).

In patients with PHA, the cardiovascular risk is significantly increased. Multiple studies showed a largely increased risk of coronary artery disease, myocardial infarction, heart failure, atrial fibrillation, and stroke in this population compared to matched patients with primary hypertension.

Symptoms and signs and laboratory test findings suggestive of PHA are summarized in Table XXXVII.

According to the Endocrine Society guidelines, investigations for PHA should be considered in patients:

- with BP values above 150/100 mm Hg in each of three measurements during separate visits (according to the 2019 PTNT guidelines expert panel, investigations for PHA should be considered in patients with grade 2–3 hypertension);
- with resistant hypertension;
- with spontaneous or diuretic-induced hypokalaemia;
- with hypertension and incidentally discovered adrenal tumour;
- with hypertension and OSA;
- with hypertension and a family history of early onset hypertension or a cerebrovascular event at a young age (< 40 years);
- in all hypertensive first-degree relatives of patients with established PHA.

In addition, investigations for PHA should be considered if the severity of target organ damage is disproportionate to the severity of hypertension.

8.5.3. Screening for primary hyperaldosteronism

The primary screening test for PHA is evaluation of the aldosterone-to-renin ratio (ARR). When evaluat-

ing and interpreting ARR, the following should be taken into consideration:

- in patients with hypokalaemia, potassium level should be brought to normal values by adequate supplementation, and dietary sodium intake should also be controlled (normal sodium diet);
- antihypertensive drug therapy should be appropriately modified:
 - drugs that significantly affect ARR should be withdrawn 4 weeks before testing, including spironolactone, eplerenone, triamterene, amiloride, thiazide/thiazide-like diuretics, and loop diuretics,
 - if ARR is nondiagnostic and hypertension may be adequately controlled using drugs that do not affect ARR (see below), the following medications should be withdrawn 2 weeks before testing: β -blockers, central α_2 -agonists (clonidine, methyldopa), nonsteroidal anti-inflammatory drugs (false-positive ARR), and ACEI, ARB, renin inhibitors, and dihydropyridine calcium antagonists (false-negative ARR),
 - drugs that have the least effect on ARR should be used to control hypertension, including verapamil, hydralazine, doxazosin, prazosin, and terazosin; however, some authors do not recommend using verapamil due to a potential effect on ARR in patients with adrenal adenoma and a somatic *KCNJ5* gene mutation;
 - in some situations, due to high BP values and concomitant conditions, appropriate modification of antihypertensive drug therapy is not possible and may be even associated with an increased cardiovascular risk; in these circumstances, the effect of drug therapy used in the patient should be taken into account;
- blood sampling for ARR should be performed in a sitting position between 9 and 10 AM, with the patient remaining upright (sitting, standing, walking) for 2–4 hours before blood collection, and the collected blood samples should be handled appropriately as agreed with the laboratory;
- due to the fact that interpretation of ARR is based on values considered abnormal in previous research studies and not the reference ranges for the assays used in the laboratories, ARR should be determined in laboratories in which the assays for aldosterone and plasma renin activity or renin level have been validated against the laboratories that have appropriate experience in the diagnosis of PHA;
- most commonly, the ARR value suggesting PHA is defined as:

- above 30 (aldosterone level in ng/dL and plasma renin activity in ng/mL/h); or
- above 750 (aldosterone level in pmol/L and plasma renin activity in ng/mL/h),
- for an elevated ARR to suggest PHA, plasma aldosterone level must be at least moderately increased [e.g., >15 ng/dL (150 pg/mL or 416 pmol/L)],
- ARR is also much affected by the lower limit of detection of plasma renin activity by a given assay, which may be different for different assays and laboratories (plasma renin activity value used for calculating ARR should not be lower than 0.2 ng/mL/min),
- in the recent years, commercial assays for plasma renin level (direct renin concentration) have been introduced; ARR conversion coefficient for renin level should be determined separately for each assay;
- other factors that may affect ARR value interpretation should also be taken into account, including age (low-renin essential hypertension in the elderly), creatinine level, concomitant conditions, difficult blood sampling, and use of hormonal drugs (e.g., oestrogen-containing preparations are associated with false-positive ARR values).

8.5.4. Confirmatory tests

The diagnosis of PHA is confirmed by establishing no effect of factors that normally decrease plasma aldosterone level or 24-hour urinary aldosterone excretion. In clinical practice, the two most commonly used tests are captopril suppression test and saline suppression test (with intravenous infusion of 2 litres of normal saline).

8.5.5. Differentiation between various forms of primary hyperaldosteronism

After the diagnosis of PHA has been established based on clinical symptoms and biochemical test findings, it is necessary to assess the nature and location of adrenal lesions. Various forms of PHA, in particular bilateral adrenal hyperplasia and adrenal adenoma, should also be differentiated.

Computed tomography (CT) is currently the standard method to evaluate adrenal lesions. Its sensitivity for detecting adrenal tumours exceeds 90%. CT allows assessment of the morphology of detected adrenal tumours.

Adrenal venous sampling is the method of choice for differentiating between various forms of PHA. It is indicated in all patients in whom adrenalectomy is considered. Exceptions include young patients (< 35–40 years of age) with a typical adenoma

on CT/MRI and normal contralateral adrenal gland who may be referred for surgery based on imaging only. However, many centres perform adrenal venous sampling also in such patients.

8.5.6. Management of primary hyperaldosteronism

In documented unilateral PHA due to an aldosterone-producing adenoma or unilateral adrenal hyperplasia, the treatment of choice is unilateral laparoscopic adrenalectomy, while patients with bilateral adrenal disease (idiopathic adrenal hyperplasia or bilateral adenomas) should be treated with aldosterone antagonists. Glucocorticoid-remediable aldosteronism should be treated with low doses of a long-acting glucocorticosteroid, e.g., dexamethasone.

In patients with bilateral adrenal disease and those with unilateral PHA who did not undergo adrenalectomy for various reasons, aldosterone antagonists are indicated. The initial spironolactone dose should be 12.5–25 mg once daily. The lowest effective dose should be determined by a gradual dose increase to 100 mg per day or more. To avoid high spironolactone doses, which may result in adverse effects, a thiazide diuretic, amiloride, or triamterene may be added. Eplerenone is a newer, selective mineralocorticoid receptor antagonist characterized by a weaker antiandrogenic effect and a weaker agonist effect on the progesterone receptor, and thus it is associated with a lower rate of adverse effects. The strength of its mineralocorticoid receptor antagonist effect has been estimated at 60% of that of spironolactone. Due to a shorter duration of action, this drug should be administered more frequently than once daily (initially 25 mg twice daily). However, eplerenone has not been licensed to treat PHA in the European Community.

8.6. Catecholamine-producing tumours

8.6.1. Definition

Adrenal catecholamine-producing tumours are known as pheochromocytomas, and the remaining extra-adrenal chromaffin cell tumours, which may also be hormonally active, are known as paragangliomas. Collectively, these are called pheochromocytoma-paragangliomas (PPGL).

8.6.2. Clinical presentation

The most common symptoms, usually paroxysmal in nature, include:

- paroxysmal BP surges (with typically large BP variation) which may last from several minutes to several hours;
- chronic hypertension;

- headache;
- excessive sweating;
- palpitation;
- pallor;
- tremor;
- anxiety;
- orthostatic hypotension.

Elevated glucose level may be found on biochemical testing. ABPM may show large BP variation and a decreased nocturnal BP fall, or even a non-dipping BP pattern and BP elevation during the night.

The provoking factors include exercise, abdominal pressure, large meals, some medications [ephedrine, phenylephrine, adrenocorticotrophic hormone (ACTH), phenothiazines, amphetamine, metoclopramide, tricyclic antidepressants, some anaesthesia drugs], stress, and alcohol intake. Catecholamine release by the tumour may also be induced by glucocorticosteroid administration. Pheochromocytomas may also remain asymptomatic (including with normal BP values).

8.6.3. Investigations for catecholamine-producing tumours

Indications for investigations for PPGL include:

- symptoms suggestive of PPGL, particularly if episodic in nature;
- medication-induced PPGL symptoms;
- an incidentally detected adrenal tumour (with or without hypertension);
- a gene mutation predisposing to PPGL or clinical evidence of a hereditary PPGL syndrome;
- a history of PPGL.

The major diagnostic criterion for a hormonally active PPGL is the finding of an elevated catecholamine metabolite serum level or urinary excretion, followed by tumour localization by imaging studies. The final diagnosis is based on histopathologic assessment of the resected tumour.

Plasma free metanephrines and urinary fractionated metanephrines are considered the most useful (i.e., most sensitive) biochemical tests. The highest sensitivity was reported for plasma free metanephrines (sensitivity 97–99%, specificity 82%). Urinary adrenaline and noradrenaline excretion is characterized by lower sensitivity and specificity, and the least diagnostic utility was shown for measurements of urinary vanillylmandelic acid and dopamine and plasma catecholamines. In rare cases, the clonidine suppression test may be performed.

Anatomical imaging studies in patients with PPGL should be performed after excessive catechol-

amine and/or their metabolite levels have been identified in plasma or urine. Localization studies for PPGL are also performed in PPGL gene mutation carriers. Useful imaging methods for PPGL include CT and MRI.

8.6.4. Management of catecholamine-producing tumours

Paroxysmal BP surges caused by catecholamine-producing PPGL may be best managed by administering phentolamine intravenously, usually at the dose of 2–5 mg repeated as needed.

Surgical removal of catecholamine-producing PPGL is the treatment of choice.

Appropriate preoperative patient preparation is important to reduce BP values, lower the heart rate, and control paroxysmal BP surges and other symptoms related to the excess of circulating catecholamines. For this purpose, α -blockers are administered orally for 2–3 weeks, including phenoxybenzamine (in increasing doses starting from 10 mg twice daily up to 1 mg/kg/day in 2–3 divided doses) or doxazosin (in gradually increasing doses starting from 2 mg up to 32 mg/day in 1–2 divided doses). If α -adrenergic receptor blockade is unsuccessful at controlling BP, a calcium antagonist (nifedipine or amlodipine) may be added as the second antihypertensive medication. In patients with significant tachycardia, addition of a cardioselective β -blocker is desirable but only after α -adrenergic receptors have been blocked. Catecholamines released by PPGL act on both α - and β -adrenergic receptors. Administering a β -blocker without previous α receptor blockade is contraindicated as it may lead to excessive α receptor activation and a significant BP rise. Combined α - and β -adrenergic receptor blockers (labetalol and carvedilol) should not be used. Correcting hypovolemia by adequate sodium and fluid intake to avoid orthostatic hypotension is also important during preoperative patient preparation.

8.6.5. Long-term care of patients with catecholamine-producing tumours

Following surgical PPGL removal, long-term patient follow-up is necessary that should include monitoring of BP values and plasma or urinary metanephrines. The initial postoperative evaluation to allow early identification of a possible tumour recurrence or development of hormonally active metastases should be undertaken depending on the overall clinical picture (genetic predisposition, tumour size, multiple tumours) at 6–12 months and then repeated annually.

8.6.6. Genetic testing in patients with catecholamine-producing tumours

The proportion of genetic forms of PPGL is currently estimated at 30–40%. Genetic testing for known mutations associated with PPGL is recommended in all PPGL patients. Modern genetic assay technologies allow testing for several PPGL-associated genes in a single sample.

8.7. Other rarer forms of secondary hypertension

Other rare forms of secondary hypertension, such as renin-secreting tumours, coarctation of the aorta, and Cushing syndrome, are summarized in Table XXXVII.

9. Recommendations on the diagnostic and therapeutic management of hypertension in children and adolescents

Hypertension is a major potentially modifiable cardiovascular risk factor. It is also a major clinical problem in adult medicine, and one of the most common chronic conditions in adolescents. In addition to the primary form, hypertension is also an important complication of other chronic conditions such as diabetes type 1 and 2, chronic kidney disease, coarctation of the aorta, congenital adrenal hyperplasia, and others. Although diabetes type 2 is relatively uncommon in Caucasian children and adolescents, children with overweight and obesity, and particularly those with carbohydrate intolerance and insulin resistance should be considered a potential risk group for hypertension. Another important problem is hypertension in children and adults born prematurely, particularly before 33 weeks of gestation, or as small for gestational age newborns.

The current guidelines are expanded and updated 2015 PTNT paediatric recommendations, previously presented in an expanded version in 2016 as The Children's Memorial Health Institute (IP-CZD) recommendations. The current edition of the PTNT paediatric recommendations has been developed based on the previously published fourth report of the National High Blood Pressure Education Program Working Group on Children and Adolescents (hereafter referred to as the Fourth Report), 2009 and 2016 paediatric ESH guidelines, ESC guidelines, AHA guidelines, 2017 American Academy of Paediatrics (AAP) guidelines, literature review, and expert opinion. Detailed recommendations were also based on the current recommendations of the respective society working groups.

Compared to the 2015 paediatric PTNT recommendations, the present edition includes extended epidemiological data on the prevalence and incidence of hypertension, extended or modified sections on the evaluation of target organ damage, hypertension in children with diabetes or chronic kidney disease, and a section on diagnostic and therapeutic challenges. A section has also been added on the approach to early diagnosis of hypertension during postdischarge care for children born below 33 weeks of gestation, as recommended in 2018 by the Polish Neonatal Society. Another important novelty is the current classification of hypertension, presented earlier in the 2016 ESH guidelines and 2016 IP-CZD guidelines.

Problems with defining target BP values have been discussed in a new subsection. The chapter on BP measurement principles includes new recommendations regarding BP measurements in newborns, neonates, and infants. References have been updated and expanded.

9.1. Epidemiology of hypertension in children and adolescents

Data from representative population studies indicate that hypertension is present in 3–5% of children and adolescents aged 0–18 years. In the OLAF and OLA studies, conducted in representative population samples, BP values above the 95th percentile for age and gender, calculated as the mean of the second and third BP measurement during a single visit, were noted in 6.9% of children aged 3 years, 7.7% of children aged 6–10 years, and 6.2% of youths aged 10–20 years.

The prevalence of hypertension among adolescents 14–18 years of age, defined in 18-year-olds using the adult definition, i.e., BP \geq 140/90 mm Hg, is 10–13%, similarly to that among young adults. Starting from puberty, hypertension is 3–4 times more prevalent in boys compared to girls. This gender difference is maintained until the fifth decade of life and is associated with a physiological BP rise during puberty in boys. In risk groups, such as obesity, chronic kidney disease, and diabetes type 1 and 2, the prevalence of hypertension is much higher ranging from 5–25% (diabetes type 1) to 30–40% (diabetes type 2). Prematurity and low birth weight are associated with a particular risk of developing hypertension. It has been estimated that at 3 years of age, hypertension is present 7.3% of children born prematurely. The risk of developing hypertension increases with younger gestational age at birth and is particularly high in persons born below 33 weeks of gestation.

Secondary hypertension is the major cause of hypertension in younger children. The higher rates of obesity in children and adolescents, the more common is primary hypertension which accounts for 50% of all hypertension cases in this age group.

9.2. Recommendations regarding screening for hypertension

According to the 2009 and 2016 ESH guidelines and the Fourth Report, BP should be measured in children above 3 years of age at least once a year during routine health supervision visits and visits related to health problems. In children below 3 years of age, BP measurement is recommended in selected cases in children with identified health problems (Tab. XXXVIII). Screening for hypertension in children below 24 months of age is not supported by society guidelines and epidemiological study findings, as BP measurements in younger children are at a high risk of failure due to lack of patient cooperation: the proportion of unreliable BP measurements is 41% in children at one year of age, 20% in children aged 3 years, and 9% of children aged 3–6 years.

9.3. Diagnosis of hypertension

9.3.1. Definitions and classification

of hypertension in children and adolescents

According to the generally accepted definition of hypertension in children, this diagnosis requires BP readings \geq 95th percentile for age, gender, and height during three independent measurements. A term “elevated blood pressure” has also been used in the literature to denote children with single BP values above 95th percentile, which is not sufficient for the diagnosis of hypertension. However, the meaning of the term “elevated blood pressure” changed when the 2017 AAP guidelines used this term to denote BP values previously categorized as prehypertension.

Classification of hypertension in children and adolescents depends on the method of BP measurement. **Due to diverging opinions on interpreting BP values in adolescents (see below), use of the adult BP classification is recommended in adolescents \geq 16 years of age.** Based on office measurements (using the auscultatory or oscillometric method), the following categories are distinguished (Tab. XXXIX):

- **normal BP** — BP values below the 90th percentile for age, gender, and height; in adolescents \geq 16 years of age, normal BP is $<$ 130/85 mm Hg;
- **high normal BP (Europe) or elevated BP (United States)** — SBP and/or DBP between the 90th and 95th percentile, and BP 130–139/85–89 mm Hg in adolescents \geq 16 years of age (note: in

Table XXXVIII. Blood pressure measurements in children and adolescents — indications and technique

BP should be measured in all children aged ≥ 3 years at least once a year and during any routine physician examination	
<ul style="list-style-type: none"> BP measurement is more reliable if the child has not eaten a meal within 30 minutes before the measurement, has not received medications that might affect BP, and has been resting in a sitting position with its back supported in a quiet environment for 5–10 minutes before the measurement During the initial consultation, BP should be measured on all four limbs. During the first year of life and until the child assumes the upright position, BP readings in the lower limbs are lower than in the upper limbs. During the second year of life in a child who stands/walks, BP readings in the lower limbs are higher by about 20 mm Hg, and at a later age they are higher by about 30–40 mm Hg Subsequent measurements should be performed on the right arm that is fully exposed, abducted and supported at the level of the heart The cuff should encircle the full circumference of the arm and cover at least two thirds of its length. The inflatable bladder should encircle at least 80% of the arm circumference, including the whole medial aspect of the arm. BP may be overestimated by as much as 30% if the cuff is too narrow, and underestimated if the cuff is too wide In infants, the body position has no significant effect on BP values. During sleep, SBP values in infants are lower by 5–7 mm Hg As readings obtained during the first measurement are usually overestimated, BP should be measured 2–3 times during a single examination BP readings above the 90th percentile by the oscillometric method require verification by the auscultatory method If the BP difference between the upper limbs is ≥ 5 mm Hg, this fact should be noted in the medical record 	
In younger children (< 3 years), BP should be measured in specific situations including:	
<ul style="list-style-type: none"> perinatal morbidity: prematurity, low birth weight, intensive therapy in the perinatal period congenital anomalies recurrent urinary tract infections, kidney and/or urinary tract disease malignancy solid organ or bone marrow transplantation use of drugs affecting BP symptoms and conditions associated with hypertension (neurofibromatosis, tuberous sclerosis, others), intracranial pressure rise 	

BP — blood pressure; SBP — systolic blood pressure

Table XXXIX. Blood pressure classification in children and adolescents based on office blood pressure measurements

	0–16 years of age	≥ 16 years of age
BP category	SBP and/or DBP percentiles	SBP and/or DBP values
Normal BP	$< 90^{\text{th}}$ percentile	$< 130/85$ mm Hg
High normal BP/prehypertension	$\geq 90^{\text{th}}$ and $< 95^{\text{th}}$ percentile	130–139/85–89 mm Hg
Hypertension	$\geq 95^{\text{th}}$ percentile	$\geq 140/90$ mm Hg
Grade 1 hypertension	95^{th} to 99^{th} percentile + 5 mm Hg	140–159/90–99 mm Hg
Grade 2 hypertension	$> 99^{\text{th}}$ percentile + 5 mm Hg	160–179/100–109 mm Hg
Grade 3 hypertension		$\geq 180/110$ mm Hg
Isolated systolic hypertension	SBP $\geq 95^{\text{th}}$ percentile and DBP $< 90^{\text{th}}$ percentile	SBP ≥ 140 and DBP < 90 mm Hg

BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure

the AAP classification, elevated BP is defined as values up to 129/80 mm Hg);

- hypertension** — mean SBP and/or DBP values $\geq 95^{\text{th}}$ percentile for age, gender, and height based on at least three independent measurements; in adolescents ≥ 16 years of age, the threshold for the diagnosis of hypertension is the same as in adults, i.e., $\geq 140/90$ mm Hg;
- white coat hypertension** — office BP measurements above the 95^{th} percentile, or $\geq 140/90$ mm Hg in adolescents ≥ 16 years of age but home BP or ABPM values within normal limits;
- grade 1 hypertension** — BP values between the 95^{th} percentile and 5 mm Hg above the 99^{th} percentile for age, gender, and height,

or 140–159/90–99 mm Hg in adolescents ≥ 16 years of age;

- grade 2 hypertension** — BP values more than 5 mm Hg above the 99^{th} percentile for age, gender, and height, or 160–179/100–109 mm Hg in adolescents ≥ 16 years of age; as use of the adult BP classification is recommended in the latter group, BP $\geq 180/110$ mm Hg is categorized as **grade 3 hypertension** in adolescents ≥ 16 years of age;
- isolated systolic hypertension** — SBP values $\geq 95^{\text{th}}$ percentile but DBP values $< 90^{\text{th}}$ percentile, or SBP ≥ 140 mm Hg but DBP < 90 mm Hg in adolescents ≥ 16 years of age.

Categories of severe hypertension and hypertensive urgencies and emergencies have not been defined

Table XL. Blood pressure classification in children based on ambulatory blood pressure monitoring*

Category	Office BP	Mean SBP and/or DBP by ABPM	SBP and/or DBP load
Normal BP	< 90 th percentile	< 95 th percentile	< 25%
White coat hypertension	≥ 95 th percentile	< 95 th percentile	< 25%
Masked hypertension	< 95 th percentile	≥ 95 th percentile	< 25%
High normal BP	≥ 90 th percentile and/or 120/80 mm Hg	< 95 th percentile	25–50%
Ambulatory hypertension	≥ 95 th percentile	≥ 95 th percentile	25–50%
Severe ambulatory hypertension	≥ 95 th percentile	≥ 95 th percentile	> 50%

*In patients ≥ 16 years of age, it is recommended to use adult cut-off values, i.e., 130/80 mm Hg for the 24-hour mean BP, 135/85 mm Hg for the daytime period and 120/70 mm Hg for the night-time period; ABPM — ambulatory blood pressure monitoring; BP — blood pressure; DBP — diastolic blood pressure; SBP — systolic blood pressure

in the classifications of hypertension in children that were adopted in European and U.S. guidelines. However, the following definitions of these conditions are used for practical reasons:

- **severe hypertension** — BP values more than 30 mm Hg above the 99th percentile for age, gender, and height;
- **hypertensive urgencies** — impending organ failure related to hypertension, requiring rapid intervention, usually with concomitant unspecific symptoms such as headache and vomiting;
- **hypertensive emergencies** — established or acute organ damage related to hypertension, mostly with organ failure, symptoms of encephalopathy, and Keith-Wagener-Barker grade 3 and/or grade 4 retinopathy on fundoscopy.
- **malignant hypertension** — in the past, this term was used to describe sudden BP increase with grade 3 and/or grade 4 retinopathy on fundoscopy, consistent with a hypertensive emergency in the present classification. According to the nomenclature in the 2016 paediatric ESC guidelines, malignant hypertension is defined as sudden BP increase with evidence of damage to at least three organs, or with concomitant microangiopathy. In practice, this definition is met by hypertension accompanying acute haemolytic-uraemic syndrome;
- **resistant hypertension** — hypertension that is not controlled despite treatment with three anti-hypertensive drugs including a diuretic.

The classification of hypertension based on ABPM also includes the category of masked hypertension, defined as abnormal BP values in ABPM and normal BP values in office measurements (Tab. XL). As similarly to office BP measurements, 95th percentile BP values by ABPM may exceed values considered normal in adults, the 2016 ESH guidelines recommend using 95th percentile-based threshold values in children and adolescents as long as they do not exceed the upper limit of normal values in adults. If 95th percentile BP values exceed normal values in adults, it

is recommended to use adult thresholds, i.e. 130/80 mm Hg for the 24-hour mean, 135/85 mm Hg for the daytime mean, and 120/70 mm Hg for the night-time mean.

9.3.2. Reference blood pressure values

9.3.2.1. Reference values for office measurements

It is recommended to use reference BP values for a given age, gender and height developed for specific BP measurement methods (auscultatory, oscillometric). For BP measurements using the auscultatory method, the most commonly used are reference values for children aged 0–18 years, developed for the population of the United States, Canada, Mexico, and Great Britain and published in the Fourth Report. For oscillometric (automated) BP measurements, reference values developed for the Polish population of children aged 3–18 years are recommended. As automated measurements are most commonly performed in everyday paediatric practice, these norms have been included in the new Polish child's health record book (2016).

9.3.2.2. Home blood pressure measurements

In children with the diagnosis of hypertension, home BP measurements using a validated oscillometric device are recommended (https://nadcisnienietetnicze.pl/dla_lekarzy/zalecenia_i_standardy/zalecenia_ptnt). Use of the reference values developed by

Table XLI. Reference home blood pressure values in boys and girls (95th percentile)

Height [cm]	Girls	Boys
120–129	119/74	119/76
130–139	120/76	121/77
140–149	122/77	125/77
150–159	123/77	126/78
160–169	124/78	128/78
170–179	125/79	132/78
180–189	128/80	134/79

Stergiou et al. for children and adolescents aged 6–18 years is recommended (Tab. XLI). No reference BP values were developed for HBPM in younger children. Evaluation based on BP measurements twice daily during at least 3 days, at equal intervals and before administration of antihypertensive medications, is considered reliable. It is recommended to perform 2–3 measurements at short intervals and record the last measurement. The optimal approach involves morning and evening BP measurements performed during 7 subsequent days. Adequate home BP measurements are considered a reliable indicator of the effectiveness of antihypertensive therapy.

9.3.2.3. Ambulatory blood pressure measurement

Ambulatory BP measurement using a validated oscillometric device is recommended in all children above 5 years of age in whom hypertension was diagnosed based on office BP measurements. Use of the reference BP values for ABPM developed by Wühl et al. and adopted in the 2014 AHA guidelines is recommended, and reference values for adults should be used in adolescents ≥ 16 years of age. Routine repeated ABPM is recommended to evaluate treatment effects.

9.3.3. Principles of blood pressure measurement

The technique of BP measurements is summarized in Table XXXVIII. Both automated (oscillometric) and auscultatory method may be used for routine measurements, and auscultatory method is used for confirming hypertension identified by automated measurements. Different principles apply to neonates and infants in whom auscultatory measurements are technically difficult and associated with a more pronounced white coat effect compared to automated (oscillometric) measurements. In this age group (up to 3–4 years of age), repeated automated measurements at short intervals are recommended. In addition, when BP measurements are indicated in newborns and neonates, they should follow the protocol described in the section *Neonatal hypertension*.

9.3.3.1. Interpretation issues

When interpreting BP measurements, age, gender, and height of the patient should be taken into consideration. Significant issues have been raised for neonates (see “Neonatal hypertension” below), children in the first year of life, and adolescents, as well as interpretation of oscillometric measurements including ABPM. In neonates and children in the first year of life in whom BP has been measured, evaluation of SBP only is recommended.

Of note, the 95th percentile SBP values for girls aged 13–18 years are much lower compared to those for boys, and at the age of 18 years, the 95th percentile values for both SBP and DBP in girls are 5–10 mm Hg lower than 140/90 mm Hg. The latter values correspond to 99th percentile in girls aged 18 years. Another phenomenon in adolescents is isolated systolic hypertension, seen particularly in boys without significant additional risk factors, frequently participating in sports. In these cases, spurious hypertension should be considered, with elevated SBP only in peripheral arteries, such as brachial artery, but normal central BP. No evidence of target organ damage is seen in these patients. For this reason, exposure to cardiovascular risk factors (intermediate phenotype) and the presence of subclinical target organ damage should also be considered when interpreting BP values (see below).

As most currently used ABPM devices are based on the oscillometric method, it should be emphasized that with this method, the mean arterial pressure (MAP) is directly evaluated, and SBP and DBP values are calculated using appropriate algorithms. In addition, results of some controlled paediatric studies (e.g., the ESCAPE study) and therapeutic recommendations (see below) are based on the analysis of MAP values. Another interpretation issue related to ABPM is the fact that using this method, higher BP values compared to office measurements are obtained in children below 10 years of age and those with the height below 120 cm. Due to lacking reference values and the above mentioned interpretation issues, routine use of ABPM is not recommended in children below 5 years of age.

In turn, 95th percentile values in tall children and adolescents may exceed BP considered normal in adults. These problems led to a change in the definition and classification of hypertension in adolescents ≥ 16 years of age (see: *Diagnosis of hypertension*).

9.3.3.2. Problems with defining target blood pressure values in children receiving antihypertensive treatment

The hypertension literature, including the ESH guidelines, the Fourth Report, the AAP guidelines, and expert opinions, defines threshold BP values for the diagnosis of hypertension and target BP values during treatment. These values differ, i.e., while the diagnosis of hypertension is defined as BP $\geq 95^{\text{th}}$ percentile, it is also recommended to lower BP below the 90th percentile in patients without concomitant conditions. However, setting these target BP values during treatment should also be associated with a change in the definition of hypertension by setting a lower threshold for the diagnosis, i.e., the 90th

percentile. This also necessitates defining the management in subjects with BP values in the 90–95th percentile range.

The current approach generates interpretation issues as it implies initiating treatment in children with BP values in the 90–95th percentile range. While non-drug therapy is not a problem, drug therapy should also be considered in those with BP values persistently in the high normal range despite non-drug therapy. Thus, a change in the definition of hypertension would be logical.

Indirect evidence in favour of setting target BP threshold at the 90th percentile in children with primary hypertension without concomitant conditions has been provided by studies in adult hypertensives, in particular the SPRINT trial and a 2016 meta-analysis that evaluated the efficacy of antihypertensive treatment in risk groups such as chronic kidney disease and diabetes. Arguments in favour of setting both the definition of hypertension in children and the target BP threshold at the 90th percentile have also been provided by the Cardiovascular Risk in Young Finns Study results. In this study, significantly higher BP values and higher arterial stiffness, as evaluated by the pulse wave velocity, were noted in adults who had high normal BP (i.e., 90–95th percentile range) in childhood and adolescence compared to those who had BP < 90th percentile in childhood and adolescence. In the 2017 AAP guidelines, new definitions of hypertension were recommended based on the SPRINT trial results. Lower target BP values (< 90th percentile or < 130/80 mm Hg) were also recommended in children with essential hypertension, with an argument that lowering BP below these thresholds leads to a further reduction in the rate of left ventricular hypertrophy. It should be noted, however, that the mean age in the SPRINT study was 67 years, and the participants were subjects with concomitant conditions who already received antihypertensive treatment. In addition, the method of BP measurements differed from those used in routine clinical practice. Furthermore, the studies cited in the AAP guidelines do not support further reduction in left ventricular mass (LVM) in children in whom BP was lowered below the 90th percentile. It should also be noted that in children and adolescents with primary hypertension, the strongest predictor of a reduction of LVM and the rate of left ventricular hypertrophy is not BP lowering but a reduction in visceral fat, as assessed by a reduction in waist circumference and normalization of metabolic disturbances. For this reason, target BP < 95th percentile (or < 140/90 mm Hg) has been recommended in the present guidelines in

children and adolescents with primary hypertension without concomitant conditions.

At the same time, the present guidelines recommend intensive non-drug treatment as the primary management strategy in essential hypertension.

Similar issues arise regarding the threshold for the diagnosis of hypertension and recommended target BP values in children with chronic kidney disease and diabetes. In paediatric patients with chronic kidney disease, drug treatment is recommended with BP values above the 90th percentile, and the target BP values depend on the presence of proteinuria. The current recommendations are based on the ESCAPE study results which showed that in children with proteinuria > 0.5 g/d, reducing MAP by ABPM below the 50th percentile is beneficial. Such benefits were not shown, however, in children with less severe proteinuria or without proteinuria. Despite this, the ESH guidelines and other expert opinions (presented in review articles) suggest target BP values below the 75th percentile in such cases. However, even studies cited in these documents do not offer any support for such a threshold.

9.4. Methods to evaluate target organ damage

Basic modalities to evaluate the severity of hypertensive target organ damage in children include evaluation of LVM, systolic function, and diastolic function by echocardiography, ECG, fundoscopy, and evaluation of renal function.

9.4.1. Evaluation of left ventricular mass

Left ventricular mass is a major criterion of target organ damage in hypertension. Echocardiography is the standard method to diagnose left ventricular hypertrophy, and ECG is only an additional diagnostic tool due to its low specificity and the need for age-specific interpretation (however, ECG also allows diagnosing arrhythmia and myocardial ischaemia, which is of practical importance as exercise/sport-based non-drug therapy is the mainstay of the management of primary hypertension). The most commonly used approach to evaluate LVM is based on the recommendations of the American Society of Echocardiography and uses the Devereaux formula. As LVM depends on height, it is recommended to calculate LVM indexed for height in meters to the power of 2.7 according to the formula suggested by DeSimone. Published reference values and percentiles of the LVM index calculated using this formula allow using this parameter in children over 1 year of age. A limitation of indexing LVM for height is the possibility to overdiagnose left ventricular hypertrophy in obese children

in comparison to indexing for fat-free body weight. Nevertheless, it is currently the most commonly used and recommended (2009 and 2016 ESH guidelines, Fourth Report, AAP) approach to evaluate LVM in children and adolescents that allows not only comparisons of echocardiographic findings in children of varying age but also comparing paediatric data with the results obtained in adults. However, as a hypertension classification consistent with the adult definitions has been introduced for adolescents ≥ 16 years of age, it is recommended to evaluate left ventricular hypertrophy in this age group using the adult approach (see below).

The principles of evaluating left ventricular systolic and diastolic function are the same as in adults. When evaluating diastolic function, a higher early (E) to atrial (A) inflow velocity ratio (E/A) in younger children should be taken into account. Tissue Doppler imaging is increasingly commonly used for the evaluation of left ventricular diastolic function, and respective paediatric reference values have been published. Findings using this method may be an additional parameter in the evaluation of target organ damage.

Definitions:

- left ventricular hypertrophy — LVM $\geq 95^{\text{th}}$ percentile for age and gender;
- severe ventricular hypertrophy — LVM index $\geq 51 \text{ g/m}^{2.7*}$.

In adolescents ≥ 16 years of age, left ventricular hypertrophy is diagnosed when LVM is $\geq 115 \text{ g/m}^2$ of body surface area in boys and $\geq 95 \text{ g/m}^2$ of body surface area in girls.

It is recommended to evaluate the relative left ventricular wall thickness (threshold value 0.42) and assess left ventricular geometry (normal geometry, concentric remodelling, concentric hypertrophy, eccentric hypertrophy).

*In adult studies, it has been shown that LVM above $51 \text{ g/m}^{2.7}$ is associated with a 4-fold higher risk of a cardiovascular event during 5 years of follow-up. LVM of $51 \text{ g/m}^{2.7}$ is approximately consistent with the 99th percentile of LVM in children and adolescents.

9.4.2. Fundoscopy

The principles of fundoscopic examination in children do not differ from those in adults. The Keith-Wagener-Barker classification is commonly used in clinical practice. A simplified classification includes 2 types of changes, benign and malignant. Benign changes are Keith-Wagener-Barker grade 1 and/or grade 2 lesions, and malignant changes are grade 3 and/or grade 4 lesions. The simplified classifica-

tion allows initial patient selection for more or less intensive treatment. Computer-assisted analysis of the width of retinal arteries and veins is increasingly used for the assessment of cardiovascular event risk, including that of stroke in adult hypertensives but this method has not been yet widely adopted in children with hypertension.

Although initial fundus evaluation is relatively simple, few paediatric hypertension specialists perform it in routine clinical practice. For this reason, this test is recommended as optional in the evaluation of children and adolescents with asymptomatic hypertension. However, it is recommended in symptomatic hypertension and hypertensive emergencies and urgencies.

9.4.3. Evaluation of renal damage

Routine methods to evaluate renal function include glomerular filtration rate (GFR) estimation using the Schwartz formula and/or serum cystatin C level measurements. Albuminuria is an indicator of hyperfiltration and/or microvascular damage. There are no commonly accepted reference values for albuminuria in children, and adult cut-off values are used in practice, with albuminuria above 30 mg/24 h corresponding to the 95th percentile values.

Hyperuricaemia is considered an abnormality specific for hypertension. However, it is not clear whether an increased uric acid level is a primary phenomenon or occurs secondarily to subclinical renal damage. Clinical and population studies indicate that in adolescents 12–17 years of age, uric acid level above 5.5 mg/dL is associated with a 2-fold increased risk of hypertension.

Non-obligatory additional tests to evaluate the extent of target organ damage in children and adolescents:

These include:

- evaluation of large artery damage [measurement of the intima-media thickness (IMT)];
- measurement of the pulse wave velocity (PWV).

During the last decade, multiple reports have been published that support using IMT and PWV measurements to evaluate target organ damage, and reference IMT and PWV values for children and adolescents aged 6–20 years have been reported (Tab. XLII and XLIII). These tests are already recommended (ESH 2016) as additional tools to evaluate target organ damage in children with hypertension. In clinical practice, however, carotid IMT and PWV measurements are still performed only in selected centres. For this reason, they are recommended as non-obligatory additional tests pending their wide introduction to clinical practice.

Table XLII. Referential values of common carotid artery intima-media thickness (50th and 95th percentile) in millimetres

Age (years)	50 th percentile [mm]		95 th percentile [mm]	
	Boys	Girls	Boys	Girls
6	0.37	0.36	0.44	0.43
7	0.37	0.37	0.44	0.43
8	0.37	0.37	0.44	0.44
9	0.37	0.37	0.45	0.44
10	0.38	0.37	0.45	0.44
11	0.38	0.38	0.45	0.44
12	0.38	0.38	0.46	0.44
13	0.38	0.38	0.46	0.45
14	0.39	0.38	0.47	0.46
15	0.39	0.38	0.47	0.46
16	0.40	0.39	0.48	0.46
17	0.40	0.39	0.48	0.46
18	0.40	0.39	0.48	0.47

Table XLIII. Referential values of pulse wave velocity (95th and 97th percentile) evaluated by tonometry (PulsePen; based on Reusz et al., Hypertension 2010) and the oscillometric method (Vicorder)

Age (years)	PulsePen (tonometry)		Vicorder (oscillometric method)	
	Boys 95 th percentile [m/s]	Girls 95 th percentile [m/s]	Boys 97 th percentile [m/s]	Girls 97 th percentile [m/s]
7	5.4	5.2	4.8	4.8
8	5.5	5.4	5.0	5.0
9	5.5	5.5	5.1	5.1
10	5.6	5.6	5.2	5.3
11	5.8	5.8	5.4	5.4
12	5.9	5.9	5.5	5.5
13	6.1	6.0	5.7	5.6
14	6.3	6.0	5.8	5.7
15	6.5	6.2	6.0	5.7
16	6.7	6.3	6.2	5.7
17	6.9	6.5	6.3	5.6
18	7.1	6.7		
19	7.3	6.9		

9.5. Principles of the differential diagnosis of hypertension in children and adolescents

Differential diagnosis of hypertension in children includes three steps (Tab. XLIV). The extent of diagnostic investigations depends on the severity of hypertension, patient's age, and concomitant conditions. Indications for more extensive investigations that include diagnostic steps 1 and 2 include younger patient's age (before puberty; an arbitrarily chosen age threshold in girls and boys in Poland is 12 years), grade 2 hypertension, and presence of target organ damage or concomitant chronic conditions. Diag-

nostic step 1 includes confirmation of the diagnosis of hypertension, exclusion of white coat hypertension, grading the severity of hypertension, evaluation of target organ damage, and basic laboratory tests to exclude secondary hypertension. Diagnostic step 2 includes tests that require hospital admission and is generally appropriate in children with grade 2 hypertension and younger children with hypertension. Diagnostic step 3 includes highly specialized tests reserved for patients in whom the diagnosis has not been established despite completed step 1 and 2 investigations or hypertension is resistant to treatment.

Table XLIV. Diagnostic steps in children and adolescents with hypertension

	Investigations	Comments
Step 1	<ul style="list-style-type: none"> Complete blood count, creatinine, sodium, potassium, chloride, calcium, bicarbonate, total cholesterol, triglycerides, HDL and LDL cholesterol, uric acid, glucose Urinalysis with culture Daily albumin excretion or albumin/creatinine ratio in a spot urine sample Kidney and renal artery Doppler ultrasound ECG Echocardiography with evaluation of LVM and the aortic arch cIMT measurement Transcranial ultrasound in neonates and infants ABPM in children > 5 years of age 	<p>Step 1 investigations should be performed in all patients with the diagnosis of hypertension</p> <p>cIMT measurement is optional</p> <p>ABPM is currently widely available; evaluation in children < 6 years of age has not been validated</p>
Step 2	<ul style="list-style-type: none"> Fasting blood glucose, oral glucose tolerance test, insulinemia in patients with BMI > 85th percentile Urinary catecholamines in younger children and all patients with grade 2 hypertension Plasma renin activity/renin level and aldosterone level in younger children and all patients with grade 2 hypertension Urinary steroid profile or urinary 17-keto- and 17-hydroxysteroids in younger children and all patients with grade 2 hypertension Thyroid hormones, vitamin D3 metabolites Renal scintigraphy (captopril test) in younger children and all patients with grade 2 hypertension 	<p>Oral glucose tolerance test is recommended as mandatory in patients with BMI > 85th percentile. Fasting insulin allows calculation of HOMA-IR, and insulin in the fasting conditions and at 120 minutes after glucose administration allows evaluation of the insulin sensitivity index. Multiple measurements during a 240-minute test allow calculation of areas under the glucose and insulin curves and are optional</p> <p>Urinary steroid profile is currently recommended over previously used urinary 17-keto- and 17-hydroxysteroids</p> <p>Measurements of thyroid hormones and vitamin D3 metabolites are recommended in patients with a suspicion of specific pathologies</p> <p>Dynamic scintigraphy is recommended to evaluate renal perfusion, urine excretion, relative renal function, and to estimate scarring (static DMSA scintigraphy is more sensitive in detecting scarring but does not allow evaluation of renal perfusion)</p>
Step 3	<ul style="list-style-type: none"> Non-invasive and invasive renal artery imaging (CTA, MRA, invasive angiography) Imaging to detect adrenal lesions/paraganglioma Non-invasive imaging of other vascular beds (visceral arteries, intracranial arteries) Molecular testing 	<p>Step 3 investigations are performed in patients in whom the diagnosis has not been established despite completed step 1 and 2 investigations and/or treatment is unsuccessful</p>

ABPM — ambulatory blood pressure monitoring; BMI — body mass index; cIMT — common carotid artery intima-media thickness; CTA — computed tomography angiography; DMSA — dimercaptosuccinic acid; ECG — electrocardiogram; HDL — high-density lipoprotein; HOMA-IR — homeostatic model assessment-insulin resistance; LDL — low-density lipoprotein; LVM — left ventricular mass; MRA — magnetic resonance angiography

The diagnosis of hypertension in children and adolescents should be confirmed by ABPM. Due to lack of reference values for younger children and the possibility of false positive diagnoses, only children above 5 years of age and/or above 120 cm in height should be routinely referred for ABPM. In younger children, the diagnosis of hypertension is based on office measurements, and ABPM is performed in individually selected cases.

In most children with hypertension, an immediate institution of antihypertensive therapy is not necessary, which usually allows complete diagnostic investigations before the treatment is started. Indications for initiating antihypertensive therapy before completion of the differential diagnosis include high

BP values (grade 2 hypertension with clinical symptoms) and/or advanced target organ damage and/or symptomatic hypertension. Except for hypertensive urgencies and emergencies, if drug treatment is necessary before completion of the diagnostic tests, long-acting dihydropyridine calcium antagonists are preferred as this drug class has the least effect on laboratory test findings.

9.6. General approach to the treatment of hypertension

General approach to and indications for the treatment of hypertension in children and adolescents are based on evaluation of the severity of hypertension, its nature (primary versus secondary), target organ




Figure 10. Treatment of hypertension in adolescents

damage, and concomitant conditions. Treatment monitoring and modifications based on ABPM are recommended (Fig. 10). Antihypertensive drug treatment and its success rates depend on the aetiology of hypertension.

9.7. Hypertension in chronic kidney disease

Hypertension secondary to chronic kidney disease is the major cause of hypertension in younger children, and the major cause of severe hypertension with target organ damage at all ages. Hypertension is present in more than 54% of children with chronic kidney disease, the more common, the lower GFR values. Hypertension is more common in children with chronic kidney disease due to glomerulopathy and occurs virtually in all in whom chronic kidney disease is due to haemolytic-uraemic syndrome. Among dialyzed children (chronic kidney disease stage 5), hypertension is present in up to 80% of patients. The pathogenesis of hypertension in chronic kidney disease includes both the renin and the volaemic mechanism. With decreasing GFR, sodium and water retention plays an increasingly important role in the pathogenesis of hypertension in patients with chronic kidney disease. Poorly controlled hypertension is a major cause of cardiovascular deaths during renal replacement therapy. In addition to proteinuria, hypertension is also the major risk factor for progression of chronic kidney disease. Goals of hypertension treatment in children with chronic kidney disease include both reduction of the risk of future cardiovascular events and delaying chronic kidney disease progression. According to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines, the BP threshold for initiating antihy-

pertensive therapy is the 90th percentile for gender and age. In contrast, the ESH guidelines (2009 and 2016) do not offer a clear threshold for therapy initiation. Based on prospective randomised studies, clinical observations, expert opinions, and the results of recently published metaanalyses of adult studies, antihypertensive therapy should be initiated in children with chronic kidney disease and BP values above the 90th percentile. It is recommended to monitor antihypertensive treatment by ABPM, and treatment effectiveness should be evaluated based on the mean 24-hour MAP. Target BP values depend on the severity of proteinuria. Reduction of the mean 24-hour MAP below the 90th percentile (50–90th percentile range) is recommended in children with chronic kidney disease without proteinuria or with proteinuria below 0.5 g per day, and below the 50th percentile in children with proteinuria above 0.5 g per day. Of note, the 2009 and 2016 ESH guidelines suggested (based on the expert opinion) reducing BP below the 75th percentile in children with chronic kidney disease without proteinuria. In our opinion, this recommendation is not justified by the ESCAPE study results which are cited by ESH. In addition, with such target BP values, the threshold for initiating antihypertensive therapy in chronic kidney disease should be automatically reduced from the 90th to the 75th percentile.

First-line antihypertensive drug classes in children with chronic kidney disease are RAAS inhibitors: ACEI and ARB. This is based on the pathomechanism of hypertension in chronic kidney disease and the published results of clinical trials and observational studies in children. Prospective multicentre studies showed the efficacy and safety of ACEI as

antihypertensive and renoprotective drugs (ramipril, enalapril), and similar data were obtained for ARB (losartan) in single-centre studies. In addition, observational studies showed better BP control in children treated with RAAS inhibitors compared to other antihypertensive drug classes. These drugs are not recommended in patients with a very low GFR ($< 15\text{--}20\text{ mL/min/1.73 m}^2$) due to a risk of significant renal function worsening and/or hyperkalaemia. Dual therapy with ACEI and ARB may result in an additional BP-lowering effect and a reduction of proteinuria. However, such treatment is currently not recommended if additional indications are not present (antiproteinuric effect) due to concerns regarding the safety of such combined treatment. Renin inhibitors were tested in clinical studies in children but their renoprotective effect was not evaluated and these drugs continue to be not licensed for use in children.

Achieving target BP in patients with chronic kidney disease usually requires multiple antihypertensive drugs. Individualization of further drug treatment depending on the clinical scenario is recommended in children. Beta-blockers are the recommended second-line drugs in children with chronic kidney disease due to their additional effect on the RAAS, antiadrenergic effect, and a reduction of proteinuria. Diuretics are recommended for fluid retention which is usually seen in children with GFR below $40\text{ mL/min/1.73 m}^2$. In children with large proteinuria or low GFR, often the diuretic dose has to be increased for an adequate therapeutic effect. Thiazide/thiazide-like diuretics retain their effectiveness only in patients with GFR above $30\text{--}40\text{ mL/min/1.73 m}^2$. Dihydropyridine calcium antagonists, previously used as first-line drugs in children with chronic kidney disease, are currently used as further choice drugs due to the fact that they increase hyperfiltration and proteinuria. However, this negative effect is absent or reduced in combination with RAAS inhibitors.

9.7.1. Hypertension in patients undergoing dialysis therapy

Hypertension is found in 55–79% of children with chronic kidney disease who require renal replacement therapy, including 56–79% treated with haemodialysis, 54–75% treated with peritoneal dialysis (in Poland 56% and 54%, respectively), and approximately 66% of patients after kidney transplantation. Of note, about 20% of these patients with hypertension remain untreated, and among those treated, hypertension is not controlled in nearly 75% of children. As BP measurements performed in dialysis units (before and after haemodialysis) show less

correlation with left ventricular hypertrophy compared to 24-hour ABPM in the interdialytic period, the diagnosis of hypertension in children on chronic dialysis treatment should be based on ABPM in the interdialytic period. The main risk factors for hypertension in children on chronic dialysis treatment are hypervolaemia and excessive salt intake. Other risk factors include young age (< 6 years), black race, female gender, acquired underlying kidney disease, anaemia in patients treated with haemodialysis, and duration of dialysis therapy, with a lower proportion of hypertension among patients undergoing dialysis therapy for a longer time. The most important element in the prevention and treatment of hypertension in children undergoing dialysis therapy is proper assessment of the volume status and achieving so called dry mass. It is believed that safe increase in body weight between dialysis sessions in children should not exceed 3% of the body dry mass. In paediatric patients undergoing peritoneal dialysis, the main cause of hypervolaemia is occult overhydration associated with uraemic cachexia. In these patients, residual diuresis plays a major role, as the higher is the latter, the lower BP increase related to hypervolaemia.

According to the 2005 National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF KDOQI) guidelines, BP values below the 95th percentile for gender, age, and height should be aimed for in children requiring chronic renal replacement therapy. Normal body dry mass should be achieved by intensification of dialysis therapy, with session duration increased to 5–8 hours, performing 4–6 procedures per week, and periodic use of haemodiafiltration and/or nocturnal dialysis. In patients undergoing peritoneal dialysis, increased ultrafiltration can be achieved by using higher osmolality dialysis fluids or icodextrin-containing fluids. Dihydropyridine calcium antagonists, ACEI, and ARB are used for drug therapy. There are no clear guidelines regarding drug choice but attention should be paid to hyperkalaemia that accompanies use of the two latter drug classes.

9.8. Renovascular hypertension

Renovascular hypertension is among the major causes of severe hypertension in children and adolescents. The most common cause of renovascular hypertension in this age group is FMD but in 20–40% of cases, renovascular hypertension is a complication of other conditions (syndromic renovascular hypertension), including neurofibromatosis type 1 ($> 15\%$). Renovascular hypertension may also be caused by a congenital or acquired (e.g., transplant




Figure 11. Diagnosis and treatment in children with renovascular hypertension. CNS — central nervous system; CTA — computed tomography angiography; MRA — magnetic resonance angiography; PTR — percutaneous transluminal renal angioplasty

renal artery stenosis) stenosis of the main renal artery or additional renal arteries and/or segmental branches.

9.8.1. Investigations for and the diagnosis of renovascular hypertension

The diagnosis of renovascular hypertension is based on a finding of a haemodynamically significant stenosis of one or both renal arteries (Fig. 11). Invasive angiography, often with selective renal artery catheterization, is still considered a reference method but should be performed only directly prior to intervention and during the same procedure if percutaneous treatment is planned based on the results of non-invasive imaging. Of note, the sensitivity and specificity of non-invasive imaging studies in children and adolescents with renovascular hypertension, such as Doppler ultrasonography (73% and 83%, respectively), MRA (80% and 62%) and CTA (93% and 81%), are significantly lower than those of conventional invasive angiography used to confirm the diagnosis.

Routine evaluation of renal vein renin activity or level is not recommended. This test may be performed in case of diagnostic uncertainties.

In the diagnostic algorithm for renovascular hypertension, scintigraphy is not recommended neither in the AAP guidelines nor in the adult guidelines, including the PTNT guidelines. A similar opinion is shared by the authors of the present guidelines but it should be noted (an expert opinion) that assessment of kidney excretory function may help guide a decision regarding surgical treatment in difficult cases (small children, percutaneous intervention not feasible), and after invasive treatment (percutaneous intervention/surgery) it allows evaluation of the treatment outcomes and is an additional criterion for the diagnosis of hypertensive nephropathy in a kidney with normal renal artery exposed to high BP values before treatment.

9.8.2. Treatment of renovascular hypertension

The ultimate and causative therapy of renovascular hypertension is an interventional treatment that

Table XLV. Drug treatment of renovascular hypertension.

Unilateral renal artery stenosis	Bilateral renal artery stenosis
ACEI/ARB (use in caution; usually in cases of lack of effect of other drugs) Dihydropyridine calcium antagonists β -blockers α -blockers Centrally acting imidazoline agonists	Diuretics Dihydropyridine calcium antagonists β -blockers α -blockers Centrally acting imidazoline agonists

ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers

eliminates the underlying cause of hypertension. Although drug treatment allows at least partial BP control, it does not cure the patient. In patients with Takayasu disease, immunosuppressive treatment should be considered causative therapy, and antihypertensive treatment, including invasive procedures, is targeted at the disease complications.

Drug treatment of renovascular hypertension depends on whether unilateral or bilateral renal artery stenosis is present (Tab. XLV).

9.8.2.1. Interventional treatment of renovascular hypertension

Interventional treatment of renovascular hypertension includes percutaneous transluminal renal angioplasty (PTRA) and surgical revascularization. PTRA may be successfully undertaken by balloon angioplasty with or without stenting. PTRA is the initial step of the interventional treatment and it should be attempted during invasive renal angiography. Complications of PTRA include mechanical vessel wall damage with formation of a pseudoaneurysm, thrombosis, arterial spasm, arterial wall laceration with bleeding, and entrapment of a balloon catheter within the vessel lumen. Some complications may require immediate surgical treatment, and thus both invasive renal angiography and PTRA should be performed in experienced paediatric centres with vascular surgical team backup. Local administration of an arterial smooth muscle relaxant should be always possible throughout the PTRA procedure. Drugs administered locally to relieve arterial spasm during PTRA include nifedipine, nitroglycerin, and sodium nitroprusside. According to experts' recommendations, prophylactic doses of low-molecular-weight heparin should be given for 1–7 days after the procedure in all cases of renal artery catheterization with PTRA, followed by administration of ASA at 1 mg/kg/day for 3–6 months.

Experience with stenting in renovascular hypertension in children and adolescents is relatively limited. Due to ongoing growth, stents mounted on

balloon catheters that can be redilated later are recommended. If it is possible to implant a stent with a diameter corresponding to the size of the renal artery in an adult person, implantation of a self-expandable stent is an alternative option.

Surgical treatment (revascularization or nephrectomy) is the ultimate approach to the treatment of renovascular hypertension. Surgical revascularization is indicated if drug therapy and PTRA were unsuccessful, and nephrectomy is indicated for unilateral renal artery stenosis with severely impaired function of the ischemic kidney. Nephrectomy is considered appropriate if the ischemic kidney is reduced in size and its relative function has decreased to below 10–15%. In children and adolescents in whom renovascular hypertension is associated with an involvement of visceral vessels and/or midaortic syndrome, the therapeutic approach must be planned individually and mostly commonly involves staged procedures, taking into consideration their possible extent, type and sequence, including renal revascularization.

Major surgical techniques used for renal revascularization in adolescents include repair using a prosthetic or autologous patch, and kidney autotransplantation following excision of the stenosed arterial segment.

9.9. Hypertension in children after surgical treatment of coarctation of the aorta

Hypertension is an invariable and major symptom of congenital coarctation of the aorta. Following interventional treatment that resulted in a correction of the anatomical stenosis, hypertension persists or develops after a period of normotension in about 32.5% (25–68%) of patients. In a large proportion of patients, exercise-induced hypertension may be diagnosed based on an exercise test.

9.9.1. Treatment of hypertension in children

after surgical treatment of coarctation of the aorta
Paediatric studies showed efficacy of ACEI (ramipril), ARB (candesartan), and β -blockers (metoprolol). AHA recommends ARB or ACEI and β -blockers as first-line drugs. In patients with coarctation of the aorta, routine annual ABPM and an exercise test every 2 years are recommended by the experts. Abnormal results of these tests are an indication for drug therapy and possible diagnostic investigations for recoarctation. According to both AHA and ESC guidelines, assessment of postprocedural aortic anatomy, including that of the aortic arch, as factors affecting development of recoarctation and severity of hypertension, requires repeated imaging studies (echocardiography, CTA, or MRA depending on the

patient's age), usually every several years. In patients with coarctation of the aorta and concomitant bicuspid aortic valve, this surveillance must also include the anatomy and (dys)function of aortic valve, and the degree of ascending aortic dilatation. In these patients, treatment of hypertension should be particularly aggressive.

9.10. Monogenic hypertension

The diagnosis of monogenic hypertension is based on the finding of a typical intermediate phenotype, which is often possible already during step 1 and 2 investigations. In some cases, a family history of hypertension associated with a typical phenotype or resistance to treatment may be ascertained (Tab. XLVI). The diagnosis of a specific form usually allows treatment directed at major abnormalities leading to hypertension. The evaluation and treatment of these forms of hypertension should be undertaken in tertiary care centres where the molecular diagnosis is available.

9.11. Primary hypertension

Primary hypertension is the major cause of hypertension in children above 12 years of age, accounting for about 50% of all cases of hypertension in the developmental period. Recently, it has been increasingly diagnosed also in younger children, including those below 6 years of age, and is associated with obesity. The predominant intermediate phenotype of primary hypertension is abnormal body composition with visceral obesity, abnormal muscle-to-adipose tissue proportion, and metabolic disturbances typical for metabolic syndrome (Tab. XLVII). In addition, a trend for higher uric acid level is typical for essential hypertension. The risk of target organ damage is related to the degree of metabolic abnormalities and the amount of visceral fat as evaluated by waist circumference.

9.11.1. Management of primary hypertension

Non-drug therapy including both dietary modifications and physical activity (moderate- to high-intensity exercise for 60 to 90 minutes daily) is of major importance in the management of primary hypertension. There are no contraindications to participate in specific types of sport/exercise. The dietary management is the same as for the prevention and treatment of obesity. In addition to limitations regarding the size, composition, and energy value of meals, a significant reduction in salt intake is also important. In practice, this calls for elimination of adding salt to foods.

Drug therapy should be considered in children with grade 1 essential hypertension in whom BP

was not adequately lowered despite 6–12 months of non-drug therapy. Drug therapy is indicated in children with grade 2 hypertension and/or target organ damage. Due to concomitant metabolic disturbances and the mechanism of action (increase in peripheral vascular resistance), β -blockers and diuretics are not recommended as first- and second-line drugs, and the preferred drug classes are ACEI, ARB, and dihydropyridine calcium antagonists. In post-pubertal women who do not use contraception, new generation β -blockers with vasodilatory properties may be recommended, as these drugs do not induce adverse metabolic effects and do not increase peripheral vascular resistance, as well as dihydropyridine calcium antagonists. Due to the fact that the risk of target organ damage is associated with metabolic disturbances and visceral obesity, it is recommended to include regular anthropometric measurements (body weight, waist circumference) in addition to evaluation of BP values and target organ damage when monitoring treatment effects.

9.12. Hypertension in children with diabetes

Diabetes type 1 is currently present in about 205,000 individuals in Poland, including about 20,000 children and adolescents. A four-fold increase in the incidence of diabetes type 1 has been noted over the last 25 years. With increasing rates of overweight and obesity in the Polish population, the number of children with diabetes type 2 also increases.

Based on few studies that used the generally accepted paediatric definition for the diagnosis, the prevalence of hypertension among children with diabetes type 1 has been estimated at 4–7%, while hypertension is present in as many as 23–40% of young patients with diabetes type 2. Consistent with the pathogenesis of diabetes type 2, a higher severity of metabolic disturbances and the metabolic syndrome is also seen in this patient group. Although hypertension is usually seen in patients with diabetes type 2, its occurrence in children and adolescents with diabetes type 1 is an increasingly common clinical problem. Hypertension is associated with an increased risk of micro- and macrovascular complications, cardiovascular disease and diabetic nephropathy which are major causes of morbidity and mortality among patients with diabetes type 1 and 2.

9.12.1. Pathogenesis of hypertension in children with diabetes

The pathogenesis of hypertension in children with diabetes type 1 is not been entirely clear. Comparison of the clinical presentation in children with essential hypertension and those with diabetes type 1 and hy-

Table XLVI. Monogenic hypertension syndromes — intermediate phenotypes, mode of inheritance, and treatment.

Syndrome	Gene	Mode of inheritance	Clinical phenotype	Serum K ⁺	Serum HCO ₃ ⁻	PRA	Serum aldosterone	Other biochemical abnormalities	Treatment
Liddle syndrome	SCNN1A SCNN1B SCNN1G	AD	Hypertension at varying age	↓ —	↑	↓	↓		Amiloride, triamterene
Apparent mineralocorticoid excess	HSD11B2	AR	More frequently low birth, nephrocalcinosis, hypertension at varying age 4 variants of disease	↓ —	↑	↓	↓	Excess of cortisol metabolites relative to cortisone metabolites	Distal nephron-acting diuretics (amiloride, triamterene), spironolactone/epplerenone, low doses of dexamethasone
Pseudohypoaldosteronism type II	WNK1 WNK4 KLHL3 CUL3	AD/AR	More frequently after puberty, clinical course and severity of biochemical abnormalities depend on the mutated gene	↑	↓	↓	↓ —	Hypercalciuria, normal GFR	Thiazide diuretics
MR receptor mutation	NR3C2	AD	In women hypertension may appear or exaggerate in the second trimester of pregnancy; may occur also in men; spironolactone may cause rise of blood pressure	↓ —	↑	↓	↓		Amiloride, triamterene, thiazide diuretics, non-steroid MR antagonists
Familial hyperaldosteronism type I (FH I)	CYP11B2	AD	Hypertension in childhood	↓	↑	↓	↑	Hybrid steroids in urine Positive dexamethasone suppression test	Dexamethasone/epplerenone/spironolactone
Familial hyperaldosteronism type II (FH II)	CLCN2	AD	Hypertension may develop in childhood but usually manifests in the 2 nd or 3 rd decade of life	↓	↑	↓	↑	Uni- or bilateral adrenal hyperplasia	Spironolactone/epplerenone, adrenalectomy
Familial hyperaldosteronism type III (FH III)	KCNJ5	AD	Varying clinical expression, severe hypertension may develop already in the first years of life Type A — severe clinical course, may require bilateral adrenalectomy; Type B — milder clinical course; drug treatment may be effective and sufficient	↓	↑	↓	↑	Hybrid steroids may be present in urine; bilateral adrenal hyperplasia may develop	Spironolactone/epplerenone, adrenalectomy

Table XLVI. Monogenic hypertension syndromes — intermediate phenotypes, mode of inheritance, and treatment.

Syndrome	Gene	Mode of inheritance	Clinical phenotype	Serum K ⁺	Serum HCO ₃ ⁻	PRA	Serum aldosterone	Other biochemical abnormalities	Treatment
Familial hyperaldosteronism type IV (FH IV)	<i>CACNA1H</i>	AD	Varying clinical expression; severe hypertension may develop already in preschool age	↓	↑	↓	↑	Normal adrenals	Spirolactone/eprenone, ARB as additional drugs Calcium antagonists probably effective as additional drugs
Familial hyperaldosteronism type V (FH V) (primary aldosteronism with seizures and neurological abnormalities, PASNA)	<i>CACNA1D</i>		Severe impairment of psychoneurological development. No family history — patients are not able to procreate due to severe disability	↓	↑	↓	↑	Normal adrenals	Spirolactone/eprenone, calcium antagonists ARB as additional drugs
11 α -hydroxylase deficiency	<i>CYP11B</i>	AR	Hypertension in childhood or infancy; precocious puberty	↓ —	↑ —	↓ —	↓	Excess urinary excretion of deoxycorticosterone and testosterone metabolites	Spirolactone, hydrocortisone
17 α -hydroxylase deficiency	<i>CYP17A1</i>	AR	Hypertension in childhood; delayed puberty	↓ —	↑ —	↓ —	↓	Sex hormone deficiency	Spirolactone
Familial glucocorticoid resistance	?	AR/AD	Hypercortisolaemia without features of Cushing syndrome	↓ —	↑ —	↓ —	↓	Hypercortisolaemia without features of Cushing syndrome	Spirolactone
Brachydactylia with hypertension	<i>PDE3A</i>	AD	Short stature, brachydactylia type E	—	—	— ↑	— ↑	Neurovascular conflict — posterior inferior cerebellar artery impingement on the medulla oblongata, possible arterial anomalies in other vascular beds	Combined treatment including ARB, β -blockers, calcium antagonists

AD — autosomal dominant; AR — autosomal recessive; ARB — angiotensin receptor blockers; GFR — glomerular filtration rate; PRA — plasma renin activity

Table XLVII. Definitions of metabolic syndrome in children according to the International Diabetes Federation, 2007

Age	Criteria
< 10 years	Metabolic syndrome should not be diagnosed. Extended diagnostic investigations are indicated in risk groups
10–15 years (< 16 years)	Waist circumference \geq 90 th percentile or \geq cut-off point for adult patients + 2 or more from the following criteria: — serum triglycerides \geq 150 mg/dL — serum HDL cholesterol < 40 mg/dL — SBP > 90 th percentile — fasting blood glucose \geq 100 mg/dL or type 2 diabetes
> 16 years	Criteria as in adults: Waist circumference \geq 94 cm in boys and 80 cm in girls + 2 or more from the following criteria: — serum triglycerides \geq 150 mg/dL — serum HDL cholesterol < 40 mg/dL in boys and < 50 mg/dL in girls — SBP \geq 130 mm Hg and/or DBP \geq 85 mm Hg or antihypertensive drug treatment — fasting blood glucose \geq 100 mg/dL or type 2 diabetes

DBP — diastolic blood pressure; HDL — high-density lipoprotein; SBP — systolic blood pressure

pertension suggests a role of common pathogenetic mechanisms, such as overweight and obesity, abnormal distribution of fat tissue, and related insulin resistance. Other factors are worse diabetes control and use of higher insulin doses. Similarly to the general population, a significant increase in the rate of hypertension since puberty is seen among children with diabetes type 1. Patients with diabetes type 1 are also characterized by an abnormal diurnal BP pattern, including non-dipping and rapid and significant morning BP surge. An association between elevated BP and an abnormal diurnal BP pattern with early markers of kidney damage suggests a role of both renal mechanisms and central BP regulation. Metabolic disturbances due to chronic hyperglycaemia, leading to arteriosclerosis and increased arterial stiffness, also contribute to the development of abnormal BP control in diabetic patients.

Although renal failure due to diabetic nephropathy usually develops only after many years of disease, early stages of diabetic nephropathy, characterized by increased urinary albumin excretion, are seen also in the paediatric population. Kidney damage due to diabetes type 1 in adolescents is directly associated with elevated BP values, and effective BP-lowering treatment reduces progression of this complication.

Among children and adolescents with diabetes type 2, hypertension is present at the time of diabetes diagnosis in 12–25% of patients and is associated

with disturbances related to insulin resistance and associated abdominal obesity. In addition, patients with diabetes type 2 present more commonly with atherogenic dyslipidaemia leading to early increased arterial stiffness, and patients with severe obesity develop renal dysfunction already prior to the development of overt diabetes type 2. In some patients, elevated urinary albumin excretion is present at the time of diabetes diagnosis. Concomitant presence of hypertension and other features of metabolic syndrome predisposes to more frequent and earlier development of cardiovascular disease and nephropathy compared to diabetes type 1. For this reason, patients with diabetes type 2 require comprehensive treatment of all disturbances related to metabolic syndrome.

9.12.2. Evaluation of hypertension in children with diabetes

In children and adolescents with diabetes, BP measurements should be performed at each visit, and at least twice a year in children below 7 years of age. In adolescents above 12 years of age with diabetes type, abnormal BP is defined as values above the 95th percentile or > 130/80 mm Hg regardless of the 95th percentile value. Performance of a 24-hour ABPM is recommended to confirm hypertension.

Due to an increased risk of cardiovascular disease in diabetic children, it is recommended to lower BP at least to the 90th percentile for age, gender, and height, or to \leq 120/80 mm Hg regardless of age.

Blood pressure lowering leads to regression of target organ damage but too intensive treatment with DBP reduction below 60 mm Hg may impair coronary flow.

Investigations for secondary hypertension should be performed using the approach discussed above.

9.12.3. Management of hypertension in patients with diabetes

The management of hypertension in young patients with diabetes should include lifestyle modifications, good metabolic control of diabetes, and drug therapy. A major role is played by non-drug therapy which included normalization of body weight (BMI below the 90th percentile for gender and age), regular physical activity (moderate- to high-intensity exercise for > 1 hour daily), and low-sodium diet (Tab. XLVIII).

For drug therapy, the recommended antihypertensive drug classes in children and adolescents with hypertension and diabetes are ACEI, or ARB in case of ACEI intolerance. Antihypertensive therapy in children with diabetes is also a nephroprotective

Table XLVIII. Treatment of hypertension in children with diabetes

Threshold values	Treatment
BP > 90 th percentile for age, gender, and height	Lifestyle changes*
BP > 90 th percentile for age, gender, and height despite life-style changes	+ ACEI/ARB
BP > 95 th percentile for age, gender, and height	Lifestyle changes* + ACEI/ARB

*Body weight reduction to normal values (body mass index < 90th percentile) and physical activity > 1 hour per day. It is recommended to monitor treatment effects using home blood pressure measurements and ambulatory blood pressure monitoring, including evaluation of nocturnal blood pressure fall (dipping). ACEI — angiotensin-converting enzyme inhibitors; ARB — angiotensin receptor blockers; BP — blood pressure

treatment and is based on similar principles. Effective drug therapy in patients with diabetic nephropathy delays development of end-stage renal failure. ACEI treatment in adolescents is continued for many years, which may lead to multiple adverse effects, such as cough, hyperkalaemia, headaches, impotence, and a risk of pseudoallergic reactions. Possible severe foetal complications should be also borne in mind, which is a potential problem when treating adolescent girls.

In one third of patients with diabetes type 2, monotherapy using ACEI or ARB is ineffective. These patients required combined drug therapy, and the second-line drugs are dihydropyridine calcium antagonists followed by vasodilating β -blockers and possible thiazide-type diuretics.

9.13. Hypertension with emergent and urgent indications for treatment

In the developmental period, hypertensive emergencies are virtually always caused by secondary hypertension, including due to acute kidney disease (acute glomerulonephritis, haemolytic-uraemic syndrome). Hypertensive urgencies related to an acute BP increase are also seen in children with primary hypertension. The management of hypertensive emergencies and urgencies has been evaluated in case reports and case series but not in controlled clinical studies, and recommendations presented in the guidelines (ESH 2009 and 2016, Fourth Report, AAP 2017) are based on expert opinions (Fig. 12). It is recommended to treat hypertensive emergencies in an intensive care unit, with intravenous line access and ECG, BP, respiratory function (pulse oximetry), and fluid balance monitoring. BP should be measured every 15 minutes until it is reduced by 30% compared to the baseline. Biochemical blood testing including renal function, electrolytes, and venous blood gases is recommended in all patients with hypertensive urgencies and emergencies, and if the aetiology of hypertension is not known, an initial differential diagnosis should also be performed including renal ultrasound with Doppler evaluation of the renal arteries and echocardiography to evaluate LVM. During subsequent hours of treatment, BP may be measured every 30–60 minutes depending on the clinical condition of the patient. The general ap-




Figure 12. Management of an acute blood pressure rise in children and adolescents

Table XLIX. Antihypertensive drugs used in hypertensive emergencies

Antihypertensive drug	Dosage	Comments
Labetalol	Bolus: 0.2–1 µg/kg per dose, maximum 40 mg/kg per dose Infusion: 0.25–3 µg/kg/hour	Contraindications: asthma, heart failure, diabetes May result in hyperkalaemia and hypoglycaemia Does not induce reflex tachycardia Onset of action: 5–10 minutes
Phentolamine	Bolus: 0.05–0.1 mg/kg per dose, maximum 5 mg per dose	May result in tachycardia Drug of choice in an adrenergic crisis Onset of action: 1–2 minutes
Furosemide	Bolus: 0.5–5 mg/kg per dose	Need to monitor potassium level (may cause hypokalaemia), useful in hypertension due to hypervolaemia Onset of action: 5–10 minutes
Hydralazine	Bolus: 0.2–0.6 µg/kg, maximum 20 mg per dose IV or IM	Often reflex tachycardia, fluid retention, headaches. Intravenous boluses should be given every 4 hours. Need for concurrent furosemide administration Onset of action: 10–20 minutes
Sodium nitroprusside	Infusion: 0.5–8 µg/kg/min	Risk of cyanide poisoning if long-term use or concomitant renal or hepatic failure Need to monitor cyanide levels during long-term use (> 48 hours) Onset of action: 1–2 minutes
Nitroglycerin	Infusion: 0.1–2 µg/kg/min	May result in methaemoglobinaemia; vasodilating effect mainly in the venous bed — effective in heart failure, limited effectiveness in children Onset of action: 2–5 minutes
Esmolol	Infusion: 100–500 µg/kg/min, maximum 1000 µg/kg/min	May result in bradycardia Contraindications: asthma, heart failure Very short duration of action Onset of action: 1–2 minutes
Nicardipine	Bolus: 30 µg/kg, maximum 2 mg per dose Infusion: 0.5–4 µg/kg/min	May induce reflex tachycardia Onset of action: 5–10 minutes
Enalaprilat	Bolus: 5–10 µg/kg per dose, maximum 1.2 mg per dose	May result in long-lasting hypotension, hyperkalaemia or acute renal failure Limited indications Onset of action: 15–30 minutes

IM — intramuscular; IV — intravenous

proach to the treatment of a hypertensive emergency in children and adolescents is based on gradual, controlled BP reduction. It is recommended to lower BP by 25–30% of the overall target BP reduction within 6–8 hours and by another 30% within the next 24–36 hours. Normal BP values (< 90th to 95th percentile) should be reached within 72–96 hours. Intravenous medications are used for the treatment of hypertensive emergencies, with the choice of the drug based on the aetiology of hypertension. In hypertensive emergencies, administration of an intravenous β -blocker (labetalol, esmolol) and a peripheral vasodilating agent (hydralazine, sodium nitroprusside, or nitroglycerin) is recommended. Due to fluid retention caused by peripheral vasodilation during prolonged therapy, an addition of a diuretic is also recommended. Oral treatment is initiated upon improvement of the general clinical condition of the patient. In hypertensive crisis due to acute or chronic kidney disease (patients on dialysis therapy), volume control and removal of excess fluid by dialysis, or using diuretics in patients with preserved glomeru-

lar filtration, is of major importance. Addition of a RAAS inhibitor is recommended in hypertensive emergencies due to microangiopathy.

In hypertensive urgencies, oral treatment is usually possible. BP should be lowered by 30% within the first 6 hours, and target BP values should be gradually reached during the next 36–48 hours. The approach to the management of an acute BP increase is shown in Figure 12, and dosing of the drugs used in hypertensive emergencies and urgencies, along with their adverse effects and contraindications, is summarized in Tables XLIX and L. In children with hypertensive urgencies and those with an acute BP increase who may be treated with oral medications, rapidly acting drugs are recommended, followed by institution of long-term antihypertensive therapy (Tab. LI).

Other selected forms of hypertension are listed in Table LII.

9.14. Neonatal hypertension

The incidence of hypertension in neonates is about 0.2–0.3%. However, it is much higher (0.81–9%)

Table L. Oral antihypertensive drugs used in hypertensive urgencies

Antihypertensive drug	Dosage	Comments
Captopril	0.1–0.2 mg/kg per dose, maximum 6 mg/kg/day	Need to monitor potassium and creatinine level Onset of action: 10–20 minutes
Clonidine	2–5 µg/kg per dose, maximum 10 µg/kg per dose	Adverse effects: dry mouth, sedation Onset of action: 30–60 minutes
Amlodipine	0.06–0.3 mg/kg per dose, maximum 5–10 mg per dose	Adverse effects: dizziness, reflex tachycardia Onset of action: 1–2 hours
Doxazosin*	1 mg per dose, maximum 4 mg/day	Adverse effects: dizziness, orthostatic hypotension Onset of action: 1–2 hours
Prazosin*	0.05–1 mg/kg/day in 3 doses, maximum 0.5 mg/kg/day	Adverse effects: dizziness, nausea, orthostatic hypotension Onset of action: 1–2 hours
Propranolol*	1 mg/kg/day in 2–3 doses, maximum 4 mg/kg/day up to 640 mg/day	Contraindications: asthma, bradycardia, cardiac arrhythmia, diabetes Adverse effects: bradycardia, bronchospasm, hypotension, Raynaud phenomenon Onset of action: 1–2 hours

*Drugs recommended in adrenergic hypertension (phaeochromocytoma/paraganglioma/neuroblastoma). In such cases, blood pressure should be first reduced using α -blockers (doxazosin, prazosin), followed by initiation of a β -blocker (propranolol)

Table LI. Recommended doses of oral antihypertensive drugs in children

Drug class	Drug	Initial dose	Number of daily doses	Maximum dose
Aldosterone antagonists	Eplerenone	25–50 mg/day	1–2	100 mg/day
	Spironolactone	1 mg/kg/day	1–2	3.3 mg/kg/day up to 100 mg/day
Angiotensin-converting enzyme inhibitors	Benazepril	0.2 mg/kg/day up to 10 mg/day	1	0.6 mg/kg/day up to 40 mg/day
	Captopril	0.3–0.5 mg/kg per dose	2–3	6 mg/kg/day up to 450 mg/day
	Enalapril	0.08–0.6 mg/kg/day	1–2	40 mg/day
	Fosinopril	0.1–0.6 mg/kg/day or 5–10 mg/day	1	40 mg/day
	Lisinopril	0.08–0.6 mg/kg/day up to 5 mg/day	1	0.6 mg/kg/day up to 40 mg/day
	Quinapril	5–10 mg/day	1	80 mg/day
	Ramipril	2.5–6.0 mg/day (6 mg/m ² /day)	1	20 mg/day
Angiotensin receptor blockers	Candesartan	0.16–0.5 mg/kg/day up to 4 mg/day	1	32 mg/day
	Irbesartan	75–150 mg/day	1	300 mg/day
	Losartan	0.75 mg/kg/day up to 50 mg/day	1	1.4 mg/kg/day up to 100 mg/day
	Valsartan	0.4 mg/kg/day	1	40–80 mg/day
	Olmesartan	2.5 mg/day	1	40 mg/day
Renin inhibitors	Aliskiren	2 mg/kg/day	1	6 mg/kg/day up to 600 mg/day
α- and β-blockers	Labetalol	1–3 mg/kg/day	2	10–12 mg/kg/day up to 1.2 g/day
	Carvedilol	0.1 mg/kg/ per dose up to 12.5 mg per dose	2	0.5 mg/kg per dose up to 50 mg/day
β-blockers	Atenolol	0.5–1 mg/kg/day	1–2	2 mg/kg/day up to 100 mg/day
	Bisoprolol/ /hydrochlorothiazide	0.04 mg/kg/day up to 2.5/6.25 mg/day	1	10/6.25 mg/day

Table LI. Recommended doses of oral antihypertensive drugs in children

Drug class	Drug	Initial dose	Number of daily doses	Maximum dose
β-blockers	Metoprolol	0.5–1.0 mg/kg/day	1–2	2 mg/kg/day
	Propranolol	1 mg/kg/day	2–3	4 mg/kg/day up to 640 mg/day
Calcium antagonists	Amlodipine	0.06–0.3 mg/kg/day	1	5–10 mg/day
	Felodipine	2.5 mg/day	1	10 mg/day
	Isradipine	0.05–0.15 mg/kg per dose	3–4	0.8 mg/kg/day up to 20 mg/day
	Nifedipine (slow release)	0.25–0.5 mg/kg/day	1–2	3 mg/kg/day up to 120 mg/day
Central α-agonists	Clonidine	2–5 μ g/kg per dose	2	10 μ g/kg/day
	Methyldopa	5 mg/kg/day	2–3	40 mg/kg/day up to 3 g/day
Diuretics	Amiloride	0.4–0.6 mg/kg/day	1	20 mg/day
	Chlorthalidone	0.3 mg/kg/day	1	2 mg/kg/day up to 50 mg/day
	Furosemide	0.5–2.0 mg/kg per dose	1–2	6 mg/kg/day
	Hydrochlorothiazide	0.5–1 mg/kg/day	1	3 mg/kg/day
	Triamterene	1–2 mg/kg/day	2	3–4 mg/kg/day up to 300 mg/day
α-blockers	Doxazosin	1 mg/day	1	4 mg/day
	Prazosin	0.05–0.1 mg/kg/day	3	0.5 mg/kg/day
	Terazosin	1 mg/day	1	20 mg/day
Vasodilators	Hydralazine	0.75 mg/kg per dose	4	7.5 mg/kg/day up to 200 mg/day
	Minoxidil	0.2 mg/kg per dose	1–3	50–100 mg/day

among prematurely born infants and with the presence of additional risk factors (umbilical vessel catheterization, patent ductus arteriosus, intraventricular haemorrhage) and concomitant conditions (40% in neonates and infants with chronic bronchopulmonary disease). Neonatal hypertension is generally of a secondary nature, related mainly to renal pathology, most commonly renovascular disease, but iatrogenic factors are also of major importance.

Despite multiple data on normal BP values in neonates depending on specific measurement techniques, the definition of hypertension is still based on the percentile values reported in the 1987 Report of the Second Task Force on Blood Pressure Control in Children and derived from BP measurements using a mercury sphygmomanometer (Tab. LIII). According to the 1987 Report of the Second Task Force, hypertension may be diagnosed in neonates when SBP values above the 95th percentile for chronological age are found on three occasions. Despite numerous methodological limitations and the fact that BP is currently nearly always measured by the oscillometric method, reference BP values given in the 1987 Report of the Second Task

Force are practical and easy to use. Table LIV shows a compilation of previous reference BP values that summarizes the 95th and 99th SBP, DBP, and MAP percentiles in 2-week-old neonates in relation to gestational age at birth.

Due to high rates of unreliable findings, including false positive results (up to 41% in children below 12 months of age), and resulting exposure to unnecessary investigations and treatment, BP measurement in healthy neonates is not recommended. BP measurements and investigations for hypertension are indicated in neonates born prematurely, those with concomitant congenital disease or other conditions associated with hypertension, and in neonates who require hospital admission. It is recommended to perform BP measurements in appropriate conditions and using the technique described in Table LV. Auscultatory technique should not be used in newborns, neonates and small children due to technical difficulties and more common white coat effect compared to automatic, oscillometric measurements. Automatic BP measurements using the oscillometric method are prone to an erroneous finding of elevated BP values at the first measurement. If BP measurements are

Table LII. Selected causes of secondary hypertension

Kidney disease	Glomerulonephritis Interstitial nephritis Kidney cystic disease Urinary tract defects Hydronephrosis Radiation nephropathy Renovascular (including vasculitis) Renin-producing tumours Obstructive lesions (renal stones, tumours, sub-pelvic stenosis) Diabetic nephropathy Hypertension after kidney transplantation	Related to medications, substances, and electrolyte disturbances	mTOR inhibitors (ciclosporin, tacrolimus) Erythropoietin Oral contraceptives (oestrogen, progestin) Glucocorticosteroids Mineralocorticoids Sympathomimetics MAO inhibitors Antidepressant drugs (SSRI, tricyclic antidepressants) Buspirone Modafinil Carbamazepine Methylphenidate Non-steroidal anti-inflammatory drugs Vitamin D overdose Hypercalcaemia Theophylline Amphetamine and derivatives (ephedrine, pseudoephedrine) Cocaine Heroin Ginseng Heavy metals Oncological drugs (anti-VEGF agents, cisplatin, carboplatin, paclitaxel, docetaxel, 5-fluorouracil)
Endocrine disease	Primary hyperaldosteronism Mineralocorticoid metabolism disturbances Congenital adrenal hyperplasia Cushing syndrome Pheochromocytoma Hyperparathyroidism Acromegaly Hyperthyroidism Hypothyroidism Carcinoid syndrome		
Cardiovascular disease	Coarctation of the aorta Aortic regurgitation Abdominal aortic syndrome		
Haematologic disease	Anaemia Polycythaemia		
Neurologic disease	Porphyrias Vegetative neuropathy Increased intracranial pressure Subcapsular hematoma Tetraplegia Guillain-Barré syndrome Brain trauma Brain tumour	Hypervolaemia	Renal failure Heart failure SIADH
Malignancies	Wilms' tumour Mesoblastic nephroma Neuroblastoma CNS malignancies	Obstructive sleep apnoea	Obesity Adenotonsillar hypertrophy Anatomical defects of the splanchnocranium
Acute stress	Burns Hypoglycaemia Hypoxia Perioperative period Psychogenic hyperventilation Abstinence in alcohol- and psychoactive substance-addicted individuals	Syndromic hypertension	Turner syndrome Marfan syndrome Klinefelter syndrome Down syndrome Klippel-Trenaunay-Weber syndrome Feuerstein-Mims syndrome von Hippel-Lindau disease von Recklinghausen disease Klippel-Feil syndrome Alagille syndrome Tuberous sclerosis Ehlers-Danlos syndrome
Gestational hypertension	Preeclampsia Eclampsia	Monogenic hypertension	Liddle syndrome Apparent mineralocorticoid excess Pseudohypoaldosteronism type II MR receptor mutation Familial hyperaldosteronism type I-IV 17- α -hydroxylase deficiency Familial glucocorticoid resistance Brachydactyly with hypertension
Reduced vascular resistance	Arteriovenous fistula Paget disease Beriberi		

CNS — central nervous system; MAO — monoamine oxidase; mTOR — mammalian target of rapamycin; SSRI — selective serotonin reuptake inhibitor; VEGF — vascular endothelial growth factor; SIADH — syndrome of inappropriate antidiuretic hormone

indicated in these age groups and the result of the initial measurement is abnormal, it is recommended to perform multiple repeated automated measurements at short intervals.

The approach to the differential diagnosis of hypertension and evaluation of target organ damage in neonates does not differ from that in older age groups (Tab. LVI).

Table LIII. Reference systolic blood pressure values (95th percentile) in neonates and infants

Age	95 th percentile SBP during the first year of life [mm Hg]	
	Boys	Girls
≤ 7 days	96	96
8–30 days	104	104
1 month	104	104
2 months	109	106
3 months	110	108
4 months	110	109
5 months	110	112
6–12 months	110	113

Table LV. Technique of blood pressure measurements in neonates

1. Measurement using an oscillometric device
2. 1.5 hours after feeding or a medical intervention
3. Child supine or prone
4. Selection of an appropriately sized cuff
5. BP measurement on the right arm
6. Earlier placement of the cuff and BP measurement after 15 minutes of a quiet rest
7. BP measurement during sleep or in a quiet awake state
8. 3 properly performed BP measurements 2 minutes apart

BP — blood pressure

Table LIV. Blood pressure values (95th and 99th percentile) at 2 weeks of life in neonates born between 26 and 44 weeks of gestation

Postconceptional age	95 th percentile	99 th percentile
44 weeks of gestations		
SBP	105	110
DBP	68	73
MAP	80	85
42 weeks of gestation		
SBP	98	102
DBP	65	70
MAP	76	81
40 weeks of gestation		
SBP	95	100
DBP	65	70
MAP	75	80
38 weeks of gestation		
SBP	92	97
DBP	65	70
MAP	74	79
36 weeks of gestation		
SBP	87	92
DBP	65	70
MAP	72	71

DBP — diastolic blood pressure; MAP — mean arterial pressure; SBP — systolic blood pressure

Postconceptional age	95 th percentile	99 th percentile
34 weeks of gestation		
SBP	85	90
DBP	55	60
MAP	65	70
32 weeks of gestation		
SBP	83	88
DBP	55	60
MAP	62	69
30 weeks of gestation		
SBP	80	85
DBP	55	60
MAP	65	68
28 weeks of gestation		
SBP	75	80
DBP	50	54
MAP	58	63
26 weeks of gestation		
SBP	72	77
DBP	50	56
MAP	57	63

9.14.1. Management of neonatal hypertension

Given the lack of long-term randomized studies to evaluate outcomes of antihypertensive therapy in neonates, most recommendations are expert opinions based on clinical experience. It is not recommended to initiate treatment in asymptomatic neonates with BP values between the 95th and 99th percentile. Initiation of drug treatment is justified when BP values are above the 99th percentile, or target organ damage is present with BP val-

ues above the 95th percentile. The general rule of drug treatment in newborns and infants is to choose medications depending on the potential aetiology of hypertension and the presence of concomitant abnormalities, and the treatment should be started with as low doses as possible. The safest approach is to use short-acting intravenous drugs (Tab. LVII). Oral antihypertensive therapy is reserved for neonates in a good overall clinical condition (Tab. LVIII).

Table LVI. Criteria for the diagnosis of target organ damage in neonates

Target organ damage	Diagnostic criteria
Eye fundus	Keith-Wagener-Barker grade 3/4 retinopathy
Albuminuria	No reference values
clMT	No reference values, technically difficult to evaluate
Features of hypertensive cardiomyopathy and aortopathy: <ul style="list-style-type: none"> Systolic dysfunction without left ventricular enlargement Left ventricular hypertrophy Indirect evidence of left ventricular diastolic dysfunction — left atrial enlargement Enlargement of the ascending aorta 	<ul style="list-style-type: none"> Ejection fraction < 60% Shortening fraction < 29% Left ventricular mass index > 47.4 ± 6.2 g/m² Left atrial dimension > 1.89 ± 0.27 cm Ascending aortic dimension > 1.04 ± 0.2 cm

clMT — common carotid artery intima-media thickness

Table LVII. Intravenous antihypertensive drugs used in neonates

Antihypertensive drugs	Dosage	Comments
Diazoxide	2–5 mg/kg per dose Rapid intravenous infusion	Slow infusion is ineffective, may cause acute hypotension Currently not routinely used for the treatment of hypertension
Enalaprilat	15 ± 5 µg/kg per dose Repeat q 8–24 hours Injections every 5–10 minutes	May result in long-term hypotension or acute kidney failure Use limited due to these adverse effects
Esmolol	Infusion: 100–300 µg/kg/min	Short-acting drug, continuous intravenous infusion necessary
Hydralazine	Infusion: 0.75–5.0 µg/kg/min Bolus: 0.15–0.6 µg/kg per dose	Frequent tachycardia; boluses given every 4 hours
Labetalol	Infusion: 0.25–3.0 µg/kg/hour Bolus: 0.2–1.0 µg/kg per dose	Contraindications: heart failure, bronchopulmonary dysplasia
Nicardipine	Infusion: 1–3 µg/kg/min	May result in reflex tachycardia
Sodium nitroprusside	Infusion: 0.15–10 µg/kg/min	Risk of cyanide poisoning if long-term use or renal failure

Table LVIII. Oral antihypertensive drugs used in neonates

Antihypertensive drug	Dosage	Dosing interval	Comments
Captopril	< 6 months: 0.01–0.5 mg/kg per dose, maximum 6 mg/kg/day	3 × day	Drug of choice in most neonates. Need to monitor potassium and creatinine level
Clonidine	5–10 µg/kg/day, maximum 25 µg/kg/day	2–3 × day	Side effects: dry mouth, somnolence, and constipation Rebound hypertension if stopped abruptly
Hydralazine	0.25–1.0 mg/kg per dose, maximum 7.5 mg/kg/day	3–4 × day	Tachycardia and fluid retention are frequent adverse effects
Isradipine	0.05–0.15 mg/kg per dose, maximum 0.8 mg/kg/day	4 × day	Effective in acute and chronic hypertension
Amlodipine	0.1–0.3 mg/kg per dose, maximum 0.6 mg/kg/day	2 × day	Hypotension less frequent than with isradipine
Minoxidil	0.1–0.2 mg/kg per dose	2–3 × day	Most potent oral vasodilator. Effective in resistant hypertension

Table LVIII. Oral antihypertensive drugs used in neonates (continued)

Antihypertensive drug	Dosage	Dosing interval	Comments
Propranolol	0.5–1.0 mg/kg per dose	3 × day	Maximum dose depends on heart rate If bradycardia is not present, the dose may be increased to 8–10 mg/kg/day Contraindicated in bronchopulmonary dysplasia
Labetalol	1.0 mg/kg/dose, maximum 10 mg/kg/day	2–3 × day	Contraindicated in bronchopulmonary dysplasia Need to monitor heart rate
Spironolactone	0.5–1.5 mg/kg per dose	2 × day	Results in potassium retention — need to monitor electrolytes Full effect seen after several days
Hydrochlorothiazide	1–3 mg/kg per dose	4 × day	Need to monitor electrolytes
Chlorothiazide	5–15 mg/kg/dose	2 × day	Need to monitor electrolytes

9.14.2. Early diagnosis of hypertension during postdischarge care for children born below 34 weeks of gestation

Prematurity and low birth weight are risk factors for the development of hypertension. It has been estimated that at 3 years of age, hypertension is diagnosed in 7.3% of children born prematurely. The risk of hypertension increases with age and is particularly high in children born at ≤ 33 weeks of gestation.

During specialist postdischarge care for children born prematurely in whom BP is measured, the approach presented above should be followed, using respective BP reference values (see: Neonatal hypertension).

9.14.2.1. Screening for hypertension during postdischarge care for children born prematurely (at ≤ 33 weeks of gestation)

The present guidelines have adopted the approach to postdischarge care for children born prematurely recommended by the Polish Neonatal Society in 2018 and by the Low Birth Weight and Nephron Number Working Group in 2017.

Children with the diagnosis of hypertension before discharge from a neonatal unit should be consulted and enlisted for specialist care in a paediatric

hypertension unit already before hospital discharge. Further diagnostic and therapeutic management should be based on the current paediatric PTNT, IP-CZD and ESC recommendations.

Children with accompanying kidney and urinary tract pathology should be enlisted for specialist care in a paediatric nephrology, hypertension, and urology unit. This will allow early planning of both the treatment of the urinary tract pathology and nephroprotective treatment.

In children in whom elevated BP values have not been identified before discharge from the neonatal unit should have BP measured at each visit. In patients below 3 years of age, automatic measurements on the right arm are recommended as the primary BP measurement method. If elevated BP values are identified, this should be confirmed by the auscultatory method. The diagnosis of hypertension is an indication for referral to a paediatric hypertension unit.

10. References

Supplementary file to this article available on-line on Arterial Hypertension website.

The inappropriateness of left ventricular mass and echoreflectivity in males with essential hypertension and different *CYP11B2* gene polymorphisms

Marina Lozinska, Vadym Zhebel, Sergiy Lozinsky

Vinnytsia National Medical University, Vinnytsia, Ukraine

Abstract

Background. The *CYP11B2* gene as the main controller of aldosterone plasma activity is likely to be responsible as for the BP level as for the expression of different traits of hypertensive cardiac remodeling such as increased left ventricular mass and myocardial fibrosis. The main objective of our study was to define the differences in myocardial remodeling depending on *CYP11B2* gene polymorphism. It was shown that some special techniques of echocardiography such as the assessment of inappropriate left ventricular mass and myocardial echoreflectivity proved additional information in patients with hypertensive heart disease. That's why these techniques were used for a more precise assessment of hypertensive cardiac remodeling.

Material and methods. Our study involved 150 males aged 45–60 years. They were divided into three groups: Group 1–50 patients with normal BP without any echocardiographic abnormalities, Group 2–52 patients with essential hypertension without left ventricular hypertrophy, and Group 3–48 patients with essential hypertension and left ventricular hypertrophy.

Results. It was found that in patients with inappropriate LVM the prevalence of CC genotype was almost twice higher than among those with appropriate LVM. On the other hand, hypertensive patients with CC genotype and LVH demonstrated higher echoreflectivity parameters.

Conclusions. We assume that CC polymorphism of *CYP11B2* may be an indicator of more expressed signs of hypertensive cardiac remodeling, in particular myocardial hypertrophy and myocardial fibrosis, in males with essential hypertension.

Key words: cytochrome P-450 *CYP11B2*; polymorphism; single nucleotide; left ventricular remodeling; essential hypertension

Arterial Hypertens. 2019, vol. 23, no. 4, pages: 240–247
DOI: 10.5603/AH.a2019.0020

Address for correspondence: Sergiy Lozinsky
Vinnytsia National Medical University, 54 Pirogova Str, 21018 Vinnytsia, Ukraine; e-mail: lozserg1@gmail.com

 Copyright © 2019 Via Medica, ISSN 2449–6170

Introduction

The *CYP11B2* gene as the main controller of aldosterone plasma activity is likely to be responsible for the BP level and expression of different traits of hypertensive cardiac remodeling. The main objective of our study was to define the differences in myocardial remodeling depending on *CYP11B2* gene polymorphism.

The increased left ventricular mass or left ventricular hypertrophy (LVH) remains the most often mentioned trait of hypertensive remodeling. A huge number of clinical trials confirmed the negative influence of LVH on the prognosis of essential hypertension. There is also some evidence that the left ventricular mass inappropriate to the BP level has additional negative predictive meaning [1–3].

Myocardial fibrosis is also an essential trait of hypertensive heart disease, but is more difficult to reveal compared with LVH. Changes in myocardial density that are following fibrosis could be detected by analysis of echoreflectivity. This technique is one of the possible approaches for the quantitative estimation of myocardial fibrosis. Echoreflectivity has been shown to have a strong correlation with collagen volume fraction [4]. Therefore, the echoreflectivity analysis was chosen for the assessment of myocardial fibrosis.

Material and methods

The study involved men who were the ambulatory patients of Vinnytsia Regional Dispensary. The sample size of the patients with EH was calculated using Altman nomogram. The statistical power β was set as 0.85 and p as 0.05. The minimal difference in LVM that needed to be determined in groups with different genotypes was accepted as $10 \text{ g/m}^{2.7}$ with the known mean SD approximately equal to $16 \text{ g/m}^{2.7}$. Based on such parameters, the minimal sample size was determined as 90 persons.

The protocol of the study was approved by the local ethics committee. The informed consent was mandatory for all participants. Between 2016 and 2017, 654 patients with EH aged 45–60 years were screened to identify 100 patients with EH. Among them, 58 had no irreversible target organs damages and 42 had left ventricular hypertrophy (LVH). Mean duration of the disease in patients with hypertension was 12.7 years with no substantial difference depending on LVH presence. Three BP measurements were performed at the first visit with 1–2 min interval between them. Additional measurements were made if the first two readings differed by $> 10 \text{ mm Hg}$.

The average of the last two BP readings was recorded. BP was measured in both arms at the first visit to detect possible between-arm differences. Then the arm with the higher value used as the reference. Diagnosis of hypertension was established according to the ESC recommendations (2018).

The control group consisted of 50 normotensive males of the same age without any pathological changes detected by echocardiography (ECG). The criteria for exclusion from the study were as follows:

- congenital or acquired heart defects;
- systemic connective tissue diseases;
- endocrine diseases;
- chronic kidney disease;
- secondary arterial hypertension;
- myocardial disease and heart failure, not associated with arterial hypertension;
- pulmonary arterial hypertension;
- hemodynamically significant arrhythmias (atrial fibrillation or flutter, AV block of 2nd and 3rd degree, high-grade premature beats);
- unsatisfactory ultrasound visualization of the heart;
- type 1 DM or uncontrolled type 2 DM;
- unstable or variant angina at the day of inclusion.

The patients included in the study did not receive antihypertensive therapy (treatment-naïve patients or those with a temporary pause in treatment for more than 1 month). Each participant underwent the following assessments: office blood pressure measurement, echocardiography with echoreflectivity analysis, and determination of the C-344T polymorphism of the aldosterone synthase gene *CYP11B2*.

Basic measurements of left ventricle such as end-diastolic and end-systolic dimensions (EDD and ESD), left ventricular mass, indexed by the body height^{2.7} (LVMI), ejection fraction (EF), and relative wall thickness (RWT) were obtained by echocardiography. Echocardiography was performed using “Sigma 5000” equipment (Kontron Medical, France). Based on echocardiography measurements the appropriateness of the left ventricular mass to the level of arterial pressure was determined by the formula proposed by De Simone et al. [1]:

$$LVMp = 55.37 + 6.64 \times \text{height (m)}^{2.7} + 0.64SW - 18.07 \times \text{gender (g)}$$

where LVMp is a predicted LVM, SW is a stroke work calculated by the formula: $SW = SBP \times SV \times 0.0144$, and the gender is 1 for men and 2 for women. In the case of exceeding the predicted values, the mass of the myocardium was considered as inappropriate.




Figure 1. Analysis of echoreflectivity. The left panel shows an left ventricle (LV) image with the region of interest (ROI) marked by a yellow rectangle. The right panel shows the grayscale spectrum of the ROI

Simultaneously with the standard ECG, we located 2 representative areas 20×10 mm in size (one — in the interventricular septum and another — in an LV posterior wall) on the images in the parasternal long axis view and saved them for the future processing. During the processing, the broadband (BB) of the black and white spectrum and mean color scale value (MCSV) of chosen regions was calculated by “Image J” software in the offline mode. Figure 1 demonstrates an example of such processing of the image. A more detailed description of this technique was published in [5].

According to majority of the sources, these parameters are the most reliable echoreflectivity markers of myocardial fibrosis. In an experimental study, its correlation with collagen volume fraction measured by biopsy was as high as 0.72 ($p = 0.03$) [4].

The polymorphism of the *CYP11B2* gene was determined in venous blood samples of all participants by the PCR method.

Genomic DNA was extracted using a set of reagents for the extraction of genomic DNA from a blood sample (LLC “NPF Synthol”, Russia). Polymorphic regions of *CYP11B2* gene were amplified by

a polymerase chain reaction. The final volume of the reaction mixture was 25 μ l and consisted of:

- specific oligonucleotide primers: 5'-CAG GAG GAG ACC CCA TGT GAC-3'; 5'-CCT CCA CCC TGT TCA GCC C-3';
- 2.5 μ l of 10x buffer for amplification;
- 2 mM of magnesium chloride;
- 0.2 mM of mixture of deoxynucleotide triphosphates (dNTP);
- 2.5 units of Taq DNA polymerase;
- 20–50 ng of genomic DNA.

25 μ l of mineral oil was poured into the test tubes.

The amplification was performed on the “Tertsik” amplifier (LLC “DNA-Technology”, Russia) using the amplification program, which includes the initial denaturation of 35 cycles at a temperature 94°C during 5 minutes.

For the identification of the alleles, we carried out a restrictive analysis of the amplicons using endonuclease restriction HaeIII (SibEnzyme, Russia) at 37°C .

The cleavage products of the polymorphic sites of *CYP11B2* gene were detected by electrophoresis in 5% agarose gel (Agarose SFR, AMRESCO, USA) in a single TBE buffer (50 mM Tris- H_3BO_3 and 2 mM EDTA, pH 8.0) for 1 hour at 3–4 V per 1 cm of gel. PbR322/AluI was used as a DNA marker of molecular weight. Gels were stained with ethidium bromide, followed by visualization of results with UV-light.

Results and discussion

A total of 50 men with normal blood pressure and 100 patients with AH were examined. Among the latter, 58 participants had hypertension without any damages of the target organs and, respectively, had normal LVM. Other 42 patients had hypertension with the ECG signs of LV hypertrophy, established based on the values of LVM index $\geq 50 \text{ g/m}^{2.7}$. The results of anthropometry and standard echocardiography are presented below (Tab. I).


The groups did not differ in age or height, but there were significant between-group differences in body mass ($p < 0.001$ by ANOVA test): the lowest values were observed in Group 1, and the highest — in Group 3 (Fig. 2). The same trend was seen for mean SBP and DBP values ($p < 0.001$) (Fig. 3).

In contrast, changes in LVM differed dramatically: the indexed mean values of LVM were almost the same in Group 1 and Group 2, while in Group 3 they were substantially higher (Fig. 3). Similar pattern of RWT changes was observed.

Table 1. Anthropometry and echocardiography measurements in Groups 1, 2 and 3


	NT (Group 1) M (SD) n = 50	EH (Group 2) M (SD) n = 58	EH + LVH (Group 3) M (SD) n = 42
Mean age (y.)	49.4 (5.0)	49.6 (5.8)	49.2 (5.8)
Height [cm]	175.1 (11.4)	176.5 (6.8)	178.4 (5.5)
Weight [kg]	81.0 (14.0)	94.7 (19.2)	103.6 (16.8)
SBP [mm Hg]	124.5 (16.4)	151.4 (18.2)	160.1 (23.0)
DBP [mm Hg]	76.1 (9.9)	92.3 (12.0)	96.1 (13.8)
EDD [mm]	48.6 (4.6)	48.9 (4.9)	52.1 (5.2)
ESD [mm]	32.7 (4.1)	33.3 (4.7)	34.3 (4.9)
EF (%)	60.5 (7.8)	59.8 (7.7)	61.9 (9.8)
LVM [g/m ²]	36.4 (14.5)	37.3 (7.0)	60.3 (12.0)
RWT	0.39 (0.06)	0.41 (0.09)	0.52 (0.11)

NT — normotension; EH — essential hypertension; EH + LVH — essential hypertension and left ventricular hypertrophy; SBP — systolic blood pressure; DBP — diastolic blood pressure; EDD — end-diastolic dimension; ESD — end systolic dimension; EF — ejection fraction; LVM — left ventricular mass; RWT — relative wall thickening

**Figure 2.** Means of body mass and 95% confidence interval (CI) in three groups of patients

We revealed that mean values of LVMP calculated using the formula (1) increased relatively evenly, while mean actual LVMI values changed unevenly and the differences between Group 3 and Group 2 were much more prominent and significant compared with the differences between Group 2 and Group 1 group (Fig. 4).

We noticed that despite very similar mean BP values in Group 2 and Group 3 (Fig. 3), Group 3 had the substantially greater LVM (Fig. 4). Moreover, the difference between actual LVM and LVMP in Group 2 was not significant [172.9 (34.9) *vs.* 162.4 (25.7) g; $p > 0.05$] while in Group 3 LVM was substantially higher than LVMP [287.4 (53.9) *vs.* 189.4 (37.8) g, $p < 0.001$ by the Wilcoxon paired test]. We believe that this is probable evidence of an intrinsic

**Figure 3.** The average values and 95% confidential interval (CI) of systolic blood pressure (SBP) (A) and diastolic blood pressure (DBP) (B) in three groups of patients




Figure 4. Average indexed left ventricular mass (LVM) and 95% confidence interval (CI) in three groups of patients

(genetic?) difference between patients with and without LVH. Therefore, some additional markers are required for more accurate prediction of appropriate LVM in these patients.

The distribution of *CYP11B2* polymorphism was almost the same in patients with normal BP and with EH regardless of LVH presence (Tab. II).

However, when all the patients were re-divided depending on predicted values of LVM, the differences in distribution become evident (Fig. 6).

As it can be seen in the diagrams, the prevalence of CC polymorphism of *CYP11B2* gene in males with inappropriate LVM was almost twice higher than among those with appropriate LVM. These differences were statistically significant by χ^2 criterion ($p = 0.015$).

Increasing echoreflectivity may be a marker of disorders the intrinsic architecture of myocardium. In theory, an increase in high-density elements of myocardium such as collagen fibers leads to the increase in ultrasound waves reflections that could be detected by the device capable to detect the difference in power of waves moving forward and backward, so-called backscatter. For more accurate estimation of backscatter, 2 or more myocardium regions were used for averaging of the results. In addition, myocardium backscatter is often compared with backscatter of the toughest heart structures of the same patient such as pericardium (calibration of backscatter). That's why this method is known as integrated calibrated backscatter.




Figure 5. Means and 95% confidence interval (CI) for actual (A) and predicted (B) indexed left ventricular mass (LVM)

Table II. The distribution of *CYP11B2* polymorphism in normotensive patients, hypertensive patients and hypertensive patients with left ventricular hypertrophy

Groups	CC	TC	TT	χ^2	p
NT (n = 50)	12	24	14	0.23	0.88
EH (n = 58)	12	29	17		
EH + LVH (n = 42)	7	24	11		

χ^2 — the significance of differences when compared EH and EH + LVH groups with NT group; NT — normotension; EH — essential hypertension; EH + LVH — essential hypertension and left ventricular hypertrophy




Figure 6. Frequencies (%) of *CYP11B2* gene polymorphisms in patients with appropriate (A) and inappropriate (B) left ventricular mass (LVM)

Table III. Mean echoreflectivity parameters in Groups 1, 2 and 3. Data are presented as means (SD)

Parameter	Group 1	Group 2	Group 3
MCSV	62.3 (28.5)	59.9 (32.4)	74.5 (36.5)
BB	105.3 (51.5)	109.0 (37.0)	135.4 (22.8)

MCSV — mean color scale value; BB — broadband of the black and white spectrum

Another way of reflected signal estimation is processing of grayscale images of myocardium by the external software in the offline mode such as “Image J”. Since the gray scale has 256 standard gradations represented by a certain number of pixels, the general image information can be represented as a column (frequency) graph, which displays the number of pixels for each tint. The most useful parameters are the mean color scale value (MCSV) and broadband (BB). As with the integrated calibrated backscattering analysis, in order to obtain more objective information, a minimum of 2 regions of interest (ROI) were chosen: one is in the middle of the interventricular septum, and the other — in the posterior wall of left ventricle. The values of MCSV and/or BB could be calculated as a mean of these two readings.

Echoreflectivity was estimated in all of the patients in the above-mentioned manner. Obtained results are shown below (Tab. III).

In patients with EH and LVH (Group 3) the values of MCSV were higher than in normotensive and hypertensive patients without LVH, although the statistical significance of the differences was low ($p = 0.066$). The range of the grayscale spectrum (BB) in patients with LVH was significantly higher ($p < 0.001$) than in other study groups (Fig. 7) and looked similar to the trend of LVM (Fig. 4). This fact

supports our suggestion about intrinsic differences between patients with and without LVH.

Echoreflectivity was also analyzed in groups created on the basis of the predicted values of LVM and having appropriate or inappropriate LVM. As it was mentioned earlier, these groups consisted of 45 and 105 men respectively. The mean values of MCSV and BB were higher in males with inappropriate LVM than in those with appropriate LVM (Fig. 8).

At the present time, we know that hypertensive cardiac remodeling includes the increase in the thickness of muscle fibers and myocardial mass but also changes in microcirculation with the extension of relative coronary insufficiency and myocardial fibrosis. The detection of exceed in myocardial mass is a relatively simple diagnostic task. However, myocardial fibrosis and coronary failure often remain unnoticed, which leads to the underestimation of their role in hypertensive heart disease. On the other hand, the old question of whether LVH is always a pathological process in persistent hypertension, and where the borderline passes between compensatory and pathological hypertrophy, still remains open. Our recent results allow assuming that the determination of the appropriateness of the left ventricular myocardial mass to the level of blood pressure could be useful not only concern-




Figure 7. Means and 95% confidence interval (CI) for mean color scale (MCSV) (A) and broadband of the black and white spectrum (BB) (B) in three groups of patients




Figure 8. Means and 95% confidence interval (CI) for mean color scale (MCSV) (A) and broadband of the black and white spectrum (BB) (B) in groups with appropriate and inappropriate left ventricular mass (LVM)

ing the severity of hypertrophy but also concerning echorefectivity that is considered a marker of myocardial fibrosis. In this case, a greater prevalence of the inappropriate LVM in patients with such a structure of the gene *CYP11B2* could indicate on a genetic predisposition for more expressive manifestations of hypertensive heart disease at the same level of blood pressure. Therefore, we can assume that the CC polymorphism of the *CYP11B2* gene could serve as a marker of more expressed remodeling, including myocardial fibrosis and myocardial hypertrophy.

The method used to determine the appropriate mass of the left ventricle in this study showed almost linear growth of the calculated values in the

study groups, while the real values had a character that resembles an exponential curve. Therefore, despite the proven additional predictive value of the appropriate LV mass, this method requires adaptation to real practice. Another conclusion is that the mass of left ventricle does not depend directly on the level of BP. Consequently, other factors, responsible for the hypertensive cardiac remodeling, besides the hemodynamic load, may be hypothesized. There is growing evidence that at least some of these factors may be of genetic origin and aldosterone synthase gene could be among them. At least, the data obtained are not in controversy with such a hypothesis, but to some extent they support it.

Therefore, the next step may be to compare the mass and myocardial reflectivity in patients with different *CYP11B2* polymorphisms, standardized for other parameters and risk factors.

References

1. de Simone G, Verdecchia P, Pedrini S, et al. Prognosis of inappropriate left ventricular mass in hypertension: the MAVI Study. *Hypertension*. 2002; 40(4): 470–476, doi: [10.1161/01.HYP.0000034740.99323.8A](https://doi.org/10.1161/01.HYP.0000034740.99323.8A), indexed in Pubmed: [12364349](https://pubmed.ncbi.nlm.nih.gov/12364349/).
2. Shemirani H, Hemmati R, Khosravi A, et al. Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction. *J Res Med Sci*. 2012; 17(2): 133–137, indexed in Pubmed: [23264785](https://pubmed.ncbi.nlm.nih.gov/23264785/).
3. Lim YH, Lee JU, Kim KS, et al. Association between inappropriate-ness of left ventricular mass and left ventricular diastolic dysfunction: a study using the tissue Doppler parameter, e/e' . *Korean Circ J*. 2009; 39(4): 138–144, doi: [10.4070/kcj.2009.39.4.138](https://doi.org/10.4070/kcj.2009.39.4.138), indexed in Pubmed: [19949602](https://pubmed.ncbi.nlm.nih.gov/19949602/).
4. Ciulla M, Paliotti R, Hess DB, et al. Echocardiographic patterns of myocardial fibrosis in hypertensive patients: endomyocardial biopsy versus ultrasonic tissue characterization. *J Am Soc Echocardiogr*. 1997; 10(6): 657–664, doi: [10.1016/S0894-7317\(97\)70028-2](https://doi.org/10.1016/S0894-7317(97)70028-2), indexed in Pubmed: [9282355](https://pubmed.ncbi.nlm.nih.gov/9282355/).
5. Hiremath P, Bauer M, Cheng HW, et al. Ultrasonic assessment of myocardial microstructure. *J Vis Exp*. 2014(83): e50850, doi: [10.3791/50850](https://doi.org/10.3791/50850), indexed in Pubmed: [24458028](https://pubmed.ncbi.nlm.nih.gov/24458028/).

Sleep duration and cardiovascular risk: results of the large-scale epidemiology study ESSE-RF

Mikhail Bochkarev¹, Lyudmila Korostovtseva¹, Elena Medvedeva¹, Oxana Rotar¹, Yurii Sviryaev^{1,2}, Yulia Zhernakova³, Svetlana Shalnova⁴, Alexandra Konradi^{1,5}, Irina Chazova^{3,6}, Sergey Boytsov^{4,7}, Eugene Shlyakhto¹

¹Almazov National Medical Research Centre, St. Petersburg, Russian Federation

²Sechenov Institute of Evolutionary Physiology and Biochemistry of RAS, St. Petersburg, Russian Federation

³Russian Cardiology Research and Production Complex, Moscow, Russian Federation

⁴National Research Centre for Preventive Medicine, Pirogov University, Moscow, Russian Federation

⁵ITMO University, St. Petersburg, Russian Federation

⁶M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russian Federation

⁷National Medical Research Center of Cardiology, Moscow, Russian Federation

Abstract

Background. The recent data suggest that sleep disorders are associated with cardiovascular diseases. We assessed the relation between self-reported sleep duration and cardiovascular and metabolic disorders in the large-scale epidemiological study.

Material and methods. The ESSE-RF is a population-based cross-sectional study involving 22,258 participants aged 25–64 years from 13 regions of the Russian Federation. In 2012–2014, all subjects underwent a structured interview including questions about average daily sleep duration, lifestyle, complaints and diseases. The current analyses considered the associations with the following disorders: obesity, hypertension, coronary artery disease, myocardial infarction, stroke (cerebral thrombosis or hemorrhage) and diabetes mellitus.

Results. Altogether 20,359 respondents were included in the final analysis. The mean self-reported sleep duration was 7.0 h per night: 23.3% participants reported sleeping less than 6 h while 4.5% subjects slept more than 9 h. We found both short and long sleep duration to be associated with self-reported cardiovascular diseases. The association was independent of age, sex, body mass index, blood pressure, lipids and glucose levels. The multivariable odds were higher for obesity in short-sleepers compared to those sleeping 7–8 h. In the meanwhile, the association was U-shaped for coronary artery disease. A J-shaped relation was found for myocardial infarction. No relation was found for hypertension, diabetes mellitus or stroke.

Conclusions. Differences in sleep duration may have health consequences given associations between short and long sleep duration and cardiometabolic outcomes.

Key words: epidemiology; obesity; sleep; risk factors; cardiovascular diseases

Arterial Hypertens. 2019, vol. 23, no. 4, pages: 248–255
DOI: 10.5603/AH.a2019.0017

Address for correspondence: Lyudmila Korostovtseva, MD, PhD

Almazov National Medical Research Centre, St. Petersburg, Russian Federation; e-mail: lyudmila_korosto@mail.ru

 Copyright © 2019 Via Medica, ISSN 2449–6170

Introduction

Increasing evidence indicates that sufficient sleep duration and sleep quality are important for the primary and secondary cardiovascular prevention [1, 2]. The leading sleep medical associations recommend 7–9 hours of daily sleep for adults [3–5]. The association between the cardiovascular event risk and sleep duration is characterized by the U-shape curve which implies different mechanisms affecting prognosis in the long- and short-sleepers [6]. Moreover, the majority of cross-sectional and observational studies show an increased rate of obesity, cardiovascular diseases, stroke and mortality in subjects with poor sleep quality, as well as in short- and long-sleepers [7]. A number of experimental studies showed that short sleep is potentially associated with the adverse endocrine, immune, and metabolic effects. However, the underlying mechanisms remain unclear. Nevertheless, the following mechanisms are discussed: sympathetic activation, disruption of energy balance, proinflammatory state, impaired insulin sensitivity, enhancement of lipid metabolism abnormalities, etc. [8–10]. Experimental studies demonstrated blood pressure elevation after one night of partial sleep deprivation [11] and its decline after sleep prolongation [12]. All these factors are known to be involved in the cardiovascular continuum promoting atherosclerosis progression and increasing risk of cardiovascular events [4]. Some authors indicate that different sleep duration and sleep disturbances might be associated with different outcomes. Thus, CARDIA study showed that long sleep duration is mostly associated with increased risk of dyslipidemia [13]. Cross-sectional and prospective studies demonstrated that the prevalence of stroke and myocardial infarction (MI) is higher in both short and long sleepers, but the sleep debt mostly increases risk of MI [7, 14].

Complaints related to short sleep and poor sleep quality are more often reported by elderly people. Some studies showed that these changes are more frequent and start earlier in women than in men [15]. Moreover, based on the Whitehall II Study, only in women short duration of sleep is associated with higher risks of hypertension. The gender-related differences are mostly explained by the effects of sex hormones, and in particular major hormonal shifts more pronounced in women than in men. At the same time, psychosocial and behavioral factors can also have an impact on sleep characteristics in men and women [16].

The multicenter study “Epidemiology of cardiovascular disease in different regions of the Russian Federation — ESSE-RF” is the first epidemiological

study to evaluate the sleep duration among Russians [17]. The main objective of this epidemiological study was to study the prevalence of risk factors and cardiovascular diseases in 13 regions of the Russian Federation (RF) with different climate, geographic, economic and demographic characteristics, to elaborate the risk model for Russian population, and to investigate the traditional and new cardiovascular risk factors. We hypothesize that short and long sleep can be one of the new possible risk factors for cardiovascular diseases (CVD).

The aim of this cross-sectional analysis was to investigate the relationship between self-reported sleep duration and various cardiovascular and metabolic disorders.

Material and methods

A representative population-based sample of male and female individuals aged 25 to 64 years old was enrolled from 13 Russian regions and cities (North Ossetia — Alania Republic (North Caucasus), Volgograd (South), Vologda (North-West), Voronezh (Centre), Ivanovo (Centre), Kemerovo (West Siberia), Krasnoyarsk (East Siberia), Orenburg (Volga region), Vladivostok (Far East), St Petersburg (North West), Tomsk (West Siberia), Ekaterinburg (West Siberia), Tyumen (Ural)). The survey was accomplished within the period from November 1, 2012 to November 25, 2014. The study was approved by the Institutional Review Boards of 3 main centers: Almazov National Medical Research Centre (St Petersburg), National Research Center for Preventive Medicine (Moscow), Russian Cardiology Research and Production Complex (Moscow) and the associate centers. Detailed study design and enrollment process were described previously elsewhere [17]. All participants gave written informed consent. The response rate was on average 80%.

Overall, 22,258 participants underwent the ESSE-RF survey (8541 men, 38.4%). Out of all included subjects, 1899 (8.5%) respondents were excluded due to the missing data: lab tests ($n = 887$), sleep module ($n = 542$); inconsistent data ($n = 289$); 112, 16 and 53 did not report their height, weight and waist/hip ratio, respectively. Therefore, in total 20,359 respondents were included in the final analysis [7, 746 men, 38%; mean age — 48 (25; 64) years].

All subjects underwent a structured interview. The questionnaire was designed on a modular type and included questions regarding social and demographic characteristics, life style and habits (includ-

ing cigarette smoking, alcohol consumption and physical activity), anamnesis, etc. in accordance with the adapted international methods. Alcohol abuse was considered when ≥ 168 g of ethanol per week was consumed by men and ≥ 84 g of ethanol per week by women. The level of physical activity was considered low when a subject reported less than 150 minutes of moderate or less than 75 minutes of intense aerobic physical activity per week, which is the recommended minimum level for adults (walking at medium or high speed, or any other equivalent activity) [18].

History was recorded in the module “diseases” by answering the question “Have your doctor ever told that you have/had the following diseases?” followed by the list of 17 pathologies. In the present paper, we analyzed hypertension, coronary artery disease (CAD), myocardial infarction (MI), stroke (cerebral thrombosis or hemorrhage), obesity, and diabetes mellitus (DM). Participants were asked to provide information about average sleep duration in hours (during one month before the survey): “What was your daily sleep duration? Please, include the naps”. Sleep duration of 6 hours or less was considered short [19], ≥ 9 hours was considered long [20]. Physical examination included anthropometric measurements (waist circumference, height, and weight). Body mass index (BMI) was calculated by Quetelet index — body weight [kg]/height² [m²]. Obesity was diagnosed in case of BMI ≥ 30 kg/m². Hypertension was considered when office systolic blood pressure (SBP) was ≥ 140 mm Hg and/or diastolic blood pressure (DBP) was ≥ 90 mm Hg or antihypertensive therapy was ongoing at the time of the survey. Blood samples were collected according to standardized protocols after ≥ 12 -hour fasting on the day of the survey before the interview and anthropometric measurements were taken. Blood samples were centrifuged at low speed 900 g for 20 minutes at +4°C. Serum was immediately frozen and stored at temperature below –20°C until they were transferred by special logistic services to the laboratory at the responsible participating center.

The following parameters were evaluated: total cholesterol, low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, glucose, creatinine, uric acid (Abbot Architect c8000, USA). Glomerular filtration rate (GFR) was estimated by the formula CKD-EPI [21].

Statistical analysis

All statistical analyses were performed using IBM SPSS Statistics v.21 (USA). Each parameter was tested for normal distribution using the Kolmogorov-Smirnov test.

In case of normal distribution the parameters are presented as mean and standard deviation. In case of non-normal distribution the parameters are presented as median and range (minimum; maximum). Comparative analysis of the quantitative variables was performed using Student's t-test. Fisher's exact test and χ^2 were used for categorical variables. ANOVA was applied for multiple comparisons. Logistic regression analysis was used to determine predictors among categorical parameters. Sleep duration was included as dependent variable. Cardiovascular diseases (hypertension, CAD etc.), metabolic disorders and other traditional risk factors (age, BMI, office SBP and DBP, smoking, alcohol overuse, cholesterol levels, fasting glucose etc.) were included as independent variables in the univariate analysis. Those factors that had significant predictive value ($p < 0.05$) in the univariate analysis were included in a multivariate model (multinomial logistic regression). Closely correlated factors were not included in the same analysis (e.g. BMI in obesity analysis, glucose level in DM analysis etc.). We estimated odds ratios (ORs) and 95% confidence intervals (95% CI) for sleep parameters associated with each risk factor and disorder. Direct standardization of data reported from each region was performed according to the European standards. Differences were considered significant at p -level < 0.05 .

Results

Mean sleep duration was 7 (1; 16) hours. The life style characteristics were as following: 4440 (21.8%) smokers, 674 (3.3%) subjects reported alcohol abuse, low physical activity (less than 5 times a week) — 14209 (69.8%) respondents. About one third of subjects ($n = 7175$, 35%) were overweight ($25 \leq \text{BMI} < 30$ kg/m²), every fifth respondent ($n = 4287$, 21%) had obesity I degree, the rate of obesity II and III degree was significantly lower ($n = 1609$, 8% and $n = 722$, 4%, respectively). Every 20th patient ($n = 939$, 5%) had weight deficit ($\text{BMI} < 19.9$ kg/m²). Normal fasting glucose level was found in 14961 (74%) participants, while 2323 (11%) participants had impaired fasting glucose. Diabetes mellitus was newly diagnosed (based on fasting plasma glucose) in 1960 (10%) patients, while 968 (5%) participants reported previously diagnosed DM. All the subjects were divided into groups based on the sleep duration for the last month: ≤ 6 hours, $6 < \text{sleep} < 7$ hours, $7-8$ hours, $8 < \text{sleep} \leq 9$ hours and > 9 hours of sleep (Tab. I). The majority of subjects reported 7–8 hours (33.3%) and from 6 to 7 hours (32.6%) of sleep

Table I. Clinical and demographic characteristics of the study participants depending on sleep duration (n = 20359)

Variable	All	≤ 6 hours	6 < sleep < 7 hours	7–8 hours	8 < sleep ≤ 9 hours	> 9 hours	p
Age (years)	48 (25; 64)	50 (25; 64)	48 (25; 64)	48 (25; 64)	47 (25; 64)	46 (25; 64)	< 0.001
25–34 n = 4304 (%)	21.1	20.8	33.6	33.08	6.78	5.62	$\chi^2 = 84.822$ p < 0.001
35–44 n = 4078 (%)	20	20.57	34.69	34.69	6.2	4.36	
45–54 n = 5681 (%)	27.9	24.55	32.7	33.25	5.42	4.01	
55–64 n = 6296 (%)	30.9	25.84	30.5	30.54	6.25	4.3	
Gender, men/women n (%)	7746 (38%) 12613 (62%)	1714 (22.1%) 3045 (24.1%)	2590 (33.4%) 4057 (32.1%)	2695 (34.8%) 4092 (32.4%)	424 (5.4%) 823 (6.5%)	323 (4.1%) 596 (4.7%)	$\chi^2 = 30.6$; < 0.001
BMI [kg/m ²]	27.4 (15; 68)	27.8 (15; 68)	27.0 (15; 59)	27.4 (15; 54)	27.0 (15; 53)	27.0 (16; 51)	< 0.001
Waist circumference [cm] Men, Women	92 (41; 160) 85 (44; 160)	92 (55; 150) 87.5 (44; 160)	92 (52; 152) 85 (50; 160)	92 (41; 160) 86 (45; 143)	92 (48; 135) 84 (57; 35.5)	93 (60; 134) 85 (56; 146)	< 0.05 < 0.001
SBP [mm Hg]	131 (83; 233)	131 (87; 240)	130 (80; 240)	130 (79; 240)	127 (85; 222)	128 (83; 240)	< 0.001
DBP [mm Hg]	81 (48; 137)	81 (47; 150)	81 (40; 146)	81 (40; 150)	80 (48; 134)	81 (44; 130)	< 0.001
HR [beat per min]	73 (42; 153)	73 (43; 150)	73 (41; 165)	73 (42; 135)	73 (45; 132)	73 (43; 128)	0.042
Obesity n = 6648 (%)	33	36.3	31.7	31.8	30.8	32.9	$\chi^2 = 34.5$; p < 0.001
DM (history) n = 968 (%)	4.7	5.4	4.4	4.5	5.1	5.2	$\chi^2 = 7.2$; p = 0.13
Hypertension n = 7670 (%)	38	40.8	36.7	37.1	34	37.6	$\chi^2 = 30$; p < 0.001
CAD n = 2116 (%)	10.0	13.4	8.7	9.7	10.3	11.9	$\chi^2 = 70.6$; p < 0.001
MI n = 443 (%)	2.2	2.6	1.7	2.2	2.6	2.8	$\chi^2 = 15.8$; p = 0.003
Stroke n = 422 (%)	2.1	2.2	1.9	2.2	2.4	1.6	$\chi^2 = 4.2$; p = 0.4
Smoking n = 4440 (%)	21.8	24.1	21.9	20.1	18.9	24.7	$\chi^2 = 37.4$; < 0.001
Alcohol abuse n = 674 (%)	3.3	3.2	3.2	3.2	4.1	4.2	0.2
Low physical activity n = 14209 (%)	69.8	57.3	71.6	70.0	77.4	59.4	$\chi^2 = 24.3$; < 0.001

BMI — body mass index; CAD — coronary artery disease; DBP — diastolic blood pressure; DM — diabetes mellitus; MI — myocardial infarction; SBP — systolic blood pressure

daily. Almost every 4th participant reported usual short sleep (23.3%), while only 4.5% were long-sleepers. The similar distribution was found both in men and women. Subjects with longer sleep duration (> 9 hours) were younger compared to those sleeping ≤ 6 hours. Prevalence of short-sleepers increased in elder subjects.

Those sleeping > 8 hours had the lowest BMI, while short-sleepers had higher BMI values. SBP also increased in short sleepers. Heart rate, glucose and creatinine levels and GFR were also associated with sleep duration, while no significant relation was found between sleep duration and total cholesterol, LDL or triglycerides (Tab. II). At the same time

Table II. Laboratory parameters of the study participants depending on sleep duration (n = 20,359)

Variable	All	≤ 6 hours	6 < sleep < 7 hours	7–8 hours	8 < sleep ≤ 9 hours	> 9 hours	p
Cholesterol [mmol/L]	5.4 (1.7; 15.7)	5.3 (2.1; 14)	5.3 (2.2; 11)	5.3 (2.1; 12)	5.3 (2.4; 10)	5.3 (2.2; 16)	0.64
LDL [mmol/L]	3.3 (0.5; 12.1)	3.3 (0.5; 10)	3.3 (0.6; 8.6)	3.3 (0.7; 8.9)	3.3 (1.0; 7.3)	3.2 (0.8; 12)	0.06
HDL [mmol/L]	1.4 (0.2; 3.8)	1.4 (0.4; 3.8)	1.4 (0.4; 3.9)	1.4 (0.2; 3)	1.4 (0.5; 2.8)	1.3 (0.4; 3)	0.015
Triglyceride [mmol/L]	1.2 (0.1; 16.1)	1.2 (0.1; 14)	1.2 (0.1; 16)	1.2 (0.2; 16)	1.2 (0.3; 10)	1.2 (0.3; 19)	0.15
Glucose [mmol/L]	5.1 (2.5; 25.5)	5.1 (2.5; 24)	5.1 (2.5; 25.5)	5.1 (2.7; 22.5)	5.0 (3; 24)	5.1 (2.6; 21)	0.024
Creatinine [μmol/L]	69.3 (31; 918)	67.0 (33; 734)	67.4 (31; 700)	68.0 (32; 653)	67.0 (39; 461)	67.0 (41; 918)	0.022
GFR [μmol/L/min × 1.73]	100 (5.4; 173)	99.5 (7; 152)	100.4 (7; 173)	100.0 (6; 166)	100.5 (9; 138)	100.0 (5; 138)	0.021
Uric Acid, [mmol/L] Men/Women	346 (81; 1000) 270 (80; 1130)	340 (110; 800) 270 (80; 777)	350 (100; 1000) 270 (80; 1030)	341 (81; 850) 267 (80; 925)	344 (163; 650) 260 (110; 1130)	330 (126; 810) 260 (89; 676)	< 0.05 > 0.05

HDL — high density lipoprotein; GFR — glomerular filtration rate; LDL — low density lipoprotein

Table III. Association between sleep duration and cardiovascular diseases (OR; 95% CI)

Sleep duration		Obesity	Diabetes Mellitus	Hypertension	Coronary Artery Disease	Myocardial Infarction	Stroke
≤ 6 h	Model 1	1.2*** (1.1; 1.3)	1.2* (1.02; 1.4)	1.2*** (1.1; 1.3)	1.4*** (1.3; 1.6)	1.2 (0.9; 1.5)	1.0 (0.8; 1.3)
	Model 2	1.1** (1.04; 1.3)	1.0 (0.9; 1.2)	1.1 (1.0; 1.2)	1.3*** (1.2; 1.5)	1.1 (0.9; 1.5)	0.9 (0.7; 1.2)
6 < sleep < 7 h	Model 1	1.0 (0.9; 1.1)	1.0 (0.9; 1.2)	1.0 (0.9; 1.1)	0.8* (0.7; 0.9)	0.7* (0.6; 0.9)	0.9 (0.7; 1.1)
	Model 2	1.0 (0.9; 1.1)	1.0 (0.9; 1.2)	1.0 (0.9; 1.1)	0.9 (0.8; 1.0)	0.8 (0.6; 1.0)	0.9 (0.7; 1.1)
7–8 h		Reference variable					
8 < sleep ≤ 9 h	Model 1	1.0 (0.8; 1.1)	1.1 (0.9; 1.5)	0.8* (0.7; 0.9)	1.1 (0.9; 1.3)	1.2 (0.8; 1.7)	1.1 (0.7; 1.7)
	Model 2	1.0 (0.9; 1.2)	1.2 (0.9; 1.6)	0.9 (0.8; 1.1)	1.1 (0.9; 1.4)	1.3 (0.9; 2.0)	1.2 (0.8; 1.8)
> 9 h	Model 1	1.0 (0.9; 1.2)	1.2 (0.9; 1.6)	1.0 (0.9; 1.2)	1.3* (1.02; 1.6)	1.3 (0.8; 2.0)	0.8 (0.4; 1.3)
	Model 2	1.1 (0.9; 1.3)	1.3 (0.9; 1.8)	1.1 (1.0; 1.3)	1.5** (1.1; 1.8)	1.6* (1.02; 2.4)	0.8 (0.5; 1.4)

Model 1 — unadjusted; Model 2 — adjusted for sex, age, body mass index, office blood pressure, smoking and low physical activity; *p < 0.05; **p < 0.01; ***p < 0.001

HDL cholesterol was significantly lower in long-sleepers. Gender-specific differences were shown for uric acid: the highest levels of uric acid were found in men sleeping 6–7 hours.

Short- and long-sleepers less often had low physical activity ($\chi^2 = 24.3$; $p < 0.001$) and smoked more often ($\chi^2 = 37.4$; $p < 0.001$) than normal sleepers. The rate of alcohol abuse was not significant in groups with different sleep duration.

We also found (Tab. I) a U-shaped relation between sleep duration and other cardiovascular risk factors and diseases: short- and long-sleepers had higher incidence of obesity, hypertension, CAD and MI. There were no significant differences for DM and stroke.

Logistic regression showed a higher probability of obesity, hypertension and CAD (Tab. III) in short-sleepers. Six-to-seven-hour sleep was associated with

lower probability of CAD and MI. Moreover, sleep duration from 8 to 9 hours was associated with the lowest risk of hypertension (OR = 0.8; CI: 0.7–0.9, $p = 0.037$). At the same time sleep over 9 hours was associated with the higher risk of CAD (OR = 1.3; CI: 1.02–1.6, $p = 0.043$). After adjustment for sex, age, BMI, office blood pressure, smoking and low physical activity the associations were weaker but remained significant (Tab. II). Compared with subjects sleeping 7–8 h, the multivariable OR (95% CI) was higher for obesity in short-sleepers — 1.1 (1.03; 1.2), meanwhile the association was U-shaped for CAD, and J-shaped for MI. No associations were found for hypertension, DM and stroke.

Discussion

Based on the data from the epidemiological study ESSE-RF the median sleep duration in Russian citizens is 7 hours. Almost every 4th citizen (23.3%) is a short-sleeper. This conforms with the results of the National Health Interview Survey [22] — 29% (8% subjects sleeping ≤ 5 h/day and 21% those sleeping 6 h/day), but the prevalence of short-sleepers among Russian population is significantly higher than the data reported in the Sleep Heart Health Study (9.2%) [23]. These differences are due to the various approaches for sleep assessment. The first study, similarly to ours, estimated average daily sleep duration, while the second one identified mean sleep duration on weekends and workdays. In both studies, the proportion of long-sleepers is greater than in our cohort — 4.5% *vs.* 7.6% and 9% in SHHS and NHIS, respectively.

Based on our analysis, short sleep duration is associated with the increased risk of obesity, hypertension and CAD. The incidence of CAD and MI was higher for both short- and long-sleepers. No significant differences between subjects with various sleep duration were found regarding alcohol abuse. However, short- and long-sleepers reported lower prevalence of low physical activity and smoked more frequently. Therefore, our data do not confirm any definite and unidirectional relationship between sleep duration and cardiovascular risk factors.

The data on sleep duration and sleep quality in Russian population is lacking. The ESSE-RF is the first study which estimated sleep duration in Russia. At the same time, sleep quality was assessed in few other studies. Participants of the HAPIEE study 45–69 years old reported frequent spontaneous sleep interruptions in 20%; and unsatisfying sleep in 10% respondents [24]. Sleep quality was associated with

angina, arthritis and depression in the analysis of the data from Russian population performed by the SAGE investigators [25].

Unlike other studies, our analysis did not show associations between short or long sleep duration with DM, hypertension or stroke. The Sleep Heart Health Study demonstrated higher risk for hypertension [23] for both short- (OR = 1.66, CI 1.35–2.04, $p < 0.0001$) and long-sleepers (OR = 1.30, CI: 1.04–1.62, $p < 0.0001$). In addition, both short-sleepers (OR = 2.01, CI: 1.5–2.70, $p < 0.005$) and long-sleepers (OR = 2.22, CI: 1.69–2.91, $p < 0.005$) had higher risk of stroke [19]. The meta-analyses of 24 prospective cohorts including 474 684 participants with short (≤ 5 –6 h) (OR = 1.15, CI: 1.00–1.31, $p = 0.047$) and long sleep duration (> 8 –9 h) (OR = 1.65, CI: 1.45–1.87, $p < 0.0001$) showed higher risk of fatal and non-fatal stroke compared to reference subjects sleeping 7–8 h per day [7].

Limitations of the study

One of the most significant limitations of our study is the absence of objective (instrumental) verification of sleep duration, although according to multiple studies self-reports correlate with the actigraphy data [26]. Another limiting factor is the cross-sectional design of our study. Short or long sleep duration is not always habitual. It might result from common sleep disorders (e.g., decrease in sleep time and low sleep quality in insomniacs, sleep apnea-related significant reduction in sleep quality). We also did not analyze the factors limiting sleep duration — the duration of work time, the time which subjects waste to get to the workplace, work schedule, chronotype and etc., because these factors were not included in the structured interview according to the primary design of the ESSE-RF study.

Conclusions

Our data support the concept of the relation between sleep and cardiometabolic disorders and provide additional evidence on the unfavorable impact of extreme sleep duration variations. We demonstrated that sleep duration is highly variable in Russian population with significant prevalence of short sleepers. However, unlike published data, in our cohort not all cardiovascular diseases were associated with sleep duration. The multivariable odds ratio was higher for obesity in short-sleepers compared with those who slept 7–8 hours. Meanwhile the U-shaped association was found for coronary artery disease. Association with myocardial infarction is characterized

by the J-shaped relation. There were no associations for hypertension, diabetes mellitus and stroke. We believe that our results provide important information for the understanding of sleep epidemiology and relation between sleep and cardiovascular risk.

Acknowledgements

The publication was supported by the Grant of the President of Russian Federation for the Leading Scientific Schools of Russia HW-5508.2018.7 (agreement No. 075-15-2019-161, 23.05.2019).

On behalf of the ESSE-RF study investigators from Russia: St Petersburg, Almazov National Medical Research Centre: Elena Baranova; Moscow, Russian Cardiology Research and Production Complex: Elena Oshchepkova; National Research Center for Preventive Medicine: Raphael Oganov, Galina Muromtseva, Yulia Balanova; Alania, North Ossetian State Medical Academy: George Tolparov; Vladivostok, Tihoookeanskij State Medical Academy: Vera Nevzorova, Natalia Kulakova; Volgograd, Volgograd State Medical University: Sergey Nedogoda; Vologda, Institute of Territory Socio-economic Development: Alexandra Shabunova; Voronezh, Voronezh State Medical University named after N.N. Burdenko: Galina Furmenko; Ivanovo, Ivanovo cardiologic dispensary: Olga Belova; Krasnoyarsk, Krasnoyarsk State Medical University: Yuri Greenstein, Marina Petrova; Orenburg, Orenburg State Medical University: Roman Libis; Samara, Samara regional clinical cardiology dispensary: Dmitry Dupliakov; Tomsk, Tomsk Research Institute of Cardiology: Vladimir Kaveshnikov; Tyumen, Tyumen State Medical Academy: Alexey Efanov; Kemerovo, Research Institute for Complex Problems of Cardiovascular Diseases: Galina Artamonova, Elena Indukaeva.

Conflict of interest

None declared.

References

- Bochkarev MV, Korostovtseva LS, Sviryaev YV. [Sleep quality and duration cardiovascular diseases: is there an association?]. *Arterial'naya Gypertenziya*. 2014; 19(450): 461.
- Williams JA, Zimmerman FJ, Bell JF. Norms and trends of sleep time among US children and adolescents. *JAMA Pediatr*. 2013; 167(1): 55–60, doi: [10.1001/jamapediatrics.2013.423](#), indexed in Pubmed: [23403646](#).
- Hirshkowitz M, Whiton K, Albert SM, et al. National Sleep Foundation's sleep time duration recommendations: methodology and results summary. *Sleep Health*. 2015; 1(1): 40–43, doi: [10.1016/j.sleh.2014.12.010](#), indexed in Pubmed: [29073412](#).
- Mukherjee S, Patel SR, Kales SN, et al. American Thoracic Society ad hoc Committee on Healthy Sleep. An Official American Thoracic Society Statement: The Importance of Healthy Sleep. Recommendations and Future Priorities. *Am J Respir Crit Care Med*. 2015; 191(12): 1450–1458, doi: [10.1164/rccm.201504-0767ST](#), indexed in Pubmed: [26075423](#).
- Watson NF, Badr MS, Belenky G, et al. Consensus Conference Panel. Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society on the Recommended Amount of Sleep for a Healthy Adult: Methodology and Discussion. *J Clin Sleep Med*. 2015; 11(8): 931–952, doi: [10.5664/jcsm.4950](#), indexed in Pubmed: [26235159](#).
- Kripke DF, Garfinkel L, Wingard DL, et al. Mortality associated with sleep duration and insomnia. *Arch Gen Psychiatry*. 2002; 59(2): 131–136, doi: [10.1001/archpsyc.59.2.131](#), indexed in Pubmed: [11825133](#).
- Cappuccio FP, Cooper D, D'Elia L, et al. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J*. 2011; 32(12): 1484–1492, doi: [10.1093/eurheartj/ehr007](#), indexed in Pubmed: [21300732](#).
- Stamatakis KA, Punjabi NM. Effects of sleep fragmentation on glucose metabolism in normal subjects. *Chest*. 2010; 137(1): 95–101, doi: [10.1378/chest.09-0791](#), indexed in Pubmed: [19542260](#).
- St-Onge MP. The role of sleep duration in the regulation of energy balance: effects on energy intakes and expenditure. *J Clin Sleep Med*. 2013; 9(1): 73–80, doi: [10.5664/jcsm.2348](#), indexed in Pubmed: [23319909](#).
- Reutrakul S, Van Cauter E. Sleep influences on obesity, insulin resistance, and risk of type 2 diabetes. *Metabolism*. 2018; 84: 56–66, doi: [10.1016/j.metabol.2018.02.010](#), indexed in Pubmed: [29510179](#).
- Almeida FR, Perry JC, Futuro-Neto HA, et al. Cardiovascular function alterations induced by acute paradoxical sleep deprivation in rats. *Clin Exp Hypertens*. 2014; 36(8): 567–571, doi: [10.3109/10641963.2014.881843](#), indexed in Pubmed: [24678694](#).
- Haack M, Serrador J, Cohen D, et al. Increasing sleep duration to lower beat-to-beat blood pressure: a pilot study. *J Sleep Res*. 2013; 22(3): 295–304, doi: [10.1111/jsr.12011](#), indexed in Pubmed: [23171375](#).
- Petrov ME, Kim Y, Lauderdale D, et al. Longitudinal associations between objective sleep and lipids: the CARDIA study. *Sleep*. 2013; 36(11): 1587–1595, doi: [10.5665/sleep.3104](#), indexed in Pubmed: [24179290](#).
- Hu L, Zhang B, Zhou W, et al. Sleep duration on workdays or non-workdays and cardiac-cerebral vascular diseases in Southern China. *Sleep Med*. 2018; 47: 36–43, doi: [10.1016/j.sleep.2017.11.1147](#), indexed in Pubmed: [29880146](#).
- Kiejna A, Rymaszewska J, Wojtyniak B, et al. Characteristics of sleep disturbances in Poland — results of the National Health Interview Survey. *Acta Neuropsychiatr*. 2004; 16(3): 124–129, doi: [10.1111/j.0924-2708.2004.00063.x](#), indexed in Pubmed: [26984163](#).
- Cappuccio FP, Stranges S, Kandala NB, et al. Gender-specific associations of short sleep duration with prevalent and incident hypertension: the Whitehall II Study. *Hypertension*. 2007; 50(4): 693–700, doi: [10.1161/HYPERTENSIONAHA.107.095471](#), indexed in Pubmed: [17785629](#).
- Rotar O, Boyarinova M, Orlov A, et al. Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. *Eur J Epidemiol*. 2017; 32(3): 251–254, doi: [10.1007/s10654-016-0221-z](#), indexed in Pubmed: [28039558](#).
- Piepoli MF, Hoes AW, Agewall S, et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J*. 2016; 37(29): 2315–2381, doi: [10.1093/eurheartj/ehw106](#), indexed in Pubmed: [27222591](#).
- Grandner MA, Patel NP, Gehrman PR, et al. Problems associated with short sleep: bridging the gap between laboratory and epidemiological studies. *Sleep Med Rev*. 2010; 14(4):

- 239–247, doi: [10.1016/j.smrv.2009.08.001](https://doi.org/10.1016/j.smrv.2009.08.001), indexed in Pubmed: [19896872](https://pubmed.ncbi.nlm.nih.gov/19896872/).
20. Grandner MA, Drummond SPA. Who are the long sleepers? Towards an understanding of the mortality relationship. *Sleep Med Rev.* 2007; 11(5): 341–360, doi: [10.1016/j.smrv.2007.03.010](https://doi.org/10.1016/j.smrv.2007.03.010), indexed in Pubmed: [17625932](https://pubmed.ncbi.nlm.nih.gov/17625932/).
 21. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009; 150(9): 604–612, doi: [10.7326/0003-4819-150-9-200905050-00006](https://doi.org/10.7326/0003-4819-150-9-200905050-00006), indexed in Pubmed: [19414839](https://pubmed.ncbi.nlm.nih.gov/19414839/).
 22. Sabanayagam C, Shankar A. Sleep duration and cardiovascular disease: results from the National Health Interview Survey. *Sleep.* 2010; 33(8): 1037–1042, doi: [10.1093/sleep/33.8.1037](https://doi.org/10.1093/sleep/33.8.1037), indexed in Pubmed: [20815184](https://pubmed.ncbi.nlm.nih.gov/20815184/).
 23. Gottlieb DJ, Redline S, Nieto FJ, et al. Association of usual sleep duration with hypertension: the Sleep Heart Health Study. *Sleep.* 2006; 29(8): 1009–1014, doi: [10.1093/sleep/29.8.1009](https://doi.org/10.1093/sleep/29.8.1009), indexed in Pubmed: [16944668](https://pubmed.ncbi.nlm.nih.gov/16944668/).
 24. Gafarov VV, Gagulin IV, et al. GromovaEA, Sleep disorders in 45–69-year-old population in Russia/Siberia (Epidemiology study). *Int J Med Med Sci.* 2013; 3(6): 470–475.
 25. Koyanagi Ai, Garin N, Olaya B, et al. Chronic conditions and sleep problems among adults aged 50 years or over in nine countries: a multi-country study. *PLoS One.* 2014; 9(12): e114742, doi: [10.1371/journal.pone.0114742](https://doi.org/10.1371/journal.pone.0114742), indexed in Pubmed: [25478876](https://pubmed.ncbi.nlm.nih.gov/25478876/).
 26. Lauderdale DS, Knutson KL, Yan LL, et al. Self-reported and measured sleep duration: how similar are they? *Epidemiology.* 2008; 19(6): 838–845, doi: [10.1097/EDE.0b013e318187a7b0](https://doi.org/10.1097/EDE.0b013e318187a7b0), indexed in Pubmed: [18854708](https://pubmed.ncbi.nlm.nih.gov/18854708/).

Effect of short-term physical exercise on serum markers of skeletal muscle damage in hypertensive patients treated with a combination of statin and angiotensin-converting enzyme inhibitor

Paweł Deska¹, Michał Nowicki²

¹Department of Internal Medicine District Hospital, Kłobuck, Poland

²Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Łódź, Poland

Abstract

Background. Muscle strain during physical exercise may lead to muscle damage and hyperkalaemia. Commonly prescribed drugs including statins and angiotensin-converting enzyme inhibitors (ACEI) may increase serum potassium and cause muscle damage. We postulated that the risk may be even higher if the patients are treated with a combination of statin and ACEI.

The aim of the study was to compare the effect of moderate intensity short-term physical exercise on the changes of muscle injury markers serum carbonic anhydrase 3 and creatine kinase in patients with arterial hypertension receiving ACEI and statin.

Material and methods. Eighteen patients with arterial hypertension treated with ACEI were included in a prospective placebo-controlled cross-over study. 18 healthy individuals served as controls. Hypertensive patients underwent 30-minute exercise test, which was repeated two times in a random order after the administration of ACEI with statin or ACEI with placebo. Each treatment period lasted 8 weeks separated by 2-week wash-out. Normotensive subjects underwent a single exercise test. Serum carbonic anhydrase 3 (CAIII) and creatine kinase (CK) activity were measured before and after exercise and recovery.

Results. At baseline and during the exercise CAIII was significantly higher in healthy volunteers compared to hypertensive patients. CAIII increased significantly during exercise only after treatment with both ACEI and statin. Serum CK was higher in hypertensive patients treated with ACEI plus statin during all exercise tests.

Conclusions. Addition of statin to ACEI in patients with arterial hypertension does not increase the risk of muscle damage during moderate intensity short-term physical exercise.

Key words: physical exercise; arterial hypertension; carbonic anhydrase III; creatine kinase; angiotensin-converting enzyme inhibitor; HMG-CoA reductase inhibitor

Arterial Hypertens. 2019, vol. 23, no. 4, pages: 256–262
DOI: 10.5603/AH.a2019.0018

Address for correspondence: Prof. Michał Nowicki, MD

Department of Nephrology, Hypertension and Kidney Transplantation, Medical University of Łódź, Pomorska 251, 92–213 Łódź, Poland;
tel: +48 42 201 44 00, fax: 42 201 44 01; e-mail: nefro@wp.pl

 Copyright © 2019 Via Medica, ISSN 2449–6170

Introduction

Exercise-induced muscle damage is the consequence of a complex interactions of events, which seem to include muscle fibres damage due to myofibril injury (rupture of myofibrils), impaired excitation-contraction coupling associated with local ATP depletion, changes in the intracellular calcium homeostasis, oxidative stress and inflammation [1]. Vigorous physical exercise may affect the integrity of muscle cells and cause a release of muscle cell enzymes into the extracellular compartment. Muscle damage is a frequent event and many individuals are susceptible to muscle damage induced by physical exercise or caused by pharmacotherapy [2–4]. Serum concentration of creatine kinase and myoglobin are sensitive markers of muscle damage and myopathy [5, 6]. Creatine kinase (CK) is an enzyme expressed in large amounts in muscle cells. It catalyses the reversible process of transferring the phosphate group from phosphocreatine to adenosine diphosphate (ADP) thus rebuilding the adenosine diphosphate (ATP) inventory. The concentration of creatine kinase increases manifolds after the skeletal muscle damage caused by trauma, intramuscular drug injection, intense physical exercise, convulsions, myositis, muscular dystrophies and myotonia [7, 8].

Serum carbonic anhydrase III has been a well-established serum marker of skeletal muscle damage. Carbonic anhydrase 3 is a metalloenzyme found in the cytosol of a body cell. It catalyses the enzymatic reaction of hydrogen ion formation from water and carbon dioxide [9]. The enzyme was first detected in human skeletal muscle cells in 1979 [10–12]. Carbonic anhydrase 3 is selectively expressed in skeletal muscle, but not in the heart muscle, which was used in the differential diagnosis of stenocardia; however, a clinical interest in the routine measurement of this marker has diminished after the introduction of highly sensitive markers of myocardial ischaemia [13]. A significant increase in carbonic anhydrase 3 activity in the blood was reported after physical exercise and in several neuromuscular diseases that resulted in microdamage of muscle cells [14, 15].

Most patients with multiple coexisting diseases including arterial hypertension or coronary artery disease require an administration of statin. Taking into account a large proportion of patients treated with statins and the changes of lifestyle that have occurred in the modern societies aimed at increasing recreational physical activity including short-term and prolonged high-intensity exercises the potential risk of such adverse effects as hyperkalaemia and

muscle damage of these drugs is becoming clinically relevant [11, 12].

The aim of the study was to assess the effect of a moderate intensity short-term standardized physical exercise on the changes of serum creatine kinase and carbonic anhydrase III activity in patients with arterial hypertension treated with an angiotensin-converting enzyme inhibitor alone or in a combination with statin.

Material and methods

In a prospective, cross-over and placebo-controlled study 18 patients with essential hypertension and 18 healthy individuals who served as a control group were included. The study design is presented in Figure 1.

The study protocol was approved by the Local Bioethics Committee. All subjects gave a written informed consent for the participation in the study.

The inclusion criteria were as follows: arterial hypertension diagnosed according to the 2013 ESH/ESC criteria [17], previously untreated or treated with maximum two antihypertensive drugs in therapeutic doses, women or men aged 18–70 years, serum potassium concentration less than 5.2 mmol/l at the time of screening, total cholesterol > 190 mg/dL or LDL-cholesterol > 115 mg/dL.

The exclusion criteria included any secondary form of hypertension, motor organ disorders, inherited hypercholesterolemia, uncontrolled symptomatic heart failure (NYHA III and IV), uncontrolled arrhythmia, atrioventricular block II° or III°, symptomatic aortic stenosis, history of myocarditis or pericarditis, acute infections, hyperthyroidism, chronic kidney disease stage 3A or higher, i.e. estimated glomerular filtration rate calculated using the CKD-EPI [18] formula equal or smaller than 60 mL/min/1.73 m², serum potassium higher than 5.5 mmol/L found at least twice at any time in the past, history of statin intolerance, uncontrolled diabetes mellitus, chronic liver disease, mental illness, history of non-compliance.

Exercise tests were conducted on a bicycle ergometer (Kettler Stratos, Ense-Parsit, Germany) following the same protocol in all participants. Each time, the exercise followed 20-minute preparation including the rest in a sitting position. A peripheral venous catheter was placed to withdraw blood for laboratory measurements. After a baseline blood sample was taken, the patients started the exercise that lasted 30 minutes with a load to achieve oxygen consumption in the range of 55–60% maximum based on the




Figure 1. Study design and flowchart. ECG — electrocardiography

heart rate. After 15 and 30 minutes, blood samples were taken for laboratory tests. Upon the completion of exercise, the patients were asked to spend another 30 minutes in a sitting position to recover. After 30 minutes of the rest that followed the exercise the last blood sample was taken. During each examination the patients were asked to drink 500 mL of still low-mineralized water. The blood samples after the formation of blood clot were immediately centrifuged, and the serum was separated into separate test tubes frozen at -80°C until laboratory measurements.

Creatine kinase was measured in plasma by the kinetic method using a Cobas Integra 400 Plus biochemical analyser (Roche, Munich, Germany).

Carbonic anhydrase 3 was measured in plasma by the immunoenzymatic method using the Cloud Clone Corp test. (Houston, USA).

All patients from the study group had been receiving a stable dose of ramipril 10 mg each morning for at least 6 months before the study. The whole study lasted 18 weeks and was divided into 3 stages. After the first exercise test, the patients were randomly divided into two groups. An even parity of the numbers generated in MS Excel using RAND function was used for randomization.

During the first 8-week study period the patients received simvastatin in a dose of 40 mg or placebo depending on the treatment order of the group. The drug and placebo were prepared by the hospital

pharmacy in a form of tablets in identical appearance as the active drug. After 8 weeks of treatment, during which the study visits were held every 2 weeks the second exercise test was carried out following exactly the same scheme. The second test was followed by a wash-out period during which the study drug test or placebo were discontinued for two weeks. The wash-out period was followed by the third period lasting 8 weeks during which the patients received either drug or placebo. At the end of that period the patients underwent the third exercise test. The adherence to the therapy was verified by the counting of the packages and tablets of medicines returned by the patients at each visit. In a group of 18 healthy volunteers who were not taking any drugs the exercise test was carried out once according to the same protocol. The creatine kinase and carbonic anhydrase III activity were measured before each exercise test and immediately at its end and after a rest period.

Descriptive statistics included a calculation of the arithmetic mean and standard deviation (SD). Normality of the distribution of variables was examined with the Shapiro-Wilk test. Means of both groups were compared with two-sided t-test or Mann-Whitney test depending on the distribution of each variable. ANOVA was used to analyse repeated measurements. $p < 0.05$ was taken as statistically significant.

Table I. Serum creatine kinase activity (before exercise, after 30-min exercise, after 30-min recovery)

	Before exercise [IU/L]	After 30-min exercise [IU/L]	After 30-min recovery [IU/L]
ACEI	59 ± 34	59 ± 27	58 ± 26
ACEI + statin	88 ± 62	94 ± 51	90 ± 62
ACEI + placebo	62 ± 32	68 ± 33	68 ± 27
Control group	48 ± 24	55 ± 31	51 ± 30

ACEI — angiotensin converting enzyme inhibitor

Table II. Serum carbonic anhydrase 3 activity ($p < 0.05$), (before exercise, after 30-min exercise, after 30-min recovery)

	Before exercise [U/L]	After 30-min exercise [U/L]	After 30-min recovery [U/L]
ACEI	15475 ± 8304	17326 ± 11628	19419 ± 21159
ACEI + statin	18412 ± 92556	18101 ± 12228	26585 ± 23537
ACEI + placebo	14619 ± 9093	15744 ± 5736	15419 ± 9662
Control group	38122 ± 24333	32800 ± 25163	33699 ± 34927

ACEI — angiotensin converting enzyme inhibitor

Results

All initially qualified patients completed the study. None of participants reported any adverse reaction to the study drugs that led to the withdrawal of the treatment. Serum creatine kinase and carbonic anhydrase III activity both at the rest and during the physical exercise remained within the normal range in both groups.

The results of serum creatine kinase activity measurements are shown in Table I. There were significant differences in serum creatine kinase activity between the patients receiving ACEI and statin and patients treated only with ACEI or healthy volunteers at baseline and during the exercise test and after recovery ($p < 0.05$). The serum creatine kinase activity was higher in hypertensive patients treated ACEI combined with statin compared to the patients treated with ACEI only or healthy volunteers. There were no significant changes of creatinine kinase during the exercise in each group.

The carbonic anhydrase 3 serum activity is shown in Table II. The activity was significantly higher in the control group compared to the hypertensive patients treated with ACEI or with both ACEI and statin with the exception of ACEI plus statin group after 30-minute recovery where the difference was not significant ($p < 0.05$).

Figure 2 shows the percentage changes of carbonic anhydrase activity 3 during the short-term physical exercise in all parts of the study. The largest increase in the carbonic anhydrase 3 activity was found in patients treated with both ramipril and simvastatin.

In the control group, the carbonic anhydrase 3 activity decreased during the exercise but later after the recovery a small nominal increase was noted.

Discussion

The main result of our study is the demonstration of the lack of an increased risk of muscle damage after the administration of the combination of statin and ACEI in hypertensive patients during a moderate short-term physical exercise.

During the treatment with statin, muscle damage was frequently reported, manifested mostly by a muscle pain associated with modest or mild increase in the serum markers of muscle damage, e.g. serum creatine kinase [19–21]. No clinical symptoms that might have suggested statin-induced muscle damage were seen in our patients during the study and the physical exercise was very well-tolerated.

Previously the incidents of the severe complication of statin therapy including rhabdomyolysis and severe hyperkalaemia and renal failure have also been reported [16, 22]. A rhabdomyolysis was described mostly after a mechanical muscle damage including intramuscular injections leading to muscle damage [23].

Post-exercise muscle damage usually does not result in any relevant clinical consequences and remains subclinical but could be detected as an increase in specific serum markers of muscle damage determined in laboratory tests. Only in extreme cases it can lead to rhabdomyolysis. Rhabdomyolysis after




Figure 2. Percentage changes of carbonic anhydrase 3 activity from baseline during the exercise test. ACEI — angiotensin converting enzyme inhibitor

physical exercise was also reported in healthy athletes not taking any drugs and in the amateurs taking part in recreational sport activities. Most of the affected subjects were marathon runners, cyclists and those practicing other exhausting disciplines in unfavourable weather conditions [24–27]. However, the information about the risk of such events in a general hypertensive population is missing. Therefore we were not able to directly compare our results with the results of other authors.

The choice of a particular statin for the study also needs to be discussed. In our study, simvastatin in a dose of 40 mg/day was used and the treatment duration was 8 weeks. We choose simvastatin for the study due to its common use in our country [28]. Simvastatin has a good safety profile and does not need to be reduced in mild renal function impairment that is commonly seen in hypertensive patients.

In order to evaluate the muscle damage each participant was first asked about the history of episodes of muscle weakness and myalgia and unexplained changes in urine colour. It has been reported that such symptoms may occur in 7–29% of statin-treated patients, although most often in those receiving the highest recommended doses of the drug [29].

Muscle cell damage can lead to a release of numerous substances specifically expressed in the skeletal muscle cells into the blood, including ions and en-

zymes. Among them such markers as creatine kinase, myoglobin and skeletal muscle-specific carbonic anhydrase III have been best studied [14, 15].

The mean creatine kinase activity remained within the normal range in our patients during the whole study. Despite that we found that creatine kinase activity in hypertensive patients was significantly higher in patients treated with ramipril combined with simvastatin when compared to the treatment with ACEI alone. This may suggest the effect of statins on the subclinical muscle cell damage. The lack of any significant increase in muscle damage markers in hypertensive patients who received only an ACEI may suggest that the effect could be attributed only to a statin. We have also looked at the post-exercise changes of muscle damage markers and we found a small non-significant numerical increase in these markers during the recovery from exercise. Even small changes in creatine kinase activity during exercise seem to confirm the effect of exercise on the integrity of muscle cells, which is consistent with earlier studies performed by other authors but in different populations and different experimental conditions [30, 31].

The determination of serum creatine kinase activity alone, although common in clinical practice may be insufficient since often even in patients reporting the symptoms indicative of myalgia, there is no detectable increase in the serum activity of this enzyme [32]. That is why we decided to determine also the

activity of carbonic anhydrase 3 that is a more selective and sensitive marker of muscle damage [15, 33].

In the available literature a significant increase in carbonic anhydrase 3 activity was described in several conditions leading to overload and muscle damage [14, 15].

To maximize the safety of the patients, we decided to choose the intensity and duration of physical exercise that would be well tolerated by the patients and remain in a range mimicking recreational physical activity. Each time during the study, the participants were asked to drink 500 ml of low-mineralized water for proper hydration in order to maintain adequate diuresis and reducing the risk of dehydration [34].

Despite the small group size the study had a crossover design to increase the statistical power by allowing the intra-group comparisons, as each patient received both study drugs and a placebo. The subjects were also carefully selected to ensure the homogeneity of the population.

The low number of study participants was also the result of long study protocol, which included at least a six-month period of ramipril treatment at a dose of 10 mg/24 h before the start of exercise tests, and then a total of ten-week treatment after randomisation. For safety reason we excluded the patients with chronic kidney disease stage 3a and higher. In such patients, the expected risk of complications including severe hyperkalaemia resulting from renal failure may have been much higher reported as high as 50% in some studies [35]. In addition, the patients with a creatinine clearance below 60 mL/min/m² require a reduction of the dose of ramipril and or statin, which could hinder the interpretation of our results.

Our results may have some implications for clinical practice in frequent cases of the treatment of hypertensive patients with the combination of ACEI and statin. Our results suggest that such the combination has a favourable safety profile.

Conclusions

Moderate physical exercise in hypertensive patients treated with an angiotensin-converting enzyme inhibitor in combination with statin seems to be safe and does not increase the risk of clinically significant muscle damage.

References

- Nikolaidis M, Jamurtas A, Paschalis V, et al. The Effect of Muscle-Damaging Exercise on Blood and Skeletal Muscle Oxidative Stress. *Sports Med.* 2008; 38(7): 579–606, doi: [10.2165/00007256-200838070-00005](#).
- Siracusa J, Koulmann N, Sourdrille A, et al. Phenotype-Specific Response of Circulating miRNAs Provides New Biomarkers of Slow or Fast Muscle Damage. *Front Physiol.* 2018; 9: 684, doi: [10.3389/fphys.2018.00684](#), indexed in Pubmed: [29922177](#).
- Tomaszewski M, Stepień KM, Tomaszewska J, et al. Statin-induced myopathies. *Pharmacol Rep.* 2011; 63(4): 859–866, doi: [10.1016/s1734-1140\(11\)70601-6](#), indexed in Pubmed: [22001973](#).
- Mammen A. Statin-Associated Autoimmune Myopathy. *N Engl J Med.* 2016; 374(7): 664–669, doi: [10.1056/nejmra1515161](#), indexed in Pubmed: [26886523](#).
- Lee G. Exercise-induced rhabdomyolysis. *R I Med J* (2013). 2014; 97(11): 22–24, indexed in Pubmed: [25365815](#).
- Fitzgerald K, Redmond E, Harbor C. Statin-induced Myopathy. *Glob Adv Health Med.* 2012; 1(2): 32–36, doi: [10.7453/gahmj.2012.1.2.008](#), indexed in Pubmed: [24278816](#).
- Cervellini G, Comelli I, Benatti M, et al. Non-traumatic rhabdomyolysis: Background, laboratory features, and acute clinical management. *Clin Biochem.* 2017; 50(12): 656–662, doi: [10.1016/j.clinbiochem.2017.02.016](#), indexed in Pubmed: [28235546](#).
- Lott JA, Stang JM. Serum enzymes and isoenzymes in the diagnosis and differential diagnosis of myocardial ischemia and necrosis. *Clin Chem.* 1980; 26(9): 1241–1250, indexed in Pubmed: [6994925](#).
- Monti DM, De Simone G, Langella E, et al. Insights into the role of reactive sulphhydryl groups of Carbonic Anhydrase III and VII during oxidative damage. *J Enzyme Inhib Med Chem.* 2017; 32(1): 5–12, doi: [10.1080/14756366.2016.1225046](#), indexed in Pubmed: [27766895](#).
- Harju AK, Booterabi F, Kuuslahti M, et al. Carbonic anhydrase III: a neglected isozyme is stepping into the limelight. *J Enzyme Inhib Med Chem.* 2013; 28(2): 231–239, doi: [10.3109/14756366.2012.700640](#), indexed in Pubmed: [22803676](#).
- Beuerle JR, Azzazy HM, Styba G, et al. Characteristics of myoglobin, carbonic anhydrase III and the myoglobin/carbonic anhydrase III ratio in trauma, exercise, and myocardial infarction patients. *Clin Chim Acta.* 2000; 294(1-2): 115–128, doi: [10.1016/s0009-8981\(99\)00261-2](#), indexed in Pubmed: [10727678](#).
- Deska P, Nowicki M. Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin. *J Physiol Pharmacol.* 2017; 68(1): 133–138, indexed in Pubmed: [28456777](#).
- Feng HZ, Jin JP. Carbonic Anhydrase III Is Expressed in Mouse Skeletal Muscles Independent of Fiber Type-Specific Myofibrillar Protein Isoforms and Plays a Role in Fatigue Resistance. *Front Physiol.* 2016; 7: 597, doi: [10.3389/fphys.2016.00597](#), indexed in Pubmed: [28018233](#).
- Väänänen HK, Syrjäälä H, Rahkila P, et al. Serum carbonic anhydrase III and myoglobin concentrations in acute myocardial infarction. *Clin Chem.* 1990; 36(4): 635–638, indexed in Pubmed: [2108824](#).
- Osterman PO, Askmark H, Wistrand PJ. Serum carbonic anhydrase III in neuromuscular disorders and in healthy persons after a long-distance run. *J Neurol Sci.* 1985; 70(3): 347–357, doi: [10.1016/0022-510x\(85\)90176-5](#), indexed in Pubmed: [3932601](#).
- Laufs U, Scharnagl H, Halle M, et al. Treatment Options for Statin-Associated Muscle Symptoms. *Dtsch Arztebl Int.* 2015, doi: [10.3238/arztebl.2015.0748](#).
- Guidelines for the management of arterial hypertension. [www.escardio.org](#) (10.1159/isbn.978-3-318-01088-6).
- KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int.* 2013; 3(1): Suppl.
- Manoj K, Jain N, Madhu SV. Myopathy in Patients Taking Atorvastatin: A Pilot Study. *Indian J Endocrinol Metab.* 2017; 21(4): 504–509, doi: [10.4103/ijem.IJEM_79_17](#), indexed in Pubmed: [28670530](#).
- Khine H, Yuet WC, Adams-Huet B, et al. Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. *Am Heart J.* 2016; 179: 1–9, doi: [10.1016/j.ahj.2016.05.015](#), indexed in Pubmed: [27595674](#).

21. Allen SC, Mamotte CDS. Pleiotropic and Adverse Effects of Statins-Do Epigenetics Play a Role? *J Pharmacol Exp Ther*. 2017; 362(2): 319–326, doi: [10.1124/jpet.117.242081](https://doi.org/10.1124/jpet.117.242081), indexed in Pubmed: [28576976](https://pubmed.ncbi.nlm.nih.gov/28576976/).
22. Osaki Y, Nakagawa Y, Miyahara S, et al. Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy. *Biochem Biophys Res Commun*. 2015; 466(3): 536–540, doi: [10.1016/j.bbrc.2015.09.065](https://doi.org/10.1016/j.bbrc.2015.09.065), indexed in Pubmed: [26381177](https://pubmed.ncbi.nlm.nih.gov/26381177/).
23. Muscal E. Rhabdomyolysis: Practice Essentials, Background, Pathophysiology. Medscape 2015. <https://emedicine.medscape.com/article/1007814-overview#showall>.
24. Gautam PL, Luthra N, Nain S. Sports Induced Cardiac Arrest: A Case of Missed Rhabdomyolysis. *J Clin Diagn Res*. 2015; 9(9): UD01–UD02, doi: [10.7860/JCDR/2015/10275.6507](https://doi.org/10.7860/JCDR/2015/10275.6507), indexed in Pubmed: [26500986](https://pubmed.ncbi.nlm.nih.gov/26500986/).
25. Tunstall Pedoe DS. Marathon cardiac deaths: the London experience. *Sports Med*. 2007; 37(4-5): 448–450, doi: [10.2165/00007256-200737040-00046](https://doi.org/10.2165/00007256-200737040-00046), indexed in Pubmed: [17465632](https://pubmed.ncbi.nlm.nih.gov/17465632/).
26. Rae DE, Knobel GJ, Mann T, et al. Heatstroke during endurance exercise: is there evidence for excessive endothermy? *Med Sci Sports Exerc*. 2008; 40(7): 1193–1204, doi: [10.1249/MSS.0b013e31816a7155](https://doi.org/10.1249/MSS.0b013e31816a7155), indexed in Pubmed: [18580397](https://pubmed.ncbi.nlm.nih.gov/18580397/).
27. Sinert R, Kohl L, Rainone T, et al. Exercise-induced rhabdomyolysis. *Ann Emerg Med*. 1994; 23(6): 1301–1306, doi: [10.1016/s0196-0644\(94\)70356-6](https://doi.org/10.1016/s0196-0644(94)70356-6), indexed in Pubmed: [8198305](https://pubmed.ncbi.nlm.nih.gov/8198305/).
28. Sliż D, Filipiak KJ, Naruszewicz M, et al. Standards of statin usage in Poland in high-risk patients: 3ST-POL study results. *Kardiologia Pol*. 2013; 71(3): 253–259, doi: [10.5603/KP.2013.0037](https://doi.org/10.5603/KP.2013.0037), indexed in Pubmed: [23575780](https://pubmed.ncbi.nlm.nih.gov/23575780/).
29. Strokes ES, Thompson PD, Corsini A, et al. European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J*. 2015; 36(17): 1012–1022, doi: [10.1093/eurheartj/ehv043](https://doi.org/10.1093/eurheartj/ehv043), indexed in Pubmed: [25694464](https://pubmed.ncbi.nlm.nih.gov/25694464/).
30. Kim M, Chun J, Jung HAH, et al. Capillarisin attenuates exercise-induced muscle damage through MAPK and NF- κ B signaling. *Phyto-medicine*. 2017; 32: 30–36, doi: [10.1016/j.phymed.2017.04.007](https://doi.org/10.1016/j.phymed.2017.04.007), indexed in Pubmed: [28732805](https://pubmed.ncbi.nlm.nih.gov/28732805/).
31. Callegari GA, Novaes JS, Neto GR, et al. Creatine Kinase and Lactate Dehydrogenase Responses after Different Resistance and Aerobic Exercise Protocols. *J Hum Kinet*. 2017; 58: 65–72, doi: [10.1515/hukin-2017-0071](https://doi.org/10.1515/hukin-2017-0071), indexed in Pubmed: [28828078](https://pubmed.ncbi.nlm.nih.gov/28828078/).
32. Laufs U, Filipiak KJ, Gouni-Berthold I, et al. SAMS expert working group. Practical aspects in the management of statin-associated muscle symptoms (SAMS). *Atheroscler Suppl*. 2017; 26: 45–55, doi: [10.1016/S1567-5688\(17\)30024-7](https://doi.org/10.1016/S1567-5688(17)30024-7), indexed in Pubmed: [28434484](https://pubmed.ncbi.nlm.nih.gov/28434484/).
33. Vasilaki A, Simpson D, McArdle F, et al. Formation of 3-nitrotyrosines in carbonic anhydrase III is a sensitive marker of oxidative stress in skeletal muscle. *Proteomics Clin Appl*. 2007; 1(4): 362–372, doi: [10.1002/prca.200600702](https://doi.org/10.1002/prca.200600702), indexed in Pubmed: [21136689](https://pubmed.ncbi.nlm.nih.gov/21136689/).
34. Muscal E. Rhabdomyolysis: Practice Essentials, Background, Pathophysiology. Medscape 2015. <https://emedicine.medscape.com/article/1007814-overview#showall>.
35. Sarafidis PA, Blacklock R, Wood E, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. *Clin J Am Soc Nephrol*. 2012; 7(8): 1234–1241, doi: [10.2215/CJN.01150112](https://doi.org/10.2215/CJN.01150112), indexed in Pubmed: [22595825](https://pubmed.ncbi.nlm.nih.gov/22595825/).

Central-to-peripheral systolic blood pressure different phenotypes and relation to accuracy of daily used cuff devices

Ahmed Bendary¹, Mina Magdy², Sahar Abdoul Aal¹, Hisham Rashid¹

¹Banha Faculty of Medicine, Banha University, Banha, Egypt

²National Heart Institute, Giza, Egypt

Abstract

Background. Cuff blood pressure (BP) measurement has been the standard method for taking BP in routine daily practice for more than a century. However, some concerns were raised about the accuracy of this method which could lead to misclassification of BP in many situations.

We aimed primarily to confirm a recent major discovery that distinct BP phenotypes based on central-to-peripheral systolic blood pressure (SBP) amplification do exist, and whether application of a validated cuff BP method (e.g. oscillometric) could accurately discriminate these differences.

Material and methods. Among 106 participants (mean age 62 ± 11 ; 58% males) undergoing coronary angiography, intra-arterial BP was measured at 3 points (ascending aorta, brachial and radial arteries). Central-to-peripheral SBP amplification (SBPamp) was defined as ≥ 5 mm Hg SBP increased from aorta-to-brachial and/or from brachial-to-radial arteries. A validated cuff BP device (oscillometric) was used to measure BP at 4 different time points.

Results. Four different BP phenotypes were confirmed based on the magnitude of SBPamp; phenotype I, both aortic-to brachial and brachial-to radial SBPamp; phenotype II, only aortic-to-brachial SBPamp; phenotype III, only brachial-to-radial SBPamp; and phenotype IV, no SBPamp at all. Aortic SBP was significantly higher in phenotypes-III and IV compared to phenotypes-I and II ($p = 0.001$). This was not discriminated using a validated cuff BP device measurement ($p = 0.996$). Results for the pulse pressure (PP) followed the same pattern.

Conclusion. Distinct BP phenotypes do exist based on SBPamp. A validated cuff BP method failed to discriminate this. Improving quality of BP measurements in daily practice is a priority.

Key words: blood pressure; catheterization; phenotypes; cuff devices

Arterial Hypertens. 2019, vol. 23, no. 4, pages: 263–270
DOI: 10.5603/AH.a2019.0019

Introduction

Blood pressure (BP) measurement in a proper way is regarded as one of the most important measurements in daily clinical practice [1]. This is because accurate diagnosis of hypertension (HTN), accompanied by lifestyle modifications (with or without

anti-hypertensive medications) can lead to substantial reductions of the future cardiovascular (CV) risk [2]. Despite many concerns raised about the accuracy of cuff BP measurements used in daily practice [3], this method has not changed significantly over the past century. Thanks to a recent individual patient data systematic review and meta-analysis [4], it has

Address for correspondence: Dr. Ahmed Bendary, MD

Cardiology Department, Banha Faculty of Medicine, Banha University, Egypt, Postal Code no. 13518

e-mail: ahmed.bendary@fmed.bu.edu.eg; dr_a_bendary@hotmail.com

been shown that routinely used cuff BP devices are exposed to inaccuracies when compared to intra-arterial (invasive) BP values, especially for systolic blood pressure (SBP) in the range of 120–159 mm Hg. Accordingly, this could have huge implications on how HTN is correctly diagnosed in the first place.

Cuff BP devices (both oscillometric and standard Korotkoff sounds) use arterial signals at an isolated point in a peripheral artery (usually the brachial artery) to measure BP [5, 6]. However, there are large inter-individual variability in arterial characteristics (e.g. stiffness, diameter, etc.) and in the way BP is transmitted from central-to-peripheral vasculature (e.g. increased SBP amplification in some, but not in others) [7–10]. Therefore, measuring BP at an isolated arterial point may overlook these fine phenotypic differences.

This notion has been recently raised by Picone et al [11], who discovered for the first time that there are 4 distinctive phenotypes of BP (based on central-to-peripheral SBP amplification as measured invasively), and that these different phenotypes were not discriminated at all by cuff BP devices used in daily routine practice. Importantly, they cautioned that these findings may not be generalizable to other patients beyond their study population and that future research is warranted to corroborate these findings and to test whether such phenotypes would be present among sample populations other than those examined in their work. Therefore, we found that it may be of considerable interest if we could replicate these novel findings among a group of patients with different ethnicity and characteristics.

Material and methods

Study subjects

In the period from November 2018 to April 2019, this observational study included patients with a clinical indication for coronary angiography at National Heart Institute, Giza, Egypt. Among 181 patients screened, seventy-five patients were excluded leaving 106 eligible patients for study procedures. Patients were *excluded* with the following criteria that may introduce errors in intra-arterial BP measurement; atrial fibrillation or aortic stenosis ($n = 16$); a cuff BP inter-arm difference of > 5 mm Hg ($n = 8$); inability to measure BP in both arms for whatever reason ($n = 10$); use of femoral arterial access for coronary angiography (due to inaccessibility of upper limb arteries; $n = 11$). We also *excluded* patients with medical (radial artery spasm; $n = 6$) or technical issues that detracted the quality of pressure waveforms recorded

($n = 5$). Nineteen patients did not provide a consent. Included patients' clinical characteristics including anthropometric measures and clinical history were recorded at the angiography preassessment (usually 1 day before the procedure) by nursing staff. Other clinical information was extracted from the hospital medical records. The study was approved by the local ethical committee and all participants provided an informed consent.

Intra-arterial BP measurement

The right radial artery was used for catheter access. All patients were examined under stable haemodynamics without moving or talking. They were also devoid of any medications that could induce an acute vasoactive response as per the ARTERY guidelines (Association for Research into Arterial Structure and Physiology) [12]. After the clinical procedure, intra-arterial BP was measured with a fluid-filled system using 5F (18% of cases) and 6F (82% of cases) catheters, including a 5–6F Judkins Left (*Cordis*) and 5–6F Multipurpose (*Cordis*) catheters. Fluoroscopy was used to confirm the catheter position at each arterial site and the catheter was flushed before all waveform recordings. Stable pressure waveforms were recorded for a minimum of 20 seconds at each arterial site to reduce the influence of respiratory variation. Intra-arterial BP measurements began with the catheter in the proximal ascending aorta. The catheter was then pulled back to the upper arm (midhumerus) for brachial waveform measurement. Finally, the catheter was pulled back to the wrist, and the sheath was partially removed to allow the most distal radial waveform measurement possible. Waveforms were recorded via Dräger, Infinity Delta series, Germany.

Cuff BP measurement

Because BP value may change over time, cuff BP was measured at 4 different time points (for each patient): first, during the angiography preassessment visit; second, in the waiting room before catheterization, simultaneously on both arms with 2 identical devices; third, immediately before commencing the angiogram in the catheterization laboratory; and fourth, after the clinical procedure simultaneous with intra-arterial brachial BP. For all cuff measurements, participants were asked to remain still and quiet throughout the recordings. Cuff BP was measured with the automated oscillometric method using Omron HEM-907 device (which has been validated according to international protocols [13]). For cuff and intra-arterial measurements, pulse pressure (PP) was

calculated as SBP — diastolic BP. Mean arterial pressure (MAP) was calculated as DBP + 1/3 PP.

Defining BP phenotypes

As stated in Picone et al [11] methodology, the amount of SBP increase (SBP amplification) between the aorta-to-brachial and brachial-to-radial arteries was used to define the BP phenotypes. When SBP increased by ≥ 5 mm Hg between the aortic-to-brachial or brachial-to-radial arteries, this was considered an SBP amplification. The threshold of 5 mm Hg was selected because it represents a difference in BP generally greater than what could be attributed to measurement variability [14, 15]. SBP increases of < 5 mm Hg between the aortic-to-brachial or brachial-to-radial arteries were not considered an SBP amplification. Phenotypic differences' delineation employs SBP specifically because SBP is more closely related to cardiovascular disease and outcomes compared with other BP indices [16, 17]. Moreover, there is little variability in diastolic BP between the central-to-peripheral arteries [4].

Statistical analysis

Data management and statistical analysis were done using SPSS vs.25. (IBM, Armonk, New York, United States). Numerical data was summarized as means and standard deviations or medians and ranges. Categori-

cal data was summarized as numbers and percentages. Comparisons between four groups were done using One-way ANOVA or Kruskal-Wallis test for normally and non-normally distributed numerical variables respectively. Post hoc analysis was done in case of significant overall effect. All post hoc analysis was Bonferroni adjusted. Categorical data was compared using Chi-square test. All p values were two sided. P values less than 0.05 were considered significant.

Results

Study population

Generally, participants' criteria were typically those of patients undergoing coronary catheterization: middle to older age (mean age 62 ± 11 years), with male gender preponderance (61%) and overweight to obese [mean body mass index (BMI) 30 ± 4 kg/m²]. Between-group analysis showed no statistically significant differences in all baseline characteristics (except for age) (Tab. I).

BP phenotypes and cuff BP values

Four different BP phenotypes were observed according to the amount of aortic-to-brachial and brachial-to-radial SBP amplification (Fig. 1):

Table I. Baseline characteristics of study population*

		Phenotype I (n = 27)	Phenotype II (n = 29)	Phenotype III (n = 26)	Phenotype IV (n = 24)	p value
Age (years)	Mean \pm SD	56 \pm 10 ^a	58 \pm 8 ^a	69 \pm 9 ^b	68 \pm 9 ^b	< 0.001
Gender	Males n (%)	15 (55.6)	19 (65.5)	14 (53.8)	13 (54.2)	0.788
	Females n (%)	12 (44.4)	10 (34.5)	12 (46.2)	11 (45.8)	
Hypertension	Yes n (%)	18 (66.7)	18 (62.1)	16 (61.5)	16 (66.7)	0.965
Diabetes	Yes n (%)	12 (44.4)	12 (41.4)	12 (46.2)	10 (41.7)	0.982
Smoking	Yes n (%)	10 (37.0)	12 (41.4)	10 (38.5)	10 (41.7)	0.982
Obesity	Yes n (%)	8 (29.6)	9 (31.0)	8 (30.8)	8 (33.3)	0.994
BMI [kg/m ²]	Mean \pm SD	30 \pm 4	30 \pm 3	30 \pm 3	31 \pm 5	0.845
Known dyslipidaemia	Yes n (%)	5 (18.5)	6 (20.7)	5 (19.2)	5 (20.8)	0.996
FH of premature CAD	Yes n (%)	6 (22.2)	7 (24.1)	6 (23.1)	6 (25.0)	0.996
PH of CVD	Yes n (%)	20 (74.1)	23 (79.3)	20 (76.9)	18 (75.0)	0.97

*One-way ANOVA was used for age and BMI. Chi-square test was used for categorical data. Post hoc analysis was done in case of significant overall effect and different letters indicate significant pair. All post hoc were Bonferroni adjusted; BMI — body mass index; CAD — coronary artery disease; FH — family history; PH — past history; CVD — cardiovascular disease; SD — standard deviation




Figure 1. Flow-chart of identification of various blood pressure (BP) phenotypes




Figure 2. Case presentations of the 4 different blood pressure (BP) phenotypes based on differences in systolic blood pressure (SBP) amplification between aortic-to brachial and brachial-to-radial arteries. Recorded SBP is reported above each pressure waveform. A. Phenotype I (case no. 11); B. Phenotype II (case no. 3); C. Phenotype III (case no. 17); D. Phenotype IV (case no. 14)

- both aortic-to-brachial and brachial-to-aortic SBP amplification (≥ 5 mm Hg) in 27 patients (25.47%; phenotype I) (Fig. 2A);
 - aortic-to-brachial but not brachial-to-radial SBP amplification in 29 patients (27.35%; phenotype II) (Fig. 2B);
 - no aortic-to-brachial, but brachial-to-radial SBP amplification in 26 patients (24.52%; phenotype III) (Fig. 2C);
 - neither aortic-to-brachial nor brachial-to-radial SBP amplification in 24 patients (22.64 %; phenotype IV) (Fig. 2D).
- Aortic SBP was significantly different between the 4 BP phenotypes (overall p value = 0.001) and was significantly higher in phenotypes-III and IV when compared to phenotype I (Fig. 3A; Tab. II). On the other hand, there was no statistically significant differences between groups as regard brachial SBP (Fig.




Figure 3. Cuff, intra-arterial aortic, and brachial blood pressure (BP) across the 4 BP phenotypes. **A.** Systolic BP (SBP); **B.** Pulse pressure (PP) — measured at the aorta (light bars), brachial artery (striated bars), and cuff BP measures (dark bars) across each BP phenotype. *p* values on the figure represent significant differences in aortic SBP and PP between the specific phenotypes. *p* > 0.05 for all other comparisons. Data are mean ± SE of the mean

3A). Despite this marked variation in SBP amplification from central-to-peripheral vasculature across the 4 distinct BP phenotypes, there was no significant difference in standard cuff SBP measurements between the 4 groups (Tab. III). Of note, this lack of discrimination was consistent across all the 4 time

points for cuff BP measurement and for the average of all cuff BP readings (*p* values > 0.50 for all comparisons; Fig. 3A; Tab. III).

Findings for PP followed the same pattern as for SBP; aortic PP was significantly different across the 4 BP phenotypes (Fig. 3B; Tab. II), but cuff BP measurement did not discriminate this accurately whether measures at different time points of using the average of all cuff BP readings (*p* values > 0.30 for all comparisons; Fig. 3B; Tab. III).

Discussion

To the best of our knowledge, this study is the 1st in the literature that reaffirms the major findings provided by Picone et al [11] who discovered the presence of 4 different BP phenotypes based on the magnitude of central-to-peripheral SBP amplification. Notably, these various phenotypes were not discriminated by cuff BP measurements as used in routine daily practice. These findings make sense and imply that the practice of using standard one-for-all cuff BP devices should be revisited.

The clinical consequences of these findings are many, failure of a daily used cuff BP device to accurately discriminate the higher intra-arterial SBP (and PP) among phenotypes III and IV (groups with little or no aortic-to-brachial SBP amplification) could lead to misclassification of BP and potentially missing the opportunity of implementing lifestyle changes or even initiating antihypertensive medications.

Table II. Haemodynamic parameters across the 4 study groups*

		Group I (n = 27)	Group II (n = 29)	Group III (n = 26)	Group IV (n = 24)	<i>p</i> value
Aortic SBP [mm Hg]	Mean ± SD	122 ± 22 ^a	126 ± 26 ^{a,c}	140 ± 26 ^{b,c}	146 ± 24 ^b	0.001
Brachial SBP [mm Hg]	Mean ± SD	139 ± 22	141 ± 28	139 ± 26	140 ± 26	0.988
Radial SBP [mm Hg]	Mean ± SD	156 ± 29 ^a	140 ± 29 ^{b,c}	156 ± 39 ^{a,c}	137 ± 25 ^{b,d}	0.038
Aortic-to-brachial SBPamp [mm Hg]	Median (range)	15 (5–55) ^a	10 (5–50) ^a	0 (–5–0) ^b	0 (–10–0) ^b	< 0.001
Brachial-to-radial SBPamp [mm Hg]	Median (range)	10 (5–60) ^a	0 (–10–0) ^b	20 (5–60) ^a	0 (–5–2) ^b	< 0.001
Aortic MAP [mm Hg]	Mean ± SD	93 ± 16	93 ± 15	94 ± 16	92 ± 13	0.961
Aortic DBP [mm Hg]	Mean ± SD	76 ± 16	74 ± 13	72 ± 13	73 ± 12	0.739
Aortic PP [mm Hg]	Mean ± SD	46 ± 17 ^a	52 ± 21 ^a	73 ± 21 ^b	73 ± 28 ^b	< 0.001
Brachial PP [mm Hg]	Mean ± SD	62 ± 17	60 ± 24	62 ± 31	61 ± 28	0.997
Radial PP [mm Hg]	Mean ± SD	77 ± 24	65 ± 26	79 ± 26	63 ± 30	0.05
Heart rate [bpm]	Mean ± SD	80 ± 11	81 ± 9	80 ± 11	81 ± 10	0.978

*One-way ANOVA was used. Kruskal Wallis test was used for aortic to brachial SBPamp and brachial to radial SBPamp. Post hoc analysis was done in case of significant overall effect and different letters indicate significant pair. All post hoc were Bonferroni adjusted; Bpm — beat per minute; DBP — diastolic blood pressure; MAP — mean arterial pressure; PP — pulse pressure; SBPamp — systolic blood pressure amplification

Table III. Cuff blood pressure (BP) across the 4 study groups*

	Group I (n = 27)	Group II (n = 29)	Group III (n = 26)	Group IV (n = 24)	p value
Cuff SBP (pre-assessment) [mm Hg]	132 ± 24	133 ± 21	133 ± 22	131 ± 25	0.984
Cuff SBP (waiting room — left arm) [mm Hg]	131 ± 18	130 ± 16	133 ± 21	132 ± 24	0.976
Cuff SBP (waiting room — right arm) [mm Hg]	133 ± 18	132 ± 17	134 ± 21	131 ± 26	0.944
Cuff SBP (waiting room — average) [mm Hg]	132 ± 18	131 ± 16	133 ± 21	132 ± 24	0.981
Cuff SBP (pre-diagnostic cath) [mm Hg]	133 ± 17	131 ± 17	134 ± 22	133 ± 26	0.98
Cuff SBP (simultaneous with intra-arterial brachial) [mm Hg]	138 ± 19	138 ± 27	137 ± 28	136 ± 31	0.993
Cuff SBP (average of all) [mm Hg]	133 ± 18	135 ± 15	134 ± 22	134 ± 24	0.996
Cuff PP (pre-assessment) [mm Hg]	52 ± 12	51 ± 13	54 ± 20	51 ± 12	0.814
Cuff PP (waiting room — left arm) [mm Hg]	52 ± 12	52 ± 13	55 ± 14	51 ± 15	0.651
Cuff PP (waiting room — right arm) [mm Hg]	55 ± 13	54 ± 13	57 ± 13	52 ± 13	0.534
Cuff PP (waiting room — average) [mm Hg]	53 ± 12	53 ± 12	57 ± 14	51 ± 15	0.472
Cuff PP (pre-diagnostic cath) [mm Hg]	54 ± 11	52 ± 13	57 ± 16	51 ± 13	0.503
Cuff PP (simultaneous with intra-arterial brachial) [mm Hg]	57 ± 13	59 ± 20	57 ± 18	55 ± 20	0.889
Cuff PP (average of all) [mm Hg]	54 ± 10	53 ± 12	56 ± 13	53 ± 10	0.805

*One-way ANOVA was used. No post hoc analysis was done due to non-significant overall effect; PP — pulse pressure; SBP — systolic blood pressure

Since aortic BP is more closely related to cardiovascular risk relative to upper arm BP values [18], we suggest that patients in phenotypes III and IV might be subjected to a higher future risk due to underestimation of high BP. However, the lack of amplification of SBP and PP may contribute to this risk more than the isolated value at a certain arterial segment (e.g. aorta) as shown in some patients with end-stage renal disease [19]. On the other hand, it could be speculated that excessive SBP amplification itself may enhance end-organ damage at vulnerable sites but examining whether clinical outcomes would differ between various BP phenotypes should be the focus of a prospective cohort study with a large sample size enabling the power to detect associations.

Of course, the mechanisms underlying differences between the 4 BP phenotypes were not addressed in the current study, but explanations do exist and are multifaceted. These differences may be related to the interplay between ventricular output (e.g. stroke volume, chronotropy and contractility), large conduit arterial wall characteristics (e.g. elas-

ticity) and criteria of small resistance arteries [20]. For instance, ejection of a good cardiac output into a healthy vascular system i.e. central arteries with good compliance that buffers the rapid increase in SBP, could lead to a downstream SBP augmentation considering the progressive peripheral tapering of vessels coupled with decreased wall thickness but increased stiffness [21]. On the contrary, lower ventricular inotropy and increased stiffness of central arteries relative to peripheral ones could lead to a high aortic SBP to a level that surpasses any peripheral amplification effect. This is more common with older age. Interestingly, patients in phenotypes-III and IV in the current study (groups with little or no peripheral SBP amplification) were significantly older than those in phenotypes-I and II (groups with high level of peripheral SBP amplification).

Thus, considering this complex interplay underlying the phenomenon of SBP amplification, it becomes unsurprising for cuff BP devices to be far less than accurate for dissecting these subtle differences using a one-size-for-all cuff methods. However, we

should stress that this study (among others) is not meant at all to undermine the clinical value of cuff BP measurement, but rather suggests that developments could be applied to this method in order to improve its accuracy so that it could be used one day as a risk refinement tool.

Some limitations to this study deserve mention, first, we did not include a dedicated intra-arterial pressure waveform analysis device and we did not use multiple cuff devices for BP measurements due to limited resources and lack of fund. Second, we used a fluid-filled system rather than solid catheters for intra-arterial BP measurement, and this may introduce few errors if the system was not carefully handled (for example, impingement of the arterial wall in small arteries). Finally, our findings are not generalizable outside the examined population (patients with a clinical indication for coronary angiography). Having said this, there is no compelling case that cuff BP devices would be necessarily inaccurate among all patients. For example, the observed 4 phenotypes may be much less distinct among younger healthy people with less advancing age and no disease affecting the vascular system such as diabetes. However, this is to be examined in further large-scale cohort studies.

Conclusion

This study confirms that distinct intra-arterial BP phenotypes do exist based on SBP central-to-peripheral amplification. A daily used validated cuff BP method failed to discriminate this. Improving quality of BP measurements in routine practice by taking this phenotypic variation into account should be a future research focus.

Acknowledgment

We express our deep gratitude for Dr. Mohamed Bendary, who inspired the statistical analysis of this work. We are also thankful to all technical staff who helped in intra-arterial BP waveform recording.

Funding

None.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki dec-

laration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

- Pickering TG, Hall JE, Appel LJ, et al. Council on High Blood Pressure Research Professional and Public Education Subcommittee, American Heart Association. Recommendations for blood pressure measurement in humans: an AHA scientific statement from the Council on High Blood Pressure Research Professional and Public Education Subcommittee. *J Clin Hypertens (Greenwich)*. 2005; 7(2): 102–109, doi: [10.1111/j.1524-6175.2005.04377.x](https://doi.org/10.1111/j.1524-6175.2005.04377.x), indexed in Pubmed: [15722655](https://pubmed.ncbi.nlm.nih.gov/15722655/).
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet*. 2016; 387(10022): 957–967, doi: [10.1016/S0140-6736\(15\)01225-8](https://doi.org/10.1016/S0140-6736(15)01225-8), indexed in Pubmed: [26724178](https://pubmed.ncbi.nlm.nih.gov/26724178/).
- Bordley J, Connor CAR, Hamilton WF, et al. Recommendations for human blood pressure determinations by sphygmomanometers. *Circulation*. 1951; 4(4): 503–509, doi: [10.1161/01.cir.4.4.503](https://doi.org/10.1161/01.cir.4.4.503), indexed in Pubmed: [14870262](https://pubmed.ncbi.nlm.nih.gov/14870262/).
- Picone DS, Schultz MG, Orthal P, et al. Accuracy of Cuff-Measured Blood Pressure: Systematic Reviews and Meta-Analyses. *J Am Coll Cardiol*. 2017; 70(5): 572–586, doi: [10.1016/j.jacc.2017.05.064](https://doi.org/10.1016/j.jacc.2017.05.064), indexed in Pubmed: [28750701](https://pubmed.ncbi.nlm.nih.gov/28750701/).
- Benmira A, Perez-Martin A, Schuster I, et al. An ultrasound look at Korotkoff sounds: the role of pulse wave velocity and flow turbulence. *Blood Press Monit*. 2017; 22(2): 86–94, doi: [10.1097/MBP.0000000000000231](https://doi.org/10.1097/MBP.0000000000000231), indexed in Pubmed: [27902494](https://pubmed.ncbi.nlm.nih.gov/27902494/).
- Amoore JN. Oscillometric sphygmomanometers: a critical appraisal of current technology. *Blood Press Monit*. 2012; 17(2): 80–88, doi: [10.1097/MBP.0b013e32835026b0](https://doi.org/10.1097/MBP.0b013e32835026b0), indexed in Pubmed: [22228040](https://pubmed.ncbi.nlm.nih.gov/22228040/).
- Picone DS, Schultz MG, Climie RED, et al. Aortic-to-brachial stiffness gradient and kidney function in type 2 diabetes. *J Hypertens*. 2016; 34(6): 1132–1139, doi: [10.1097/HJH.0000000000000916](https://doi.org/10.1097/HJH.0000000000000916), indexed in Pubmed: [27035734](https://pubmed.ncbi.nlm.nih.gov/27035734/).
- Redheuil A, Yu WC, Mousseaux E, et al. Age-related changes in aortic arch geometry: relationship with proximal aortic function and left ventricular mass and remodeling. *J Am Coll Cardiol*. 2011; 58(12): 1262–1270, doi: [10.1016/j.jacc.2011.06.012](https://doi.org/10.1016/j.jacc.2011.06.012), indexed in Pubmed: [21903061](https://pubmed.ncbi.nlm.nih.gov/21903061/).
- Murgo JP, Westerhof N, Giolma JP, et al. Aortic input impedance in normal man: relationship to pressure wave forms. *Circulation*. 1980; 62(1): 105–116, doi: [10.1161/01.cir.62.1.105](https://doi.org/10.1161/01.cir.62.1.105), indexed in Pubmed: [7379273](https://pubmed.ncbi.nlm.nih.gov/7379273/).
- Peng X, Schultz MG, Picone DS, et al. Arterial reservoir characteristics and central-to-peripheral blood pressure amplification in the human upper limb. *J Hypertens*. 2017; 35(9): 1825–1831, doi: [10.1097/HJH.0000000000001400](https://doi.org/10.1097/HJH.0000000000001400), indexed in Pubmed: [28505065](https://pubmed.ncbi.nlm.nih.gov/28505065/).
- Picone DS, Schultz MG, Peng X, et al. Discovery of New Blood Pressure Phenotypes and Relation to Accuracy of Cuff Devices Used in Daily Clinical Practice. *Hypertension*. 2018; 71(6): 1239–1247, doi: [10.1161/HYPERTENSIONAHA.117.10696](https://doi.org/10.1161/HYPERTENSIONAHA.117.10696), indexed in Pubmed: [29632105](https://pubmed.ncbi.nlm.nih.gov/29632105/).
- Sharman JE, Avolio AP, Baulmann J, et al. Validation of non-invasive central blood pressure devices: ARTERY Society task force consensus statement on protocol standardization. *Eur Heart J*. 2017; 38(37): 2805–2812, doi: <https://dx.doi.org/10.1093/eurheartj/ehx100>, indexed in Pubmed: [28158489](https://pubmed.ncbi.nlm.nih.gov/28158489/).
- El As, Topouchian JA, Darne BM, et al. Validation of the Omron HEM-907 device for blood pressure measurement. *Am J Hypertension*. 2002; 7(4): 237–241, doi: [10.1097/00126097-200208000-00006](https://doi.org/10.1097/00126097-200208000-00006), indexed in Pubmed: [12198340](https://pubmed.ncbi.nlm.nih.gov/12198340/).

14. Stergiou GS, Lourida P, Tzamouranis D. Replacing the mercury manometer with an oscillometric device in a hypertension clinic: implications for clinical decision making. *J Hum Hypertens*. 2011; 25(11): 692–698, doi: [10.1038/jhh.2010.107](https://doi.org/10.1038/jhh.2010.107), indexed in Pubmed: [21107434](https://pubmed.ncbi.nlm.nih.gov/21107434/).
15. O'Brien E, Atkins N, Stergiou G, et al. European Society of Hypertension International Protocol revision 2010 for the validation of blood pressure measuring devices in adults. *Blood Press Monit*. 2010; 15(1): 23–38, doi: [10.1097/mbp.0b013e3283360e98](https://doi.org/10.1097/mbp.0b013e3283360e98), indexed in Pubmed: [20110786](https://pubmed.ncbi.nlm.nih.gov/20110786/).
16. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. *Am J Cardiol*. 1971; 27(4): 335–346, doi: [10.1016/0002-9149\(71\)90428-0](https://doi.org/10.1016/0002-9149(71)90428-0), indexed in Pubmed: [5572576](https://pubmed.ncbi.nlm.nih.gov/5572576/).
17. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. *Lancet*. 2002; 360(9349): 1903–1913, doi: [10.1016/s0140-6736\(02\)11911-8](https://doi.org/10.1016/s0140-6736(02)11911-8), indexed in Pubmed: [12493255](https://pubmed.ncbi.nlm.nih.gov/12493255/).
18. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol*. 2010; 55(13): 1318–1327, doi: [10.1016/j.jacc.2009.10.061](https://doi.org/10.1016/j.jacc.2009.10.061), indexed in Pubmed: [20338492](https://pubmed.ncbi.nlm.nih.gov/20338492/).
19. Safar ME, Blacher J, Pannier B, et al. Central pulse pressure and mortality in end-stage renal disease. *Hypertension*. 2002; 39(3): 735–738, doi: [10.1161/hy0202.098325](https://doi.org/10.1161/hy0202.098325), indexed in Pubmed: [11897754](https://pubmed.ncbi.nlm.nih.gov/11897754/).
20. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. *Hypertension*. 2009; 54(2): 375–383, doi: [10.1161/HYPERTENSIONAHA.109.134379](https://doi.org/10.1161/HYPERTENSIONAHA.109.134379), indexed in Pubmed: [19564542](https://pubmed.ncbi.nlm.nih.gov/19564542/).
21. Gaddum N, Alastruey J, Chowienczyk P, et al. Relative contributions from the ventricle and arterial tree to arterial pressure and its amplification: an experimental study. *Am J Physiol Heart Circ Physiol*. 2017; 313(3): H558–H567, doi: [10.1152/ajpheart.00844.2016](https://doi.org/10.1152/ajpheart.00844.2016), indexed in Pubmed: [28576835](https://pubmed.ncbi.nlm.nih.gov/28576835/).

The prevalence of left atrial enlargement in Polish patients with atrial fibrillation — a single center study

Anna Szymańska¹, Anna E. Płatek², Joanna Syska-Sumińska¹, Anna Gorajek¹, Mirosław Dłużniewski¹

¹Department of Heart Diseases, Medial Centre of Postgraduate Education, Warsaw, Poland

²Department of General and Experimental Pathology with Centre for Preclinical Research and Technology (CEPT), Medical University of Warsaw, Warsaw, Poland

Abstract

Background. Atrial fibrillation (AF) remains one of the major causes of cardiovascular morbidity worldwide. Left atrial enlargement (LAE) is a common risk factor of AF. Left atrial enlargement is also connected with a higher prevalence of heart failure in AF patients. The aim of this study was to assess the prevalence of LAE in Polish patients with AF.

Material and methods. Transthoracic echocardiography was performed in consecutive AF patients hospitalized in the Department of Heart Diseases. We assessed LAE using a two-dimensional method. Left atrial (LA) size was classified into the 4 categories: normal (LAE values < 39 mm in women and < 41 mm in men), mildly enlarged (39–42 mm in women and 41–46 mm in men), moderately enlarged (43–46 mm in women and 47–51 mm in men), and severely enlarged (≥ 47 mm in women and ≥ 52 mm in men).

Results. We analyzed 113 individuals with AF (mean age 77.2 ± 9.8 years; 37.2% men). Of these, 71 (62.8%) patients had LAE (age 77.6 ± 9.9 years; 36.6% men). LA was mildly enlarged (39–42 mm in women and 41–46 mm in men) in 20 (28.2%) patients, moderately enlarged (43–46 mm in women and 47–51 mm in men) was observed in 30 (42.3%), and severely enlarged (≥ 47 mm in women and ≥ 52 mm in men) in 21 (29.6%) patients. The incidence of heart failure was significantly higher in AF patients with LAE [39 (54.9%) compared to the patients without LAE — 12 (28.6%) $p = 0.01$].

Conclusions. In patients with AF, LAE was highly prevalent. Patients with AF and LAE have more often HF compared to AF patients without LAE.

Key words: left atrial enlargement; atrial fibrillation; echocardiography

Arterial Hypertens. 2019, vol. 23, no. 4, pages: 271–274
DOI: 10.5603/AH.a2019.0020

Address for correspondence: Anna Szymańska, MD, PhD
Department of Heart Diseases, Medial Centre of Postgraduate Education, Poznańska 22 Street, Warsaw 00–685, Poland;
tel: +48 22 5251263; e-mail: anna.szymanska@cmkp.edu.pl

 Copyright © 2019 Via Medica, ISSN 2449–6170

www.ah.viamedica.pl

Introduction

Atrial fibrillation (AF), the most common supraventricular arrhythmia, is found in approximately 3% adults and its prevalence is still rising. Atrial fibrillation remains one of the major causes of stroke, heart failure (HF), sudden death, and cardiovascular morbidity worldwide [1]. It occurs more often in patients with a left atrial enlargement (LAE) [2]. Left atrial (LA) size is a predictor of cardiovascular outcomes in the general population and HF patients [3]. As previously shown, LAE is also connected with higher thromboembolic risk in AF patients [4].

The aim of this study was to assess the prevalence of LAE in patients with nonvalvular AF.

Material and methods

The study was designed and conducted with the accordance of the Declaration of Helsinki and it was approved by the Regional Ethics Committee. We prospectively analyzed data on continuous hospitalizations for AF in the Department of Heart Diseases, Medial Centre of Postgraduate Education, Warsaw. Inclusion criteria were age ≥ 18 years, primary diagnosis of AF, transthoracic echocardiographic evaluation underwent during current hospitalization. We excluded patients with valvular AF, fatal condition with an estimated life expectancy of < 6 months, or those who did not give informed consent for the participation in the study. Medical history was taken in all patients on admission by a qualified physician. Data included information on thromboembolic and cardiovascular risk factors. The diagnosis of AF was made based on the rhythm documentation using a standard electrocardiogram (ECG) showing the typical pattern of AF, according to the current guidelines [2].

In all, transthoracic echocardiograms were performed in the Department's Echocardiography Laboratory using Philips Affiniti 70C Ultrasound Machines (Philips Healthcare, Andover, USA) by qualified echocardiographers. To avoid bias, measurements were taken three times, then averaged. LA diameter was measured using two-dimensional (2D) echocardiography, from the posterior aortic wall to the posterior left atrial wall, in the parasternal long-axis view at the end-ventricular systole (i.e., just before the mitral valve opening). Left atrial enlargement was classified into four categories: normal, mildly enlarged, moderately enlarged, and severely enlarged by the European Society of Cardiology guidelines [5]. Left atrial size was considered normal

when LA was < 39 mm in women and < 41 mm in men, otherwise it was considered enlarged. The mild enlargement was defined as LAE values 39–42 mm in women and 41–46 mm in men, moderate enlargement for 43–46 mm in women and 47–51 mm in men, and severe enlargement for ≥ 47 mm in women and ≥ 52 mm in men. Left ventricular ejection fraction (LVEF) was calculated using the biplane method of discs (modified Simpson's rule) [5].

All data are presented as mean \pm standard deviation (SD) for parametric variables and as percentages for categorical variables. Continuous variables were checked for the normal distribution assumption using the Kolmogorov-Smirnov statistics. Differences between the prespecified patient groups were evaluated using the Kolmogorov-Smirnov test or ANOVA with Tukey's post hoc test as appropriate. Categorical variables were tested by Pearson's χ^2 test and Fisher's exact test. A p-value < 0.05 was considered statistically significant. All statistical studies were carried out using Statistical Package for Social Sciences software (SPSS 21.0 for macOS, SPSS Inc., Chicago, IL, USA).

Results

The study population consisted of 113 individuals with AF (mean age 77.2 ± 9.8 years; 37.2% men). In this group, the mean value of LA diameter was 42.2 ± 8.2 millimeters. Hypertension was present in 97 (85.4 %) patients, diabetes mellitus in 39 (34.5 %) patients, chronic coronary syndromes in 43 (38%) patients, stroke or transient ischemic attack in 22 (19.5%) patients, HF in 51 (45.1%) patients and chronic obstructive pulmonary disease in 15 (13.3%) patients. Baseline characteristics of study patients are shown in Table I.

In the group of AF patients, we identified 71 (62.8%) patients with LAE (age 77.6 ± 9.9 years; 36.6% men) and 42 (37.2%) patients without LAE (76.6 ± 9.7 years; 33.3% men). There was no significant difference in the incidence of hypertension, diabetes mellitus, chronic coronary syndromes, chronic kidney disease, stroke or transient ischemic attack, as well as chronic obstructive pulmonary disease in these two groups. The incidence of HF was significantly higher in AF patients with LAE [39 (54.9%) compared to the patients without LAE — 12 (28.6%), $p = 0.01$]. The characteristics of the study population according to the LAE status are shown in Table II.

Table I. Baseline characteristics of patients with atrial fibrillations (AF)

	Overall patient population (n = 113)
Age (yrs)	77.2 ± 9.8
Male [n (%)]	42 (37.2)
BMI [kg/m ²]	29.1 ± 4.9
Obesity [n (%)]	33 (29.2)
SBP [mm Hg]	133.4 ± 20.6
DBP [mm Hg]	80 ± 13.6
IVSd [mm]	13.1 ± 2.6
LAE [n (%)]	71 (62.8)
Lad [mm]	42.2 ± 8.2
Hypertension [n (%)]	97 (85.4%)
Diabetes mellitus [n (%)]	39 (34.5%)
Chronic coronary syndromes [n (%)]	43 (38%)
Stroke, TIA [n (%)]	22 (19.5%)
Heart failure [n (%)]	51 (45.1%)
COPD [n (%)]	15 (13.3%)

BMI — body mass index; IVSd — intraventricular septum diameter; SBP — systolic blood pressure; DBP — diastolic blood pressure; Lad — left atrium diameter; TIA — transient ischemic attack; COPD — chronic obstructive pulmonary disease

Discussion

The assessment of LA size is crucial to determine the LA function. During the cardiac cycle, LA size is changing and in clinical practice, the maximum LA size (at the end of the left ventricle systole) is the most often used parameter. The measurement of anteroposterior LA linear dimension by 2D echocardiography in the parasternal long-axis view remains the most common echocardiographic method, because of its simplicity and reproducible.

Left atrial enlargement reflects structural remodeling associated with pathophysiologic processes in different cardiovascular diseases (CVD). Conditions such as hypertension, HF, diabetes mellitus, and obesity are the most common risk factors of LA remodeling. In hypertensive patients, associated hypertrophy and diastolic dysfunction lead to LEA. Left atrial enlargement is not the only consequence of high blood pressure, but also a predictor of outcome in hypertension [6]. Hypertension increases the risk of AF [7]. In our population of AF patients, hypertension was observed in most patients (85.4%), without significant differences between patients with and without LAE.

Previous studies have shown that LA size has been associated with adverse cardiovascular outcomes. Left atrial enlargement has been described

Table II. Baseline characteristics of the study population according to the status of left atrial enlargement (LAE)

	LAE+ (n = 71)	LAE- (n = 42)	p-value
Age (yrs)	77.6 ± 9.9	76.6 ± 9.7	> 0.05
Male [n (%)]	26 (36.6%)	14 (33.3)	> 0.05
BMI [kg/m ²]	29.7 ± 5.3	28.1 ± 4.1	> 0.05
Obesity [n (%)]	24 (33.8)	9 (21.4)	> 0.05
SBP [mm Hg]	134 ± 21.8	132.4 ± 18.7	> 0.05
DBP [mm Hg]	81.4 ± 14.1	77.1 ± 12.7	> 0.05
IVSd [mm]	13.1 ± 2.6	12.4 ± 2	> 0.05
LVEF (%)	53.5 ± 13.8	57.1 ± 10.1	> 0.05
Hypertension [n (%)]	60 (84.5)	37 (88.1)	> 0.05
Diabetes mellitus [n (%)]	26 (36.6)	13 (31)	> 0.05
Chronic kidney disease [n (%)]	25 (35.2)	11 (26.2)	> 0.05
Chronic coronary syndromes [n (%)]	28 (39.4)	15 (35.7)	> 0.05
Stroke, TIA [n (%)]	11 (15.5)	11 (26.2)	> 0.05
Heart failure [n (%)]	39 (54.9)	12 (28.6)	= 0.01
COPD [n (%)]	10 (14.1)	5 (11.9)	> 0.05

AF — atrial fibrillation; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; LAE — left atrial enlargement; IVSd — intraventricular septum diameter; LVEF — left ventricular ejection fraction; TIA — transient ischemic attack; COPD — chronic obstructive pulmonary disease

as a predictor of AF, stroke, congestive HF, and cardiovascular death. In our study, LAE was highly prevalent in nonvalvular AF patients (almost 62.8% of patients). Echocardiographically determined LA size is one of the stroke risk factors overlooked by the scores used for thromboembolic risk stratification. LA size may be an additional predictor useful in the assessment of thromboembolic events in AF patients. As we presented in our previous study, LAE has been associated with higher thromboembolic risk assessed by CHADS2 and CHA2DS2-VASc scores [4].

The clinical implications of LAE can be left ventricular dysfunction, which occurs in 20–30% AF patients [2]. Left atrial enlargement has been shown as a marker of poor prognosis in HF patients. Previous studies have demonstrated that LA size is a powerful predictor of outcome among HF patients with predominantly impaired systolic function and provides additional prognostic information beyond left ventricular systolic and diastolic function. (3) The results of our study showed, that the prevalence of HF was significantly higher in AF patients with LAE compared to AF patients without LAE. What is important, the mean value of LVEF did not differ significantly between these two groups.

Limitations in this study were a small population of the study, one center study and the lack of comparison of different methods used for assessing LA size.

Conclusions

Left atrial enlargement is highly present in the Polish population of AF patients and can carry important clinical and prognostic implications. Patients with AF and LAE are at higher risk of HF. Left atrial size can also have prognostic value. Further studies sufficiently powered to assess this issue may be needed.

Conflict of interest

The authors have no conflicts of interest to disclose.

References

1. Hoit BD. Left atrial size and function: role in prognosis. *J Am Coll Cardiol.* 2014; 63(6): 493–505, doi: [10.1016/j.jacc.2013.10.055](https://doi.org/10.1016/j.jacc.2013.10.055), indexed in Pubmed: [24291276](https://pubmed.ncbi.nlm.nih.gov/24291276/).
2. Kirchhof P, Benussi S, Kotecha D, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* 2016; 37(38): 2893–2962, doi: [10.1093/eurheartj/ehw210](https://doi.org/10.1093/eurheartj/ehw210), indexed in Pubmed: [27567408](https://pubmed.ncbi.nlm.nih.gov/27567408/).
3. Rossi A, Temporelli PL, Quintana M, et al. MeRGE Heart Failure Collaborators. Independent relationship of left atrial size and mortality in patients with heart failure: an individual patient meta-analysis of longitudinal data (MeRGE Heart Failure). *Eur J Heart Fail.* 2009; 11(10): 929–936, doi: [10.1093/eurjhf/hfp112](https://doi.org/10.1093/eurjhf/hfp112), indexed in Pubmed: [19789395](https://pubmed.ncbi.nlm.nih.gov/19789395/).
4. Hryniewicz-Szymanska A, Dłuzniewski M, Platek AE, et al. Association of the CHADS2 and CHA2DS2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. *J Thromb Thrombolysis.* 2015; 40(2): 240–247, doi: [10.1007/s11239-014-1154-6](https://doi.org/10.1007/s11239-014-1154-6), indexed in Pubmed: [25490871](https://pubmed.ncbi.nlm.nih.gov/25490871/).
5. Lang RM, Bierig M, Devereux RB, et al. American Society of Echocardiography's Nomenclature and Standards Committee, Task Force on Chamber Quantification, American College of Cardiology Echocardiography Committee, American Heart Association, European Association of Echocardiography, European Society of Cardiology. Recommendations for chamber quantification. *Eur J Echocardiogr.* 2006; 7(2): 79–108, doi: [10.1016/j.euje.2005.12.014](https://doi.org/10.1016/j.euje.2005.12.014), indexed in Pubmed: [16458610](https://pubmed.ncbi.nlm.nih.gov/16458610/).
6. Mancusi C, Cacciello G, Izzo R, et al. Left atrial dilatation: A target organ damage in young to middle-age hypertensive patients. The Campania Salute Network. *Int J Cardiol.* 2018; 265: 229–233, doi: [10.1016/j.ijcard.2018.03.120](https://doi.org/10.1016/j.ijcard.2018.03.120), indexed in Pubmed: [29628278](https://pubmed.ncbi.nlm.nih.gov/29628278/).
7. Tsioufis C, Konstantinidis D, Nikolakopoulos I, et al. Biomarkers of Atrial Fibrillation in Hypertension. *Curr Med Chem.* 2019; 26(5): 888–897, doi: [10.2174/0929867324666171006155516](https://doi.org/10.2174/0929867324666171006155516), indexed in Pubmed: [28990508](https://pubmed.ncbi.nlm.nih.gov/28990508/).

Repetytorium z Kardiologii i Hipertensjologii 2020



- ◆ **WIOSENNE**
Warszawa, 1 marca 2020 roku
- ◆ **LETNIE**
Trójmiasto, 20–21 czerwca 2020 roku
- ◆ **JESIENNE**
Warszawa, 3 października 2020 roku

Więcej informacji i rejestracja na stronie internetowej:

www.kardio.viamedica.pl



Konferencja jest skierowana do wszystkich osób zainteresowanych tematyką. Sesje satelitarne firm farmaceutycznych, sesje firm farmaceutycznych oraz wystawy firm farmaceutycznych są skierowane tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (Dz. U. z 2017 r. poz. 2211, z późn. zm.)

ORGANIZATOR



12687_FC

V Konferencja czasopisma



FOLIA CARDIOLOGICA

Warszawa, 17–18 kwietnia 2020 roku

Przewodnicząca Komitetów Naukowego i Organizacyjnego

prof. dr hab. n. med. Beata Wożakowska-Kapłon

Redaktor Naczelna czasopisma „Folia Cardiologica”

**CZASOPISMU „FOLIA CARDIOLOGICA” PATRONUJĄ
SEKCJE POLSKIEGO TOWARZYSTWA KARDIOLOGICZNEGO:**

CHORÓB SERCA U KOBIET, ECHOKARDIOGRAFII, ELEKTROKARDIOLOGII NIEINWAZYJNEJ I TELEMEDYCYN,
KARDIOLOGII DZIECIĘCEJ, KARDIOLOGII EKSPERYMENTALNEJ, INTERWENCJI SERCOWO-NACZYNIOWYCH,
NIEWYDOLNOŚCI SERCA, REHABILITACJI KARDIOLOGICZNEJ I FIZJOLOGII WYŚŁĘKU, INTENSYWNEJ TERAPII
KARDIOLOGICZNEJ I RESUSCYTACJI, RYTMU SERCA, WAD ZASTAWKOWYCH SERCA
ORAZ FARMAKOTERAPII SERCOWO-NACZYNIOWEJ

Rejestracja oraz szczegółowe informacje na stronie internetowej:

www.cardiologica.viamedica.pl



ORGANIZATOR



PATRONAT MEDIALNY



PARTNER



Konferencja jest skierowana do wszystkich osób zainteresowanych tematyką. Sesje satelitarne firm farmaceutycznych, sesje firm farmaceutycznych oraz wystawy firm farmaceutycznych są skierowane tylko do osób uprawnionych do wystawiania recept lub osób prowadzących obrót produktami leczniczymi — podstawa prawna: Ustawa z dnia 6 września 2001 r. Prawo farmaceutyczne (Dz. U. z 2017 r. poz. 2211, z późn. zm.)